Clemson University

TigerPrints
All Dissertations

Dissertations

12-2014

DEVELOPMENT OF A TRANSLATIONAL,
TISSUE-ENGINEERED APPROACH TO
REPLACEMENT OF MYOCARDIAL
INFARCT SCAR TISSUE
Jason Schulte
Clemson University, jbschul@g.clemson.edu

Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
Part of the Surgery Commons
Recommended Citation
Schulte, Jason, "DEVELOPMENT OF A TRANSLATIONAL, TISSUE-ENGINEERED APPROACH TO REPLACEMENT OF
MYOCARDIAL INFARCT SCAR TISSUE" (2014). All Dissertations. 1418.
https://tigerprints.clemson.edu/all_dissertations/1418

This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.

DEVELOPMENT OF A TRANSLATIONAL, TISSUE-ENGINEERED APPROACH TO
REPLACEMENT OF MYOCARDIAL INFARCT SCAR TISSUE

A Dissertation
Presented to
the Graduate School of
Clemson University

In Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy
Bioengineering

by
Jason Bradley Schulte
December 2014

Accepted by:
Dr. Agneta Simionescu, Committee Chair
Dr. Dan Simionescu
Dr. Martine LaBerge
Dr. Richard Visconti
Dr. Christopher Wright

ABSTRACT

Myocardial infarction (MI) affects nearly 600,000 individuals each year, and the resulting
damage initiates a pathophysiological progression towards congestive heart failure (CHF). A
shortage of donor organs precludes heart transplantation as a practical solution, and neither surgical
intervention nor stem cell therapy have yielded consistent and sufficiently positive results in clinical
investigation.
To prevent CHF, prospective therapies must target the cause of the maladaptive cardiac
remodeling which precedes it—the nonfunctional, dyskinetic infarct scar—and aim to replace it
with functional cardiac muscle. Tissue engineering holds promise for the development of novel
therapies to either halt or reverse post-MI cardiac remodeling. However, early efforts to implant
thick (> 100 µm), functional, tissue-engineered grafts have failed in animal models because such
grafts lack the vascularization, among other features, necessary for long term survival. Therefore,
the primary goal of this research was to develop a tissue-engineering approach to fulfill the need
for thick, fully vascularized, and functional myocardial grafts to replace infarct scar tissue and
prevent or reverse development of CHF in affected patients.
First, myocardial flap scaffolds based on decellularized (DCELLed) porcine leftventricular myocardium and its associated coronary arteries and veins were generated and
characterized. All scaffolds displayed a fully intact and patent vasculature to the level of capillaries,
were devoid of cellular proteins, contained only residual DNA, retained collagen, elastin, and basal
laminar components, exhibited excellent mechanical properties, and were compatible towards
seeded cells.
To evaluate the host response to the scaffold material in a xenogeneic scenario, scaffold
samples were implanted subdermally in rats. Long-term, macrophages at the implant site were
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observed to shift in polarization from an inflammatory to a more constructive, remodeling
phenotype.
In a subsequent series of studies, these scaffolds were seeded with human adipose derived
stem cells (hADSC) and exposed to stimuli reflective of the cardiac environment using a customdesigned platform. Seeded constructs were subjected to various combinations of mechanical,
electrical, and pharmacological stimuli with the objective of directing the differentiation of hADSC
into a cardiomyocyte phenotype en route to resembling functional myocardial tissue.
Finally, the feasibility of infarct scar surgical replacement with myocardial scaffold-based
grafts was evaluated in a porcine model. A surgical anastomosis of the scaffold’s vessels to the
host’s vasculature demonstrated complete perfusion of the scaffold. Hemostasis was achieved with
no major bleeding events, and no complications were encountered.
It is expected that this research will have a positive impact upon efforts to treat a growing
population of patients suffering from complications of MI. It will not only enable clinicians to
prevent or reverse the progression towards CHF—saving lives and improving the quality of life for
recipients of this therapy—but also contribute to the advancement of the cardiac tissue engineering
field.
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CHAPTER ONE: REVIEW OF LITERATURE

1.1 Introduction and Background:
1.1.1 Etiology and Pathology:
Hypertensive, hypercholesterolemic individuals often develop coronary artery
disease (CAD), which is characterized by atherosclerosis in one or both of the coronary
arteries. Atherosclerotic lesions in these arteries, especially the left anterior descending
(LAD) coronary artery, are associated with a high risk for occurrence of adverse cardiac
events, including unstable angina, acute MI, and sudden death from cardiac failure.[1]
These lesions, or atheromatous plaques (atheromas), are suspected to develop according to
the established inflammatory mechanisms of atherosclerosis, but typically do not grow
large enough to achieve any appreciable stenosis of the vessel. Rather, the mechanism
responsible for triggering cardiac events is thrombosis or subsequent thromboembolism
within the coronary arteries or their branching vessels.[1]
In the pathogenesis of MI, thrombus formation occurs following the rupture of the
endothelium and fibrous cap which overlay the atheroma. The atheroma’s lipid core is left
exposed and free to contact and activate platelets, initiating blood clot formation.[1] The
resulting thrombus occludes the coronary circulation either at the site of the lesion or
embolizes to some distal point, and all cells nourished by the occluded vessel are subjected
to severe ischemic insult if they are located distal to the blockage. Hypoxia and lack of
sufficient nutrient and waste exchange resulting from ischemia cause necrosis of the
affected cells, and the injured area, or necrotic core, becomes inflamed.[2]
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Following the inflammatory response, the tissue is remodeled into a dynamic, but
functionally inferior, scar composed of fibrous matrix proteins (i.e. collagen type I and III)
and myofibroblasts (Figure 1.1).[3] This fibrotic response is heavily favored over any
competing regenerative response (e.g. restoration of native structure and function of the
tissue) because the former is a much more rapid process, and there is a strong impetus to
repair (e.g. restore tissue integrity) injury in a vital organ such as the heart as quickly as
possible.[4] This remedy for the injury is analogous to sealing a hole in a ship’s hull with
duct tape instead of welding a new piece of metal in place of the void—it is a haphazard
attempt at repair.

Figure 1.1: Schematic of the arterial stenosis and subsequent blockage that causes acute myocardial
infarction (MI). The area of affected tissue is also shown. The cells in this area succumb to necrosis and the
tissue is remodelled into a fibrous scar.

In the first 2 days post-MI, activated macrophages contribute to increased
expression of transforming growth factor-beta (TGF-β), which is thought to drive the
phenotypic shift of interstitial cardiac fibroblasts into myofibroblasts.

These

myofibroblasts, in conjunction with increased levels of angiotensin II and TGF-β, mediate
transcription of collagen type I and III mRNAs at the site of the infarct.[3]

2

The resulting fibrosis is not localized to the necrotic core or tissue immediately
adjacent to it, but is frequently observed to affect sites remote to the infarct. In an infarct
of the left ventricular anterior wall, for example, areas of increased fibrillar collagen
deposition can appear intraseptally, in the septal endocardium, in the right ventricle, and in
the visceral pericardium.[3] This effect is most likely an indirect result of the damage
caused by the infarct and is mediated by physiologically-driven changes in cell
morphology, and therefore, changes in the expression of fibrillar matrix proteins
Following MI, the body will attempt to maintain homeostasis despite the infarctinduced death of cardiomyocytes (CM) and accompanying loss of their energetic
contribution to the stroke volume (volume of blood pumped during systole) of the left
ventricle. This means the collective demand of the body’s cells for blood will not deviate
from pre-infarct levels, and, consequently, the remaining healthy myocardium must work
harder to maintain the original cardiac output.[5] As a result, the heart undergoes changes
at both the cellular and organ level in order to normalize stroke volume.
The noncontractile infarct scar is a weak point in the ventricular wall that acts as a
stress concentration during ventricular systole.

Thus, ventricular pressure without

counteracting force evolved from wall tension in that area causes stretching and thinning
of the infarct and an increase in the radius of the chamber. Pursuant to the Law of Laplace,
which can be used to model the relationships between pressure, volume, and wall geometry
in the left ventricle, an increase in radius helps to normalize wall tension and stroke volume
initially. With time, however, this increased radius diminishes the preload (and ejection
fraction) the ventricle is able to generate, and other mechanisms of remodeling such as
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increased CM contraction force and wall thinning are enlisted to help augment preload
generation.
Increased CM contraction force is managed through cellular hypertrophy. Via
mechanotransduction, CM experience chronically increased mechanical stresses and
synthesize additional muscle filaments (actin, myosin, and titin) to handle the larger
workload. Since the ventricle increases in volume, the myocardium is under volume
overload, and it has been established that volume overload produces eccentric CM
hypertrophy.[6] Specifically, CM add muscle filaments in series rather than in parallel (as
in pressure overload scenarios) so that CM lengthen. The aggregate of this lengthening is
an increasing ventricular radius, which circles back to create the original problem of
reduced preload.
Initially, this hypertrophic response is effective in maintaining cardiac output, but
the long term effects are deleterious. Since these cells are surrounded by an extracellular
matrix (ECM) of collagen, there is an attendant increase in the synthesis of fibrous ECM
components to support the hypertrophic cells.[7,

8]

This fibrosis leads to decreased

compliance, poor diastolic filling, and chronic excessive wall stress. There is also evidence
that chronic hypertrophy involves shedding of integrins–the transmembrane proteins
responsible for myocyte-ECM adhesion—into the adjacent ECM, potentially causing
disordered mechanotransduction and diminsished transfer of myocyte contraction force to
the ECM.[9] Additionally, activation of matrix metalloproteases (MMP) under chronic
volume overload can lead to degradation of the collagen network (the perimysium) and
cause increased elasticity and muscle fiber slippage.[10] A possible manifestation of this
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slippage is the expansion of the ventricle and thinning of the ventricular wall, which leads
to global enlargement of the heart, weakening of the ventricular walls, and dangerously
reduced cardiac output.[11] Together, these constitute the hallmark symptoms of dilated
cardiomyopathy (DCM) and congestive heart failure (CHF), a fatal condition which can
result in the years immediately following an MI, especially if the infarct is left untreated
beyond reperfusion.[7, 12]
The hearts of patients with CHF consistently display such characteristic ventricular
wall distension and aneurysmal dilation, which result in the development of widespread
edema (including pulmonary edema) and severe exercise intolerance. CHF is the final
stage of a degenerative cascade of events which begins with MI and the scar tissue it
produces.[7, 12] Therapies which seek to halt progression toward CHF must necessarily
target the prevention of infarct scar formation or its replacement with functional
myocardium.

1.2 Treatment:
1.2.1 Clinical Therapeutic Options:
Orthotropic, or whole organ replacement, is currently the only curative therapy for
myocardial damage, namely prevention of left ventricular dysfunction and remodeling,
CHF or subsequent MI.[13, 14] Transplantation is limited by a severe shortage of donor
hearts, as fewer than 2,500 transplant procedures are performed annually, and over 3,000
patients perennially remain on the waiting list.[15, 16] The unmet need is not fully conveyed
by these figures, however, if one considers the annual number of patients who suffer a first
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MI (roughly 600,000).[17] This would seem to suggest the existence of a vastly underserved
population of patients who could benefit from transplantation, but are either ineligible, or
deem it futile to request a place on the waiting list.
The inflammatory response following MI occurs rapidly. It is estimated that
necrosis of CM begins 20-30 minutes after the initial blockage of the coronary
vasculature.[2] The current gold standard in clinical care post-MI is percutaneous coronary
intervention (PCI), a transcatheter procedure wherein an angioplasty balloon is used to
dilate the vessel lumen immediately adjacent to the site of thrombotic occlusion, thus
restoring flow to the downstream tissues.[18]

One complication limiting the efficacy of

PCI is ischemia-reperfusion injury, an inflammatory condition created by sudden reversal
of a hypoxic state wherein microvascular endothelial cells become activated and produce
reactive oxygen species. Currently, chest pain centers and cardiac care units have set a
benchmark door-to-balloon time (elapsed time between patient admission to completion of
PCI) of 90 minutes in order to limit the extent of damage produced by MI.[19, 20] While
minimizing door-to-balloon time has shown a direct correlation with reduced infarct scar
size, it is difficult to imagine achieving reperfusion of the ischemic tissue before CM
necrosis sets in. This means patients are inevitably faced with the development of an infarct
scar and its complications unless response and transport times dramatically increase or an
at-hand/pre-hospital admission treatment is developed.[21]
An alternative to PCI is CABG, a surgical procedure which involves using an
autograft (either a length of the saphenous vein or mammary artery) to reroute blood flow
around the thrombus (thus, bypassing it) that blocks the coronary circulation and restoring

6

blood supply to the ischemic myocardium (Figure 1.2). CABG is used frequently in an
interventionary capacity among patients with angina caused by coronary artery disease. It
can be indicated as a treatment for aborting and mitigating damaged caused by MI, but is
associated with increased morbidity (i.e. stroke, brain dysfunction) as the immediacy of its
performance following MI increases (although this correlation could be derived from
general instability of the patient prior to surgery).[22, 23] The overall efficacy of CABG as
assessed by long-term (10 year) mortality rate is favorable, with rates of only 26 – 32%
reported in several clinical trial.[22-25] PCI, including percutaneous translumenal coronary
angioplasty (PTCA) performed with either balloons or stents is associated with slightly
higher mortality rate, but presents a less invasive alternative with comparable relief of
symptoms.[26, 27]

Figure 1.2: Graphic illustration showing the points of anastomosis (attachment) of the vascular graft in
coronary artery bypass grafting surgery (CABG).

The therapies discussed above are only marginally effective in limiting the size of
the infarct scar, and focus solely on myocardial revascularization. By the time these
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treatments are implemented, they are not completely preventive in regards to scar
formation and thus do not avert the greatest threat that MI presents to patients – the
pathological progression towards CHF. These shortcomings in treatment of MI-induced
damage have prompted the development of surgical EHThniques aimed at restoring
ventricular function subsequent to remodeling and onset of DCM.
The first such attempt was the ill-fated construction of a muscular sling using the
latissimus dorsi muscle in hopes that its contraction would augment that of the
dysfunctional left ventricle in heart failure patients.[28] Another approach hypothesized that
reducing the size of dilated LV would somewhat restore cardiac efficiency by increasing
ejection fraction and stroke volume. This is known by several names: endoventricular
circular patch plasty (EVCPP), surgical ventricular reconstruction, or the Dor procedure
(after the surgeon who pioneered the EHThnique).[29] The procedure entails incising the
aneurysmal area, which is coincident with the area of the infarct scar, and threading a pursestring suture at the peri-infarct border along the endocardial wall. The circular suture
pattern is then tightened, effectively reigning in the aneurysm and reducing the chamber
diameter.[29]

EVCPP is typically performed simultaneously with CABG, and a recent

clinical trial was conducted to elucidate the added benefit, if any, of performing EVCPP
with CABG. Upon completion of the Surgical Treatment for Ischemic Heart Failure
(STITCH) trial, Jones et al. concluded that EVCPP did significantly reduce end-systolic
volume, but this effect was not associated with a decrease in the frequency of postoperative hospitalization or death from cardiac causes (the primary endpoint of the trial)
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when compared to CABG performed alone.[30] These results suggest that EVCPP is
ineffective as a treatment for DCM and in forestalling development of CHF.
A final approach to treatment of MI complications, specifically CHF, is the use of
left-ventricular assist devices (LVAD). LVADs are implantable medical devices which
mechanically pump blood from the left ventricle into the aorta, essentially replacing the
muscular function of the ventricle with an artificial pump. Originally developed as a
bridge-to-transplant therapy for end-stage heart failure patients on the transplant waiting
list, they were ultimately explored as a destination therapy for transplant-ineligible heart
failure patients.[31]

The Randomized Evaluation of Mechanical Assistance for the

Treatment of Congestive Heart Failure (REMATCH) trial of 2001 placed 129 end-stage
(New York Heart Association class IV) heart failure patients into either an optimum
medical management group or an LVAD-treated group. Results demonstrated a 48%
decrease in mortality among the LVAD-group when compared with the medical
management group. One and two year survival rates were 52% and 23%, respectively, in
the device group.[31] Despite this high mortality rate, it must be noted that these patients
were in an advanced stage of deterioration, and if the devices could drastically increase
survival at such a point, their beneficial effects might be significantly enhanced if
implanted in patients with less advanced heart failure.

The potential of LVADs is

tempered by concerns of hemocompatibility, infection, and durability, and both the
cumbersome nature of the devices and daily attention required for their operation still
represent limitations to quality of life.[31, 32]
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1.2.2 Experimental Clinical Techniques:
When it is understood that the key to limiting the impact of MI lies in restoring the
lost functionality of necrotic myocardium, the goal then becomes to replace the resultant
fibrous infarct scar with functional tissue.
The marriage of advancements in the fields of stem cell biology and percutaneous
(catheter-based) device engineering have made it possible to imagine that pluri- or
multipotent stem cells could be transplanted into infarcted myocardium in order to facilitate
a regenerative response within the scar tissue.

This approach, termed cellular

cardiomyoplasty, uses in situ injection of autologous and potentially therapeutic cells
through intracoronary or endoventricular catheter introduction (Figure 1.3).[33] A litany of
stem and progenitor cells have been proposed for use with this method, including skeletal
myoblasts, bone marrow stem cells, peripheral blood stem cells, vascular endothelial cells,
mesenchymal stem cells (MSC), adipose-derived stem cells (ADSC), umbilical cord cells,
induced pluripotent stem cells (IPSCs), endothelial progenitor cells, cardiac stem cells, and
embryonic stem cells (ESC).[34, 35] For a more in-depth discussion and analysis of studies
and clinical trials involving cellular cardiomyoplasty performed using these various cell
types, the reader is referred to several comprehensive reviews of the subject.[35-38] The
therapeutic goals and potential effects associated with this method, as outlined by
Chachques, et al. are to reduce the size of infarct scars, improve myocardial viability, limit
global ventricular dilation, improve ventricular wall compliance and diastolic function, and
provide advantageous paracrine effects.[34]
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Figure 1.3: Graphical representation of the various methods used to deliver potentially therapeutic cells via
cellular cardiomyoplasty. Intramyocardial, transendocardial, intravenous, and intracoronary routes of
administration are shown.

Despite indications of success in several clinical trials,[35] controversy lingers over
the precise mechanisms of action, most appropriate cell sources, and timing of cell
transplantation following MI. Furthermore, apparent limitations with transplanted cells,
such as cell “regurgitation” from the injection site, poor cell engraftment and integration
with host tissue, extensive apoptosis, and absent or limited differentiation into desired cell
types, must be addressed.[14, 34, 39, 40] One critical factor in the success of in situ cellular
cardiomyoplasty is the inhospitable microenvironment into which these cells are
implanted. Depending upon the timing of the procedure, the cells are either thrust into a
strong, local inflammatory response capable of inducing apoptosis (early post-MI) or into
a poorly vascularized and dense matrix of collagen (late post-MI). It would be perhaps
overly optimistic to expect a high rate of cell attachment and viability in these
environments, much less proper signaling, integration, or differentiation.[39] Intracoronary
or intramyocardial injection of stem cells is thus clearly limited by the lack of a stable cell
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delivery method, and so in situ cellular cardiomyoplasty, at least at the moment, does not
“stick”

1.2.3 Rationale for Tissue Engineering:
Just as it has in many pathologies where organ transplant is considered the gold
standard in clinical practice, tissue engineering has gained popularity as a potential therapy
for regenerating functional myocardium. The strategy of combining cells, engineered
matrices (or scaffolds), and growth factors in order to produce an implantable graft presents
clinicians with a much needed alternative to using donor organs or autografts in the
treatment of such conditions, mainly to better serve demand for organ or tissue
replacement.
Tissue engineering is a relatively young field, and myocardial tissue engineering is
younger still. As such, implantation studies of EHT are limited. The first ever clinical trial
(MAGNUM-trial) involving an EHT construct was begun in 2003, and used autologous
bone marrow cells (BMC) seeded onto a 3-D collagen type I scaffold.[41] The construct
was implanted over the epicardial surface of the post-infarct scar in a group of 10 patients
while they were undergoing CABG. Follow-up at 10 months indicated prevention of
cardiac remodeling and thickening of the scar (via cell ingrowth) with functional, healthy
tissue. There were no indications of immune or inflammatory reactions, no arrhythmias,
and the EHT appeared to integrate well with the host tissue.[41]
It is important to note that this particular EHT construct was not intended to be
functional, meaning it was neither contractile nor vascularized.[42] Its mechanism of action
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was one of providing “passive” support, and the collagen matrix most likely acted as a
stable microenvironment from which the BMC could secrete paracrine signals to the
healthy cells in the peri-infarct tissue. Regardless of the mechanism at work in this graft,
its success demonstrates the need for a scaffold in which to house transplanted cells and
offers a possible explanation for the shortcomings of cellular cardiomyoplasty. In addition,
it highlights the need for tissue engineering approaches in order to successfully replace
infarct scar and regenerate functional myocardium.

1.3 Design Requirements for Engineered Heart Tissue:
Desired characteristics of an engineered heart tissue (EHT) grafts are the
attenuation of ventricular wall remodeling or dilation, development of systolic force,
possession of sufficient compliance to withstand diastolic loading, electrical coupling of
the CM in the graft with those of the host, and the avoidance of arrhythmias, inflammation,
encapsulation, or calcification.[39, 42, 43]
If biomimicry, “remuscularization” (or restored functionality), and full replacement
of a transmural (spanning the full thickness of the ventricular wall) infarct scar are assumed
to be the goals of a particular EHT strategy, an attempt must be made to reproduce
characteristics of the native myocardium as closely as possible. In addition, the full or
partial resection of the infarct scar may be necessary for full integration and improvement
in function of infarcted hearts.[42, 44]
The average thickness of the ventricular wall is 1.5 cm, and the cell density of native
myocardium is estimated at 2 x 108 cells/cm3.[45] In the ventricles, this figure encompasses
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4 predominant cell types, each with their own specific function, and organized in such a
way as to provide the optimum function of the tissue.[39, 45] These cell types (CM, cardiac
fibroblasts (CF), vascular smooth muscle cells (VSMC), and endothelial cells (EC)) appear
in defined and consistent ratios within healthy myocardium.[46]

In addition, the

myocardium is very metabolically demanding, and is thus highly vascularized with an
estimated capillary density of 2,500 capillaries/mm2.[47] This latter point illustrates the
need for an EHT graft which is highly vascularized, as the function and survival of a graft
with poor blood supply could be limited.
The ECM of the myocardium is also of great importance, as it largely influences
the orientation of the cells, the extent of their electrical coupling, and the mechanical
properties of the tissue.[46] Developing a scaffold with both porosity and mechanical
properties comparable to native ECM is a significant challenge.
An aspect often overlooked in tissue engineering efforts, the method of surgical
implantation used in delivering EHT grafts, could be a major determinant of both their
success and feasibility. The current trend in implant delivery is toward trans-catheter
EHThniques, which are minimally invasive and thus reduce the risk of surgical
complications.[48] Since these advantages appeal to surgeons, the question then becomes
one of how to design an EHT graft which is compatible with trans-catheter delivery.
Each of these design considerations impose their own particular range of caveats
and limitations upon the potential success of a given approach to generating EHT. These
limitations will be discussed in detail in subsequent sections of this review.
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1.4 Current Strategies for Producing Engineered Heart Tissue:
Despite its short lifetime, tissue engineering and the application of its principles to
the treatment of post-MI damage and CHF have generated great interest. An assortment
of innovative tissue engineering strategies have been developed by a wide range of research
groups.[39, 40, 42, 43] These strategies include (a) the classical approach of using a synthetic
biomaterial to generate a scaffold which is then functionalized via repopulation with
appropriate cell types; (b) the same approach used above, with the exception that the
synthetic biomaterial is substituted for natural materials in creating the scaffold; (c) again,
the same approach as above, but using a combination synthetic and natural biomaterial
scaffold instead; (d) and an approach of constructing “scaffold free” cell sheets, or stacked
monolayers of cells (Figure 1.4).

Figure 1.4: Various concepts in generating engineered heart tissue (EHT): (I) natural or synthetic material
for cell repopulation; (II) cells seeded on soluble collagen and extracellular matrix (ECM) proteins; (III)
assembly of cell monolayer "sandwiches."
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1.4.1 Synthetic Biomaterials:
Synthetic biomatrices have been created using polymers with established properties
of biocompatibility and biodegradability, such as polylactic acid (PLA), poylglycolic acid
(PGA), and formulations of their copolymer, polylactic-co-glycolic acid (PLGA).[39, 42, 43]
In addition, other elastomeric polymers, including polycaprolactone (PCL), poly(glycerolsebacate) (PGS), poly(trimethylene carbonate-co-lactide) (PTMCLA), and polyurethane
(PU), have been employed to fabricate scaffolds for EHT.[39]
A variety of different materials processing approaches have been implemented to
create scaffolds with defined structures similar to the native ECM. This control over the
geometrical and chemical characteristics of scaffolds is an advantage inherent to the use of
synthetic materials. Scaffolds with defined porosity, alignment, and surface chemistry can
be generated through such methods as salt (particulate) leaching, laser sintering, and
electrospinning.[39, 43, 49]
Lesman et al. seeded highly porous PLA/PLGA grafts generated via particulate
leaching with a combination of human embryonic stem cell-derived CM, human umbilical
vein EC, and human embryonic fibroblasts which were subsequently implanted into a nude
rat model for 2 weeks.

The grafts appeared to successfully attach to the recipient

myocardium and showed evidence of neovasculature formation. Some grafts, however,
were encapsulated by fibrous tissue, indicating poor integration with the host tissue.[49]
In another study, Ke et al. implanted a PGA patch seeded with undifferentiated
mouse ESC into a rat model of MI. After evaluation of cardiac function at 8 weeks
following implantation, nearly twice the number of animals in the group which received
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the graft survived in comparison with the sham control group.[50] Similarly, BMC-seeded
PCL patches were applied to the infarcted hearts of rats, and the authors reported a
reduction in left ventricular remodeling, preservation of left ventricular systolic function,
and deEHTtion of myosin heavy chain proteins.[51] The latter seem to indicate possible
transdifferentiation of BMC into cardiac cell types.

Lack of ability to induce the

differentiation of stem cells grown on polymer grafts has been cited in the criticism of such
grafts.[42]
Owing to its elastomeric characteristics, PGS has been investigated as potential
scaffolding by several groups.[5, 52-54] Its versatility and ability to be machined into precise,
repeatable accordion like structures provided it with anisotropic mechanical properties
similar to those of the right ventricular myocardium.[55] It was reported to induce cell
alignment[54, 55] and to support the viability and vascularization of a cell-seeded scaffold
when implanted in a rat infarct model [52]. When it was compared via an implantation
study to scaffolds composed of either poly(ethylene terephthalate)/dimer fatty acid (PED)
and PED reinforced with titanium oxide (PED-TiO2), the PGS scaffold adhered to the host
myocardium while undergoing degradation. The PED did not remain attached to the host
tissue, and the PED-TiO2 contributed to increased chamber dilation and infarct scar size.[5]
Thus, the application of PGS and similar thermoplastic elastomers cast doubt on the
contention that synthetic materials cannot adequately reproduce the physiological
mechanical properties of the myocardium.[42]
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1.4.2 Natural Biomaterials:
The use of naturally occurring materials to generate scaffolds for EHT has involved
collagen, collagen gels (e.g. Matrigel), GAGs, fibrin, hyaluronic acid, and alginate.[39]
Collagen is the most widely used natural material in efforts to produce EHT, and can be
found in dry sheet, gel, or preserved in its native form as the predominant component of
the cardiac ECM.[7,

8, 39, 43]

Ergo, this section will focus predominantly on material

formulations which employ collagen as the main component. For a discussion of the other
materials mentioned above, the interested reader is directed to an extensive review of
materials, both natural and synthetic, with potential applications to myocardial tissue
engineering.[56]
The work of Zimmermann et al. over the last decade has focused on development
of an EHT construct using neonatal CM and an extracellular matrix consisting of collagen
type I and Matrigel. Implantation of this construct in an infarcted rat model has shown that
it is able to electrically couple with the host myocardium, contract for up to 8 weeks in
vivo, contribute to newly formed myocardium,

and that it is associated with wall

thickening in the infarcted area.[57, 58] One disadvantage to this approach is the use of
Matrigel, the safety of which is questionable since it is composed of ECM extracted from
mouse tumors.[59] The group addressed this issue with the claim that they had developed
both serum-free and Matrigel-free EHT constructs.[59]
Additional studies have confirmed beneficial results such as graft-host myocyte
electrical coupling, neovascularization or angiogenesis, and increased ventricular wall
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thickness in EHT grafts generated using collagen along with either neonatal rat CM, mouse
ESC, or bone marrow-derived MSC.[60-62]
A particularly unique method of generating a collagenous scaffold is that of
decellularization (DCELL), or the removal of all cell constituents and cell membrane
components which could be potentially immunogenic if implanted as an allo- or xenograft.
DCELL can employ one or both of two mechanisms, chemical and physical agitation, to
render a donor tissue completely free of epitopes which might trigger an immune response
from a graft recipient.[56] Following DCELL, the remaining tissue is composed of structural
ECM proteins (i.e. collagens, elastin, and GAGs). These proteins elicit little to no immune
response upon implantation due to the extensive evolutionary conservation of the genes
which code for them.[56] Notwithstanding the tremendous advantages offered by a scaffold
with physiologically accurate concentrations, distibutions, and organization of natural
ECM proteins, the option to create it from readily available xenogeneic tissue sources only
enhances the appeal of this method.[63, 64] Perhaps the most attractive feature of DCELL,
however, is the ability to preserve whole, intact vascular networks along with the native
ECM. This provides the means to perfuse the scaffold with media, and could even enable
direct surgical attachment of such a perfused graft to the host vasculature upon
implantation.[63, 64]
This method has been applied to tissue engineering efforts in regeneration or
replacement of the kidneys, esophagus, heart valves, urethra, bladder, skeletal muscle,
peripheral nerves, and, most recently, the myocardium.[63,

65-72]

Effective DCELL

procedures should not be so harsh that they nonspecifically degrade everything within the
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treated tissue. Rather, they must strive to remove all unwanted components, while leaving
the desired components unaltered in both conformation and quantity. For example, some
DCELL methods have used the action of enzymes to speed the process by catalyzing
protein cleavage.[73, 74] One such enzyme is the protease, trypsin, which readily degrades
elastin and fibrillin via cleavage of peptide bonds following positively charged amino acid
residues.[7, 75]
This type of nonspecific action can destroy components of the native ECM which
are actually important to maintain, especially if a subsequent attempt to repopulate a
DCELLed scaffold is to be carried out successfully. Such components include basal
laminar proteins and proteoglycans to which seeded cells would bind (e.g. collagen type
IV and laminin).[7, 76] Evaluation of several DCELL methods has shown they are effective
in accomplishing this goal, and seeded cells both adhere to and proliferate on the resulting
scaffolds.[63, 77] These studies provide proof of principle for the DCELL approach, and
their authors also suggest it can be used as a technique for whole organ replacement.[63, 72,
77]

However, due to the finite number of requisite cells which can be generated via in vitro

culture and differentiation of autologous stem cells, efforts to repopulate an entire
DCELLed organ (e.g. the heart) at the appropriate cell density are over-ambitious and
unlikely to succeed.[78] This approach becomes more feasible when applied to the
generation of smaller grafts, such as those of the dimensions needed for replacement of
infarct scars.
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1.4.3 Combination Biomaterials:
A few groups have sought to produce scaffolds which are composites of both
synthetic and natural materials in an attempt to pool their respective advantages. Stankus
et al. created electrospun scaffolds composed of type I collagen and poly(ester
urethane)urea, which they reported to improve cell adhesion despite having deficient
mechanical properties.[79] In a similar approach, neonatal CM seeded on collagen type Icoated, electrospun PCL nanofibers exhibited enhanced attachment. The cells integrated
into a nanofibrous mesh which could be stretched to provide a passive load and allow the
beating cells to contract at natural frequency. This represents an advantageous method for
mimicking the ECM and for providing mechanical stimuli.[80] Another group investigated
the in vitro performance of a dilinoleic acid (fatty acid dimer)-conjugated poly(ethylene
terephthalate) elastomer with mouse and human ESC-derived CM.

They reported

favorable results but have not generated any in vivo data up to this point.[81]
In yet another variation of this approach, Krupnick et al. delivered BMC to the
infarct scars of rat hearts after seeding the cells onto a non-woven PLA mesh reinforced
with poly(tetrafluoroethylene) (PTFE). The mesh was coated with the cells, which were
suspended in a mixture of Matrigel and collagen type I and IV before the addition of
collagenase and subsequent implantation. The grafts appeared to integrate well with the
host tissue, displaying no signs of arrhythmogenesis or inflammation and demonstrating
possible differentiation toward cardiac lineage by staining positive for myosin.[82]
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1.4.4 “Scaffold-Free” Cell Sheet Engineering:
This method for generating EHT was first conceived by Yamada et al. following
their development of temperature-responsive culture dishes composed of poly(Nisoproplyacrylamide) (PIPAAm). These unique culture surfaces alternate between being
hydrophobic and hydrophilic within a small range of temperatures (i.e. they are
hydrophobic at optimum culture conditions (37°C) and hydrophilic at room temperature (<
32°C)).[80] The researchers realized this afforded them the capability to grow entire
monolayers of cells and then readily detach them simply by altering the ambient
temperature of their PIPAAm culture vessels.[83] A critical advantage provided by this
method was the elimination of the need for proteases to detach cells from culture vessels,
thus sparing the cell-synthesized ECM from any alteration or degradation.
Okano et al. then expanded on this approach, growing monolayers of neonatal rat
CM and stacking them on each other to generate constructs of spontaneously aggregating
and beating CM in vitro.[39] The thickness of these constructs was limited to 3-6 layers, or
a thickness of about 100 µm, as a consequence of their lack of vascularization.[63] In an
attempt to overcome this problem, they devised a “polysurgery approach” wherein these
cell sheet stacks were successively implanted on top of one another through the
performance of recurrent surgical procedures.

Each individual thin stack became

vascularized prior to implantation of the next thin stack, producing a thicker tissue
construct.[83, 84]
Other cell types besides CM have been employed with this method. In particular,
cell sheets consisting of undifferentiated ADSC were implanted into a sub-acute rat model
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of infarct. Upon explantation, these constructs contained differentiated CM and newly
formed blood vessels.

They also appeared to limit the extent of ventricular wall

distension.[85] The major disadvantage of this approach is the limited ability to induce
vascularization within the constructs in vitro. Lack of blood supply restricts the thickness
of the constructs to the maximal diffusion range of oxygen and other nutrients within tissue,
a distance estimated to be about 200 µm.[63] Consequently, limited thickness translates to
extremely low mechanical properties and the creation of constructs which are not easy to
handle or implant without fear of ripping them apart.[39, 42]
These disadvantages were addressed by first attempting to reinforce the constructs
with layers of collagen gel. This resulted in improved cardiac function and integration with
the host myocardium, but it must be noted that collagen gel is not ideal for this application
since it has a lower modulus and greater compliance than other forms of collagen.[39, 86] In
a more direct approach to the problem, Murry et al. employed coculture of CM, fibroblasts,
and EC to generate prevascularized cardiac patches which could actively contract and
electrically pace. More importantly, the prevascularized patches demonstrated 10-fold
greater cell engraftment upon implantation than did patches comprised of CM alone.[87]

1.5 Limitations, Challenges, and Barriers in Myocardial Tissue Engineering:
1.5.1 Effects of Scaffold on Engineered Heart Tissue Viability and Function:
A major determinant of success in producing EHT is the ability to seed appropriate
cell types onto a scaffold and subsequently maintain their viability, promote their
integration with host tissue, and, ideally, induce their proliferation. To that end, the logical
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place to begin improving EHT design efforts lies in optimizing the scaffold for cell
attachment.[7, 46, 56] Matching the characteristics of native ECM, rather than native tissue,
is the desired outcome in those EHT strategies which attempt to repopulate a scaffold with
relevant cell types. The rationale for this is that cells will respond favorably (i.e. attach
and assume normal morphology) to a scaffold which bares similarities to the structure
which they naturally bind–the ECM.[7]
Mimicking the ECM requires that native proteins and ground substance, or
elements which mimic both their structure and surface chemistry/bioactivity, are present
within the scaffold. Reproducing native ECM structure (i.e. porosity, composition, and
interconnection of the individual constituents) is of great importance, since it will align the
mechanical properties of the scaffold with those of the physiological ECM.[7, 46, 56] Given
that the ECM’s role in relaying external mechanical stimuli to cells has been well
established, creating a scaffold with similar mechanical properties ensures that seeded cells
are relayed the same mechanical signals as they would be if they were residing within
healthy myocardium. Via the process of mechano-transduction, these mechanical signals
are translated into chemical signals which mediate intracellular pathways, and are capable
of producing changes in levels of gene expression.[46, 56] Collectively, this process has an
immense impact upon cell fate (i.e. differentiation and morphology) and survival[88]
(Figure 1.5). Furthermore, recent findings have suggested that the ECM is significantly
involved with conduction of the electrical signals responsible for synchronous contraction
of the myocardium.[89, 90]
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Figure 1.5: A diagram of the potential influences the extracellular matrix (ECM) can exert on cells.
Interaction of cells with the ECM can induce apoptosis, migration, and/or differentiation.

Matrix

characteristics such as porosity, archiEHTture, compliance, and sufrace chemistry mediate these influences.

Having outlined the cell-ECM relationship, some regard must be given to the
connections that make the cell-ECM interface possible. In the myocardium, CM attach to
the ECM through integrins and a specific protein complex, which bind laminin and
perlecan (constituents of the basal lamina), respectively.[91] Thus, when attempting to
create a scaffold which is conducive to cell attachment, it is necessary to consider
incorporating these macromolecules, or functional substitutes thereof, within the material.
Results from a recent study, however, indicate that functional analogs of ECM proteins,
such as RGD, performed poorly in inducing CM attachment when compared to the holoprotein (i.e. laminin or collagen type I).[92]
The difficulty of the scaffold creation process is only compounded when the aim of
repopulating it with cells is considered, as their addition will undoubtedly lead to changes
in the properties of the resulting EHT graft. Assuming repopulation is successful, the
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concern then becomes the graft’s ability to match the mechanical properties (Young’s
modulus between 0.2 – 0.5 kPa) of the healthy host tissue upon implantation.[43] Matching
the mechanical properties of the host tissue should be conducive to receipt of the proper
signals by the cells in the graft, and result in its successful integration. If, however, there
is compliance mismatch between the graft and the host tissue, micromotion-induced
encapsulation will occur, and the graft will fail.[5]

1.5.2 Vascularization and Growth Promoting Factors:
The success of an EHT graft is critically dependent upon the extent to which it is
vascularized. Cells, particularly CM, cannot survive without access to nutrients or a
mechanism to eliminate wastes and accomplish gas exchange.[2] As mentioned previously,
the dimensions of EHT constructs without a preformed and functional vascular network
are limited to the observed diffusional range of solutes and gasses in vivo – about 200
µm.[63] In order to produce grafts with the larger dimensions necessary for replacing an
infarct scar, strategies to overcome this limitation must be developed. The creation of a
vascular network within EHT constructs must provide the means to nurture the cells in
both the in vitro and in vivo environments. Methods for accomplishing this include the use
of continuously perfusable vascular channels, or even blood vessels, to introduce culture
media (in vitro) and blood (in vivo) into the EHT construct.[63, 93] These same channels
could then be surgically anastomosed to the host vasculature upon implantation, providing
a means of direct perfusion of the graft for enhanced integration, function, and survival.[64,
70]
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Other modes of EHT graft vascularization could involve direct incorporation of
vascular endothelial growth factor (VEGF) into the scaffold to induce angiogenesis and
neovascularization by either or both of host and graft EC. In conjunction with this,
endothelial progenitor cells (EPC) might be seeded on the graft in hopes that they will also
participate in the neovascularization process by differentiating into EC, recruiting other
stem/progenitor cells, or secreting angiogenic paracrine signals.[78]

1.5.3 Cell Sourcing and Expansion:
For EHT grafts to avoid immune rejection, the cell types incorporated in them must
necessarily be autologous. Thus, in a clinical scenario employing EHT as the therapy, the
cells used to generate the EHT graft will be the patient’s own cells.[42, 78] The possibility
of simply using terminally differentiated CM from myocardial biopsies is precluded by the
fact that these cells are essentially senescent, and display little potential for division or
turnover beyond birth.[43,

78, 88]

The focus then shifts to identifying suitable stem or

progenitor cell sources which can differentiate into the necessary cell types (CM, EC, and
VSMC; adult CF are sufficiently proliferative and can be readily harvested). Furthermore,
generating grafts of clinically relevant size will require significant populations of
phenotypically pure cells to be grown in vitro, which will be difficult to achieve using
clonal expansion culture techniques.[78]

At the very least, this will pose additional

challenges by increasing the lead time for producing EHT, as well as costs.
An extensive discussion of pertinent cell sources will not be presented here, but can
be found in several reviews.[39, 42] Briefly, ESC have been investigated for use in tissue

27

engineered grafts and EHT. ESC are extremely advantageous in that they can differentiate
into any cell type in the body, although effectively directing their differentiation, especially
toward cardiac lineages, can be difficult.[42] That aside, use of ESC in research that has
clinical applications as its endpoint is irresponsible and shows lack of forethought. ESC
can be immunologically rejected, are perpetually mired in ethical debates over the origin
of their cell lines, and the Food and Drug Administration (FDA) is unlikely to approve their
use due to concerns over their ability to form teratomas.[94] More practical sources of
pluripotent autologous stem cells include ADSC, MSC, EPC, and BMC. Several groups
have published in vitro culture methods for directing these cell types toward CM and EC
phenotypes, as well as methods for increasing proliferation and expansion toward the goal
of producing necessary cell numbers for EHT graft seeding.[95-98]

1.5.4 Bioreactors for Seeding and Preconditioning:
Since 3-D tissue constructs have so many unique properties that 2-D monolayer
cultures lack, they demand a unique form of cell culture. In the case of EHT grafts, the
goal of culture is to produce functional myocardial constructs by imparting them with
characteristics specific to myocardium, namely electrophysiological and mechanical
properties.[42]

The ideal system for accomplishing this goal is a bioreactor that is

specifically tailored to simulate the physiological environment and stimuli experienced by
native myocardium.[93, 99]
Typically, a bioreactor serves several purposes, including the facilitation of uniform
seeding of a scaffold via dynamic seeding conditions (i.e. perfusion and gentle, cyclical
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stretch/compression); the enhancement of diffusion of gasses, solvents, and mass transfer,
in general; simulation of physiological stimuli and external forces (e.g. fluid flow, shear
stress, compression and tension, blood pressure, and electrical impulses; and maintenance
of conditions to replicate the in vivo environment, such as temperature, pH, electrolyte, ion,
and metabolite concentrations, and oxygen content.[99]
There is a great deal of evidence to indicate that dynamic seeding, as well as
sustained dynamic culture conditions, can aid in producing EHT grafts with a high cell
density and enhanced cell survival. The use of perfusion, however, seems to be the
consensus method for achieving the best results, as illustrated by the findings of Radisic et
al. that use of a perfusion bioreactor increased cell density of EHT grafts to near
physiological cell density, allowed for the generation of thicker (~ 5 mm) grafts, and
facilitated mass transfer.[93, 100]
If a bioreactor is rationalized from a purely engineering design standpoint, it would
be described as a system with both inputs and outputs. In this case, the desired output is
the production of a functional myocardial tissue substitute with CM that are electrically
connected, conduct impulses, and respond to these impulses by producing a certain systolic
force.[101] With this constraint established, the task of the bioengineer then becomes to
identify the most appropriate inputs which will produce the desired output. These inputs
are the stimuli applied to the EHT construct within the bioreactor, and should strive to not
only approximate, but exceed, physiological levels. In this way, a factor of safety is built
into the EHT graft, and it should theoretically be able to handle the most elevated
conditions of heart rate, blood pressure, and external stresses which could conceivably
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occur in vivo. Examples of such exaggerated conditions might be a pulsatile flow rate
which mimics a heart rate of 200 bpm or a media inlet pressure of 200 mmHg. The same
principle should be applied to the repetitive electrical impulses and cyclical tensile
stretching or compression that the graft is exposed to in order to precondition, or “train”, it
to become a functional graft of cardiac muscle. The next section of this review will focus
on the mechanics of myocardium on both the cellular and tissue level to further expound
on the role of dynamic stimuli in myocardial tissue engineering strategies.

1.5.5 Applications of Cardiomyocyte and Myocardial Extracellular Matrix Mechanics:
The state of the art in tissue engineering assumes the premise of biomimicry, or the
ability of an engineered tissue construct to mimic the tissue which it is intended to replace,
as central to its overriding goal: the replacement or regeneration of diseased or
dysfunctional tissues.[102,

103]

This mandates that EHT not only appear analogous to

healthy, native tissue, but also replicate the function of this tissue. There are many specific
tissue types for which tissue-engineering therapies hold promise, but the development of
some present a considerably more difficult challenge than others. Mimicking the structure
and function of bone or skin, for example, is less daunting than the prospect of recreating
muscle and nervous tissue.[102, 103] Simply put, as the complexity of the tissue (in terms of
structure and function) increases, the difficulty of reengineering it follows suit.
One aspect of particular importance in determining how closely EHT mimics its
target tissue is mechanics. A thorough characterization of EHT must be performed in order
to determine its intrinsic mechanical properties, which may then be compared to those of
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the native tissue as a means to predict EHT’s ability to perform the mechanical function of
its analogue.[74] As is evident from the development of the biphasic and multiphasic
theories, these mechanical properties cannot be fully described without a prior
understanding of the tissue architecture, its components (i.e. cells, extracellular matrix, and
interstitial fluid), and their respective contributions to the overall mechanism(s) underlying
the mechanical behavior of the tissue.[104]
This divergent approach to analyzing tissue mechanics may prove particularly
useful in the development of tissue-engineered myocardium. Myocardium, or cardiac
muscle, is unique among tissues in that it plays an active mechanical role, synchronously
contracting to pump blood into both the pulmonary and arterial circulation.[78, 103] Like
other types of muscle, it stands apart because it is motile and active, performing actual
mechanical work as opposed to providing passive support or facilitating transfer of
mechanical forces (e.g. bone, membranes, cartilage, ligaments, tendons).[105]

The

component which imparts it with this dynamic character are the cardiac myocytes (CM),
which collectively shorten (contract) to “pull” on their collagenous extracellular matrix
(ECM) and compress their respective chamber walls, reducing the chamber volume (thus,
increasing chamber pressure) and forcing blood out.[105, 106]
Since CMs play such an important role in the function of myocardium, it is
desirable to develop a working knowledge of their mechanical behavior and characteristics,
especially if the aim is to reproduce myocardial tissue. Study of their cytoskeleton,
intercellular junctions, extracellular matrix linkages and the interaction of these various
mechanical components is warranted to gain a holistic understanding of the biomechanics
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of myocardium.

These investigations could also aid in the completion of specific

milestones in developing engineered myocardium, namely the efficient in vitro culture and
differentiation of adult stem cells or cardiac progenitors into phenotypically accurate adult
CMs.

1.5.5.1 The Cardiomyocyte Cytoskeleton:
Owing to their highly sophisticated mechanical function, CMs have developed one
of the most intricate cytoskeletons found among all cell types. In addition to an abundance
of aligned actin and myosin filaments (the actinomyosin complex), the CM cytoskeleton
consists of titin and a network of microtubules.[107] The actinomyosin complex and titin
constitute the bulk of the structure known as the sarcomere, repetitive units of which make
up the length of myofilaments and occupy most of the cytoplasmic volume of the CM. The
combined action of sarcomeres is responsible for the macroscopic contraction of CMs.[106,
107]

Following stimulation by an influx of Ca+2 ions, sarcomeres shorten via the sliding

filament mechanism (modeled by cross-bridge theory), and return to their original length
upon cessation of contraction with help from the spring-like recoil of highly elastic titin
molecules.[104, 106, 107]
Microtubules emanate from the microtubule organizing center and extend to the
periphery of the middle portion of CMs. Consistent with the tensegrity hypothesis of
cellular mechanics, they may act to bear compressive loads by buckling and unbuckling
during CM contraction.[108-110] In addition, there is evidence indicating that they are
mechanically coupled to other elements of the cytoskeleton, helping to transduce both
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intra- and extracellular forces throughout the cell and drive the overall intracellular
response to loading.[107] Evidence in the literature increasingly suggests that cytoskeletal
proteins assume an invaluable role in mechanosensory and mechanotransduction, thus
mediating cellular responses in normal development and in pathophysiological conditions
(e.g.

dilated

and

ischemic

cardiomyopathy,

pressure

and

volume

overload

hypertrophy).[111-122]

1.5.5.2 Cytoskeletal-Extracellular Matrix Linkages:
As crucial as the mechanical components of the cytoskeleton are to the functional
role of CMs, the points where these elements attach and integrate with the ECM are critical
in determining how myocardial tissue, and the heart as a whole, function.[3, 7, 123] These
linkages ultimately mediate the transfer of external forces (e.g. blood pressure driven by
metabolic and physiological demand) imposed on the myocardium through the myocardial
ECM into the CMs. This pathway can also be reversed, as CM contraction imparts force
on the ECM via these same linkages, manifesting as the contraction that is the pumping
action of the heart.[3, 11]
These “linkages” are actually a complex of several cytosolic, transmembrane, and
extracellular proteins, and are localized to specific areas on the periphery of each CM,
known as costameres.[107] Costameres are found at Z-disks between sarcomeres, and
effectively form mechanical “tethers” which anchor the Z-discs to ECM proteins. These
tethers consist of a chain of proteins, beginning with talins, vinculins, dystrophins, and
syntrophins in the immediately submembranous cytosol connecting to transmembrane
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integrins and dystroglycan complexes, which, in turn, are bound to laminins of the
ECM.[107, 124] The tethers form a mechanical link between the actinomyosin complex and
fibrillar collagens (type IV and I), the primary load-bearing components of the CM
cytoskeleton and myocardial ECM, respectively.[3, 107] Although this chain contains many
links so as to make the connection seem almost indirect, it serves as the primary means of
relaying mechanical signals between the two components of the tissue.

1.5.5.3 Cell-Cell Linkages:
Individual myocytes can transmit mechanical energy to and from their surrounding
ECM, but it is the summation of this individual force over billions of myocytes which
accounts for the muscular beating of the heart. In addition to interacting with the ECM,
CMs accomplish this by working in concert with one another. They are connected at their
longitudinal borders (intercalated disks) by adherens junctions, or cadherin/catenin
complexes, which link the opposing ends of actin filaments.[107] As actin filaments from
opposing cells pull against each other, cadherins act as mechanosensors and reinforce the
junctions. This facilitates the bidirectional transfer of cytoskeletal tensile stress between
cells in a manner which compounds the forces generated by sarcomeric shortening in
individual myocytes.[107]
In both this section and the previous section, linkages in the directions of both the
minor and major axes of the CM were discussed. Taken together, these linkages allows
the CM to sense and transmit mechanical stimuli with directional specificity.[107] This
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property means that CMs can integrate this information and act on it in a way which gives
the most desirable biological response to changes in their mechanical environment.

1.5.5.4 Using Models to Define Effective Mechanical Stimuli in Cell Differentiation:
Gaining an understanding of intra- and intercellular mechanics of the CM, as well
as the mechanics of CMs’ interactions with their surrounding ECM, is important in
studying pathophysiological and pathological conditions of the myocardium. Since it has
been well established that CMs and their ECM interact through the phenomenon of
mechanotransduction, and that this process elicits a biological response from the CMs, it
is of interest to be able to predict the nature and extent of this response to a given
mechanical stimulus.[107, 123] This is accomplished through the application of mathematical
models which accurately characterize the constituents of the tissue, and, given a
mathematically defined set of inputs, can output a prediction of how the tissue will respond.
Within the field of myocardial tissue engineering, for example, the goal is to
develop an EHT construct with the ability to generate systolic force and use it to effectively
replace the lost functionality of diseased myocardium. A critical component of such EHT
is donor-immunocompatible cells, specifically CMs.

Considering the criteria of

immunocompatibility and physiological cell density (2 x 108 cells/cm3), the possibility of
using allo- or xenogeneic cells is precluded, and a large number of CMs is necessary in
order to properly populate EHT.[40, 41, 45] Consequently, the cell source of choice becomes
an adult stem or progenitor cell population with cardiac lineage potential, and the approach
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becomes to culture, maximize proliferation, and differentiate these cells into a population
with high phenotypic similarity to human adult CMs.[41]
The current body of work suggests that directed differentiation of these cells into
CM requires the application of a mechanical stimulus to the cells in culture. Groups have
shown that periods of both static and dynamic stretch of monolayer and 3D in vitro cultures
induce changes in CM and stem cells, alike.[125-128] The question, then, is no longer: do
stem cells respond to mechanical stimulation by exhibiting evidence of differentiation
toward a cardiac phenotype, but becomes: what specific mechanical stimuli, delivered in
what specific way, will result in the generation an accurate adult CM phenotype from
cardiac precursors?
This begs a host of other questions about how forces imparted upon a culture
substrate are transmitted to the cells being cultured on the substrate: How much of the
original mechanical stimulus is transmitted to the cell (i.e. is it degraded, amplified, or
altered)? How does it propagate through the cell, and what type of force (i.e. compression
or tension, magnitude, frequency) corresponds with what biological response (i.e. are there
thresholds for a particular response)? The answers to such questions can only be arrived
at through the use of a model. To further complicate things, the nature of these questions
requires that the mechanical behavior of the cells and the mechanical behavior of the matrix
be separated, and that a model for each component be generated.[123]
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Several in vitro culture systems have been designed to expose cells within them to
mechanical stimuli of varying nature.[105, 125-128] These stimuli can come in the form of
uniaxial or biaxial strain, be either static or dynamic with disparate strain rates, strain
percentages, duration of strain, and frequencies. Cells can also be cultured on substrates
of either natural or synthetic materials with different stiffness, dimensionality (2D or 3D),
or degrees of anisotropy.[123, 129]
So the question remains, given the existing evidence in the field as it relates to
mechanical modeling of CM and myocardial ECM, which set of conditions will promote
the most successful differentiation of cardiac progenitors into a mature CM phenotype?
One must begin by defining the desired biological response and then must work backwards
to determine the appropriate mechanical inputs. The functions of key mediators in the
biological response to mechanotransduction, such as mechanoreceptors, signaling
molecules, and target effector proteins are involved in signaling pathways initiated by the
receipt of mechanical stimuli.[107] If thresholds can be determined for triggering the
initiating events in the pathways of choice, a model (e.g. the tensegrity model) can be used
to determine how stresses are transferred along cytoskeletal elements to specific organelles
or structures where pathway initiation occurs. Working back up the mechanical ladder, the
extracellular loads required to precipitate these intracellular stresses can be determined,
and the macroscopic loading of the EHT necessary for generation of these extracellular
loads can, in turn, be determined using a mechanical model of the ECM.
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1.5.6 Surgical Considerations:
With a lack of intrinsic regenerative capability in the myocardium, the MI-induced
necrotic core will be completely remodeled into fibrous tissue between 2-6 weeks postMI.[11, 39, 49] The timing of therapy delivery in infarct treatment is an important and, as yet,
unanswered question. A graft implanted in the acute phase could be sabatoged by the
hostile milieu of inflammatory cytokines associated with CM necrosis, while a graft
implanted in the chronic, post-scar formation phase could be impeded from integrating
with healthy tissue by the scar.[130] In order to implant a construct immediately after MI, it
would need to be ready before the event, in an “off the shelf” fashion. This possibility is
precluded by complications that arise due to the need for autologous cell sourcing and in
vitro cell proliferation, seeding, and preconditioning in a bioreactor. Such a process could
take several weeks, if not months, to complete and could not benefit the patient
immediately unless the MI was predicted.[39, 42, 43] Consequently, patients are typically
treated with PCI to abort MI and allowed to heal over the next 6 weeks before any surgical
intervention is considered.[18] While the infarct scar does form during this time, the extent
of remote fibrosis and global remodeling is usually minimal.[11, 18] The significance of this
treatment approach is that surgeons will be presented with a decision when implanting EHT
grafts: do they resect the infarct scar and then implant, or do they attach the graft directly
to either the endocardium or epicardium (depending on the surgical access used; see
discussion below)?
Whether or not grafting engineered heart tissue (EHT) directly to the fibrotic scar
inhibits proper adherence and perfusion of the graft with the host tissue through an

38

inflammatory response is unclear. A number of studies have reported positive outcomes
when implanting EHT on top of infarct scars created in animal models.[50, 51, 58] When EHT
constructs are not placed directly on the epicardium over the scar, but rather at the
endocardial surface (by means of EVCPP)[131] or in a depression made by resection of the
scar tissue, solid engraftment has been repeatedly achieved.[44, 82, 132] These opposing
implantation methods will need to be compared for efficacy by performing both with a
single type of EHT, then perhaps the difference, if one exists, can be elucidated.
An additional uncertainty that pertains to surgical methodology is the nature of the
surgical access used. Will EHT grafts be large and require attachment to the epicardium,
so as to demand a full sternotomy? Or will surgeons be able to insert a moderately sized
EHT graft through a relatively small intercostal opening? Better yet, what if there is the
possibility that an EHT graft might be small enough to be implanted percutaneously via
catheter? And finally, how will an anastomosis of the vessels used to perfuse potential
EHT grafts affect the choice of surgical approach?
In order to answer these questions, the first step which must be taken is determining
an estimate of the required size of an EHT graft. Given that a typical MI sufficient to cause
heart failure leads to the death of about 50 g of myocardium, it can be estimated that the
minimal dimensions required in an EHT graft for replacing a transmural infarct should be
approximately 2.6 cm x 2.6 cm x 1.5 cm for a square geometry or 2.9 cm (diameter) x 1.5
cm (height) for a cylindrical geometry.[39, 78, 133, 134] If attempting to adapt EHT grafts to a
catheter-based delivery, the access pathway of choice would be through the thoracic aorta
and the aortic valve into the left ventricle because this approach offers the largest
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anatomical dimensions (i.e. the largest vessel lumens). The largest catheter size approved
for use by the FDA in a translumenal aortic approach was 25 on the French scale, and the
particular application was aortic heart valve replacement.[135]

This catheter size

corresponds to a diameter of about 0.833 cm, which is much too small to accommodate a
graft of the aforementioned dimensions loaded in almost any imaginable configuration.
For EHT to one day be implemented using a trans-catheter approach, the graft dimensions
will need to be decreased, or a method must be devised to sufficiently compress a construct
containing live cells without damaging them. Until such time, it appears that the surgical
implantation method will be through some sort of “cut-down” access.[136]

1.5.7 Myocardial Tissue Engineering in the Diseased Patient:
The vast majority of patients who could benefit from a clinically feasible and costeffective EHT have some form of cardiovascular disease (CVD).[43]

In fact, CVD

encompasses high blood pressure (HBP), coronary heart disease (CHD) and its associated
complications (MI and angina pectoralis), CHF, and congenital cardiovascular defects.[17]
The American Heart Association estimates that approximately 90% of patients with CHD
have been exposed to at least one of the following risk factors: hypercholesterolemia,
hypertension, cigarette smoking and diabetes mellitus (DM). Data show that the incidence
of CVD in women with DM and a healthy weight was 54.8%, but rose to 78.8% among
obese women. Among diabetic men with a healthy weight, the prevalance of CVD was
78.6%, whereas it climbed to 86.9% among obese men.[17] Additionally, end-stage renal

40

disease and acute renal failure (ARF) are comorbidities of CVD. Of first-time diagnoses
of ARF, a combined 12.3% were associated with a hospitalization for either CHF or MI.[17]
These data serve to underscore the point that researchers developing EHT should
rid themselves of the illusion that potential candidates for their therapy will be a tabula rasa
of health. Rather, they should prepare EHT constructs to withstand a hostile, diseased
environment.

In the MAGNUM-trial discussed earlier, for example, 11 of the 20

participants were hypertensive, 13 were hypercholesterolemic, 7 were diabetic, and 10
were smokers.[41]
In terms of inflammatory processes, a few of the most threatening conditions to the
long-term viability of EHT are atherosclerosis, graft arterial disease (GAD), and
arteriolosclerosis. Atherosclerosis is the most well-known of these diseases, as it is
implicated in having a causal role in both CHD and peripheral artery disease. The
characteristic atheromas or lesions common to atherosclerosis present the potential for
tissue calcification.[1, 17, 137] GAD is distinguished from athero- and arteriosclerosis by
characteristic toto-circumferential intimal thickening, and has been observed to occur
predominantly in implanted allografts, which contain immunogenic cell constituents.[138]
EHT constructs, however, should ideally consist of nonimmunogenic ECM proteins seeded
with autologous cells, rendering them free from concerns about GAD or transplant
vasculopathy.[138]
Finally, arteriolosclerosis, or the thickening of the intimal layer in arterioles due to
hyperplasia or hyaline matrix deposition, could occur in EHT.[137] EHT grafts implanted
in hypertensive or diabetic patients would be at an increased risk of contracting
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arteriolosclerosis because of the causal role of both hypertension and diabetes in
development of arteriolosclerosis.[137]
Both atherosclerosis and arteriolosclerosis could have a major impact upon the
viability of EHT constructs, because such constructs will most likely contain a preformed
or preserved vascular network that will stenose or occlude if these diseases are present,
leading to ischemia and necrosis of the cells in the construct.

1.6 Summary and Conclusions:
It is difficult to make conjectures about the ultimate success or failure of EHT
constructs. Given the requirements placed upon them and the mechanisms or processes
that might be at work in vivo, producing an EHT construct that remains viable for some
time will be a challenging task. In the future, prevascularized scaffolds should be designed
which allow for perfusion seeding and culture in vitro, as well as the possibility of surgical
anastomosis at implantation for improved graft function and survival. Scaffolds should
possess a composition and architecture which mimic the native ECM in order to elicit
favorable host responses; facilitate cell attachment and infiltration; and to maintain desired
morphology, phenotype, and function. In designing EHT grafts and methods to produce
them, researchers should not lose sight of the limitations presented by the necessity of
autologous cell sourcing, and should investigate in vitro culture methods to optimize clonal
expansion of cell lines. Nor should they overlook the potential diseased and hostile
microenvironment that awaits their EHT graft when they are applying stimuli to
precondition their EHT constructs. Lastly, investigators should devote some thought to the
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surgical approaches for implantation of EHT and consider the desires of surgeons
themselves, as they will be the end-users of potential EHT grafts. If researchers working
to develop EHT can overcome the inherent challenges associated with it, they can alleviate
the devastation CVD causes so many patients and their families throughout the western
world.

1.7 References:
1.

2.
3.

4.
5.

6.
7.

8.

9.

10.
11.

Kovanen, P.T., Mast cells and degradation of pericellular and extracellular
matrices: potential contributions to erosion, rupture and intraplaque
haemorrhage of atherosclerotic plaques. Biochem Soc Trans, 2007. 35(Pt 5): p.
857-61.
Jowett, N., D. Thompson, and R. Boyle, Comprehensive Coronary Care. 2007:
Baillière Tindall/Elsevier.
Burlew, B.S. and K.T. Weber, Connective tissue and the heart. Functional
significance and regulatory mechanisms. Cardiology clinics, 2000. 18(3): p. 43542.
Sun, Y., Myocardial repair/remodelling following infarction: roles of local
factors. Cardiovascular research, 2009. 81(3): p. 482-90.
Stuckey, D.J., et al., Magnetic resonance imaging evaluation of remodeling by
cardiac elastomeric tissue scaffold biomaterials in a rat model of myocardial
infarction. Tissue engineering. Part A, 2010. 16(11): p. 3395-402.
Lorell, B.H. and B.A. Carabello, Left ventricular hypertrophy: pathogenesis,
detection, and prognosis. Circulation, 2000. 102(4): p. 470-9.
Graham, H.K., M. Horn, and A.W. Trafford, Extracellular matrix profiles in the
progression to heart failure. European Young Physiologists Symposium Keynote
Lecture-Bratislava 2007. Acta physiologica, 2008. 194(1): p. 3-21.
Rossi, M.A., Connective tissue skeleton in the normal left ventricle and in
hypertensive left ventricular hypertrophy and chronic chagasic myocarditis.
Medical science monitor : international medical journal of experimental and
clinical research, 2001. 7(4): p. 820-32.
Ding, B., et al., Left Ventricular Hypertrophy in Ascending Aortic Stenosis Mice:
Anoikis and the Progression to Early Failure. Circulation, 2000. 101(24): p.
2854-2862.
Kato, S., et al., Inhibition of collagen cross-linking: effects on fibrillar collagen
and ventricular diastolic function. Vol. 269. 1995. H863-H868.
Weber, K.T., Cardiac interstitium in health and disease: the fibrillar collagen
network. Journal of the American College of Cardiology, 1989. 13(7): p. 1637-52.

43

12.

13.
14.
15.
16.
17.

18.

19.

20.

21.

22.
23.

24.

25.

26.

Leor, J., et al., Ex vivo activated human macrophages improve healing,
remodeling, and function of the infarcted heart. Circulation, 2006. 114(1 Suppl):
p. I94-100.
Jawad, H., et al., Assessment of cellular toxicity of TiO(2) nanoparticles for
cardiac tissue engineering applications. Nanotoxicology, 2010.
Maltais, S., et al., The paracrine effect: pivotal mechanism in cell-based cardiac
repair. Journal of cardiovascular translational research, 2010. 3(6): p. 652-62.
Heart Transplants: Statistics. 2010 [cited 2011. February 24]; Available from:
www.americanheart.org.
Organ Procurement and Transplantation Network. 2010 [cited 2011 February
24]; Available from: http://optn.transplant.hrsa.gov/data.
Writing Group, M., et al., Heart Disease and Stroke Statistics--2009 Update: A
Report From the American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Circulation, 2009. 119(3): p. e21-181.
Esposito, G., S. Dellegrottaglie, and M. Chiariello, The extent of irreversible
myocardial damage and the potential for left ventricular repair after primary
percutaneous coronary intervention. American heart journal, 2010. 160(6 Suppl):
p. S4-10.
Blankenship, J.C., et al., Door-to-balloon times under 90 min can be routinely
achieved for patients transferred for ST-segment elevation myocardial infarction
percutaneous coronary intervention in a rural setting. Journal of the American
College of Cardiology, 2011. 57(3): p. 272-9.
Nishida, K., et al., Quality measure study: progress in reducing the door-toballoon time in patients with ST-segment elevation myocardial infarction. Hawaii
medical journal, 2010. 69(10): p. 242-6.
Yasuda, S. and H. Shimokawa, Acute myocardial infarction: the enduring
challenge for cardiac protection and survival. Circulation journal : official
journal of the Japanese Circulation Society, 2009. 73(11): p. 2000-8.
ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery.
Circulation, 2004. 110(14): p. e340-437.
Herlitz, J., et al., Death, mode of death, morbidity, and rehospitalization after
coronary artery bypass grafting in relation to occurrence of and time since a
previous myocardial infarction. The Thoracic and cardiovascular surgeon, 1997.
45(3): p. 109-13.
Herlitz, J., et al., Determinants for an impaired quality of life 10 years after
coronary artery bypass surgery. International journal of cardiology, 2005. 98(3):
p. 447-52.
Yusuf, S., et al., Effect of coronary artery bypass graft surgery on survival:
overview of 10-year results from randomised trials by the Coronary Artery
Bypass Graft Surgery Trialists Collaboration. Lancet, 1994. 344(8922): p. 56370.
Coronary artery bypass surgery versus percutaneous coronary intervention with
stent implantation in patients with multivessel coronary artery disease (the Stent

44

27.

28.

29.

30.
31.

32.

33.
34.

35.

36.
37.

38.
39.

40.
41.

or Surgery trial): a randomised controlled trial. Lancet, 2002. 360(9338): p. 96570.
Rihal, C.S., et al., Indications for Coronary Artery Bypass Surgery and
Percutaneous Coronary Intervention in Chronic Stable Angina: Review of the
Evidence and Methodological Considerations. Circulation, 2003. 108(20): p.
2439-2445.
Dumcius, A., V. Chekanov, and V. Vysockas, Current status of cardiomyoplasty
as surgical alternative for end-stage heart failure. Medicina, 2003. 39(9): p. 81522.
Dor, V., et al., Left ventricular reconstruction by endoventricular circular patch
plasty repair: a 17-year experience. Seminars in thoracic and cardiovascular
surgery, 2001. 13(4): p. 435-47.
Jones, R.H., et al., Coronary bypass surgery with or without surgical ventricular
reconstruction. The New England journal of medicine, 2009. 360(17): p. 1705-17.
Lietz, K. and L.W. Miller, Destination Therapy: Current Results and Future
Promise. Seminars in thoracic and cardiovascular surgery, 2008. 20(3): p. 225233.
Lietz, K. and L.W. Miller, Will left-ventricular assist device therapy replace heart
transplantation in the foreseeable future? Current opinion in cardiology, 2005.
20(2): p. 132-7.
Kao, R.L., W. Browder, and C. Li, Cellular cardiomyoplasty: what have we
learned? Asian cardiovascular & thoracic annals, 2009. 17(1): p. 89-101.
Chachques, J.C., Development of bioartificial myocardium using stem cells and
nanobiotechnology templates. Cardiology research and practice, 2010. 2011: p.
806795.
Sharif, F., J. Bartunek, and M. Vanderheyden, Adult stem cells in the treatment of
acute myocardial infarction. Catheterization and cardiovascular interventions :
official journal of the Society for Cardiac Angiography & Interventions, 2011.
77(1): p. 72-83.
Murry, C.E., L.J. Field, and P. Menasche, Cell-based cardiac repair: reflections
at the 10-year point. Circulation, 2005. 112(20): p. 3174-83.
Charwat, S., et al., Role of adult bone marrow stem cells in the repair of ischemic
myocardium: current state of the art. Experimental hematology, 2008. 36(6): p.
672-80.
Boyle, A.J., et al., Is stem cell therapy ready for patients? Stem Cell Therapy for
Cardiac Repair. Ready for the Next Step. Circulation, 2006. 114(4): p. 339-52.
Wang, F. and J. Guan, Cellular cardiomyoplasty and cardiac tissue engineering
for myocardial therapy. Advanced drug delivery reviews, 2010. 62(7-8): p. 78497.
Gu, Y., et al., Tissue engineering and stem cell therapy for myocardial repair.
Frontiers in bioscience : a journal and virtual library, 2007. 12: p. 5157-65.
Chachques, J.C., et al., Myocardial Assistance by Grafting a New Bioartificial
Upgraded Myocardium (MAGNUM trial): clinical feasibility study. The Annals
of thoracic surgery, 2008. 85(3): p. 901-8.

45

42.
43.
44.

45.
46.

47.

48.

49.
50.

51.

52.

53.
54.
55.
56.

57.
58.
59.

Zimmermann, W.H., Remuscularizing failing hearts with tissue engineered
myocardium. Antioxid Redox Signal, 2009. 11(8): p. 2011-23.
Jawad, H., et al., Myocardial tissue engineering: a review. Journal of tissue
engineering and regenerative medicine, 2007. 1(5): p. 327-42.
Matsubayashi, K., et al., Improved left ventricular aneurysm repair with
bioengineered vascular smooth muscle grafts. Circulation, 2003. 108 Suppl 1: p.
II219-25.
Giraud, M.N., et al., Current state of the art in myocardial tissue engineering.
Tissue engineering, 2007. 13(8): p. 1825-36.
Bowers, S.L., I. Banerjee, and T.A. Baudino, The extracellular matrix: at the
center of it all. Journal of molecular and cellular cardiology, 2010. 48(3): p. 47482.
Batra, S. and K. Rakusan, Morphometric methods for the evaluation of capillary
grouping patterns in rat heart. Advances in experimental medicine and biology,
1992. 316: p. 261-70.
Cerfolio, R.J. and A.S. Bryant, Does minimally invasive thoracic surgery warrant
fast tracking of thoracic surgical patients? Thoracic surgery clinics, 2008. 18(3):
p. 301-4.
Lesman, A., et al., Transplantation of a tissue-engineered human vascularized
cardiac muscle. Tissue engineering. Part A, 2010. 16(1): p. 115-25.
Ke, Q., et al., Embryonic stem cells cultured in biodegradable scaffold repair
infarcted myocardium in mice. Sheng li xue bao : [Acta physiologica Sinica],
2005. 57(6): p. 673-81.
Piao, H., et al., Effects of cardiac patches engineered with bone marrow-derived
mononuclear cells and PGCL scaffolds in a rat myocardial infarction model.
Biomaterials, 2007. 28(4): p. 641-9.
Radisic, M., et al., Pre-treatment of synthetic elastomeric scaffolds by cardiac
fibroblasts improves engineered heart tissue. Journal of biomedical materials
research. Part A, 2008. 86(3): p. 713-24.
Wang, Y., et al., A tough biodegradable elastomer. Nature biotechnology, 2002.
20(6): p. 602-6.
Radisic, M., et al., Biomimetic approach to cardiac tissue engineering: oxygen
carriers and channeled scaffolds. Tissue engineering, 2006. 12(8): p. 2077-91.
Engelmayr, G.C., Jr., et al., Accordion-like honeycombs for tissue engineering of
cardiac anisotropy. Nature materials, 2008. 7(12): p. 1003-10.
Akhyari, P., et al., Myocardial tissue engineering: the extracellular matrix.
European journal of cardio-thoracic surgery : official journal of the European
Association for Cardio-thoracic Surgery, 2008. 34(2): p. 229-41.
Zimmermann, W.H., et al., Cardiac grafting of engineered heart tissue in
syngenic rats. Circulation, 2002. 106(12 Suppl 1): p. I151-7.
Zimmermann, W.H., et al., Engineered heart tissue grafts improve systolic and
diastolic function in infarcted rat hearts. Nature medicine, 2006. 12(4): p. 452-8.
Naito, H., et al., Optimizing engineered heart tissue for therapeutic applications
as surrogate heart muscle. Circulation, 2006. 114(1 Suppl): p. I72-8.

46

60.
61.

62.

63.
64.

65.
66.

67.

68.
69.

70.

71.
72.

73.

74.

Kofidis, T., et al., In vitro engineering of heart muscle: artificial myocardial
tissue. The Journal of thoracic and cardiovascular surgery, 2002. 124(1): p. 63-9.
Kofidis, T., et al., Myocardial restoration with embryonic stem cell bioartificial
tissue transplantation. The Journal of heart and lung transplantation : the official
publication of the International Society for Heart Transplantation, 2005. 24(6): p.
737-44.
Xiang, Z., et al., Collagen-GAG scaffolds grafted onto myocardial infarcts in a
rat model: a delivery vehicle for mesenchymal stem cells. Tissue engineering,
2006. 12(9): p. 2467-78.
Ott, H.C., et al., Perfusion-decellularized matrix: using nature's platform to
engineer a bioartificial heart. Nature medicine, 2008. 14(2): p. 213-21.
Bar, A., A. Haverich, and A. Hilfiker, Cardiac tissue engineering:
"reconstructing the motor of life". Scandinavian journal of surgery : SJS : official
organ for the Finnish Surgical Society and the Scandinavian Surgical Society,
2007. 96(2): p. 154-8.
Badylak, S.F., et al., Esophageal reconstruction with ECM and muscle tissue in a
dog model. The Journal of surgical research, 2005. 128(1): p. 87-97.
Kim, B.S., J.J. Yoo, and A. Atala, Peripheral nerve regeneration using acellular
nerve grafts. Journal of biomedical materials research. Part A, 2004. 68(2): p.
201-9.
Lichtenberg, A., et al., In vitro re-endothelialization of detergent decellularized
heart valves under simulated physiological dynamic conditions. Biomaterials,
2006. 27(23): p. 4221-9.
Chen, F., J.J. Yoo, and A. Atala, Acellular collagen matrix as a possible "off the
shelf" biomaterial for urethral repair. Urology, 1999. 54(3): p. 407-10.
Borschel, G.H., R.G. Dennis, and W.M. Kuzon, Jr., Contractile skeletal muscle
tissue-engineered on an acellular scaffold. Plastic and reconstructive surgery,
2004. 113(2): p. 595-602; discussion 603-4.
Schultheiss, D., et al., Biological vascularized matrix for bladder tissue
engineering: matrix preparation, reseeding technique and short-term
implantation in a porcine model. The Journal of urology, 2005. 173(1): p. 276-80.
Gilbert, T.W., T.L. Sellaro, and S.F. Badylak, Decellularization of tissues and
organs. Biomaterials, 2006. 27(19): p. 3675-83.
Badylak, S.F., D. Taylor, and K. Uygun, Whole-Organ Tissue Engineering:
Decellularization and Recellularization of Three-Dimensional Matrix Scaffolds.
Annual review of biomedical engineering, 2010.
Wang, B., et al., Fabrication of cardiac patch with decellularized porcine
myocardial scaffold and bone marrow mononuclear cells. Journal of biomedical
materials research. Part A, 2010. 94(4): p. 1100-10.
Eitan, Y., et al., Acellular cardiac extracellular matrix as a scaffold for tissue
engineering: in vitro cell support, remodeling, and biocompatibility. Tissue
engineering. Part C, Methods, 2010. 16(4): p. 671-83.

47

75.

76.

77.

78.
79.

80.
81.

82.

83.

84.

85.

86.

87.

88.
89.

Evnin, L.B., J.R. Vasquez, and C.S. Craik, Substrate specificity of trypsin
investigated by using a genetic selection. Proceedings of the National Academy of
Sciences of the United States of America, 1990. 87(17): p. 6659-63.
Vracko, R., et al., Basal lamina of rat myocardium. Its fate after death of cardiac
myocytes. Laboratory investigation; a journal of technical methods and pathology,
1988. 58(1): p. 77-87.
Ross, E.A., et al., Embryonic stem cells proliferate and differentiate when seeded
into kidney scaffolds. Journal of the American Society of Nephrology : JASN,
2009. 20(11): p. 2338-47.
Zimmermann, W.H., et al., Heart muscle engineering: an update on cardiac
muscle replacement therapy. Cardiovascular research, 2006. 71(3): p. 419-29.
Stankus, J.J., J. Guan, and W.R. Wagner, Fabrication of biodegradable
elastomeric scaffolds with sub-micron morphologies. Journal of biomedical
materials research. Part A, 2004. 70(4): p. 603-14.
Shin, M., et al., Contractile cardiac grafts using a novel nanofibrous mesh.
Biomaterials, 2004. 25(17): p. 3717-23.
Jawad, H., Fray, M. E., Boccaccini A., Nanocomposite Elastomeric Biomaterials
for Myocardial Tissue Engineering Using Embryonic Stem Cell-derived
Cardiomyocytes. Advanced Engineering Materials, 2010. 12(12): p. B664-B674.
Krupnick, A.S., et al., A novel small animal model of left ventricular tissue
engineering. The Journal of heart and lung transplantation : the official
publication of the International Society for Heart Transplantation, 2002. 21(2): p.
233-43.
Sekiya, S., et al., Bioengineered cardiac cell sheet grafts have intrinsic
angiogenic potential. Biochemical and biophysical research communications,
2006. 341(2): p. 573-82.
Shimizu, T., et al., Polysurgery of cell sheet grafts overcomes diffusion limits to
produce thick, vascularized myocardial tissues. The FASEB journal : official
publication of the Federation of American Societies for Experimental Biology,
2006. 20(6): p. 708-10.
Miyahara, Y., et al., Monolayered mesenchymal stem cells repair scarred
myocardium after myocardial infarction. Nature medicine, 2006. 12(4): p. 45965.
Furuta, A., et al., Pulsatile cardiac tissue grafts using a novel three-dimensional
cell sheet manipulation technique functionally integrates with the host heart, in
vivo. Circulation research, 2006. 98(5): p. 705-12.
Stevens, K.R., et al., Physiological function and transplantation of scaffold-free
and vascularized human cardiac muscle tissue. Proceedings of the National
Academy of Sciences of the United States of America, 2009. 106(39): p. 1656873.
Curtis, M.W. and B. Russell, Cardiac tissue engineering. The Journal of
cardiovascular nursing, 2009. 24(2): p. 87-92.
Coghlan, H.C., et al., The structure and function of the helical heart and its
buttress wrapping. III. The electric spiral of the heart: The hypothesis of the

48

90.

91.

92.

93.
94.
95.

96.

97.
98.

99.

100.

101.

102.

anisotropic conducting matrix. Seminars in thoracic and cardiovascular surgery,
2001. 13(4): p. 333-41.
Lunkenheimer, P.P., et al., The myocardium and its fibrous matrix working in
concert as a spatially netted mesh: a critical review of the purported tertiary
structure of the ventricular mass. European journal of cardio-thoracic surgery :
official journal of the European Association for Cardio-thoracic Surgery, 2006. 29
Suppl 1: p. S41-9.
Belkin, A.M. and N.R. Smalheiser, Localization of cranin (dystroglycan) at sites
of cell-matrix and cell-cell contact: recruitment to focal adhesions is dependent
upon extracellular ligands. Cell adhesion and communication, 1996. 4(4-5): p.
281-96.
LaNasa, S.M. and S.J. Bryant, Influence of ECM proteins and their analogs on
cells cultured on 2-D hydrogels for cardiac muscle tissue engineering. Acta
biomaterialia, 2009. 5(8): p. 2929-38.
Radisic, M., et al., Cardiac tissue engineering using perfusion bioreactor systems.
Nature protocols, 2008. 3(4): p. 719-38.
Haider, K.H., et al., De novo myocardial regeneration: advances and pitfalls.
Antioxidants & redox signaling, 2010. 13(12): p. 1867-77.
Okura, H., et al., Cardiomyoblast-like cells differentiated from human adipose
tissue-derived mesenchymal stem cells improve left ventricular dysfunction and
survival in a rat myocardial infarction model. Tissue engineering. Part C,
Methods, 2010. 16(3): p. 417-25.
Gwak, S.J., et al., In vitro cardiomyogenic differentiation of adipose-derived
stromal cells using transforming growth factor-beta1. Cell biochemistry and
function, 2009. 27(3): p. 148-54.
Lee, W.C., et al., Cardiomyogenic differentiation potential of human adipose
precursor cells. International journal of cardiology, 2009. 133(3): p. 399-401.
Hristov, M., W. Erl, and P.C. Weber, Endothelial progenitor cells: mobilization,
differentiation, and homing. Arteriosclerosis, thrombosis, and vascular biology,
2003. 23(7): p. 1185-9.
M. Radisic, H.P., G. Vunjak-Novakovic, Cardiac-tissue engineering, in
Principles of Tissue Engineering, R.L. R. Lanza, J. Vacanti, Editor. 2007,
Academic Press: Boston. p. 551-568.
Radisic, M., et al., Mathematical model of oxygen distribution in engineered
cardiac tissue with parallel channel array perfused with culture medium
containing oxygen carriers. American journal of physiology. Heart and
circulatory physiology, 2005. 288(3): p. H1278-89.
Bursac, N., et al., Cultivation in rotating bioreactors promotes maintenance of
cardiac myocyte electrophysiology and molecular properties. Tissue engineering,
2003. 9(6): p. 1243-53.
Khademhosseini, A., J.P. Vacanti, and R. Langer, Progress in tissue engineering.
Scientific American, 2009. 300(5): p. 64-71.

49

103.

104.
105.
106.
107.

108.
109.

110.

111.

112.

113.
114.

115.

116.

117.

118.

Vunjak-Novakovic, G., et al., Bioengineering heart muscle: a paradigm for
regenerative medicine. Annual review of biomedical engineering, 2011. 13: p.
245-67.
Fung, Y., Biomechanics: Mechanical Properties of Living Tissue. 2 ed. 1993,
New York: Springer-Verlag.
Ethier, C., Introductory Biomechanics from Cells to Organisms. 2007, New York:
Simmons-Cambridge.
Alberts B, J.A., Lewis J, Raff M, Roberts K, Walter P, ed. Molecular Biology of
The Cell. 4 ed. 2002, Garland Science: New York.
McCain, M.L. and K.K. Parker, Mechanotransduction: the role of mechanical
stress, myocyte shape, and cytoskeletal architecture on cardiac function. Pflugers
Archiv : European journal of physiology, 2011. 462(1): p. 89-104.
Ingber, D.E., Tensegrity I. Cell structure and hierarchical systems biology.
Journal of cell science, 2003. 116(Pt 7): p. 1157-73.
Brangwynne, C.P., et al., Microtubules can bear enhanced compressive loads in
living cells because of lateral reinforcement. The Journal of cell biology, 2006.
173(5): p. 733-41.
Wang, N., et al., Mechanical behavior in living cells consistent with the tensegrity
model. Proceedings of the National Academy of Sciences of the United States of
America, 2001. 98(14): p. 7765-70.
Aihara, Y., et al., Cardiac ankyrin repeat protein is a novel marker of cardiac
hypertrophy: role of M-CAT element within the promoter. Hypertension, 2000.
36(1): p. 48-53.
Gerdes, A.M., Remodeling of ventricular myocytes during cardiac hypertrophy
and heart failure. The Journal of the Florida Medical Association, 1992. 79(4): p.
253-5.
Icardo, J.M. and J.L. Ojeda, Effects of colchicine on the formation and looping of
the tubular heart of the embryonic chick. Acta anatomica, 1984. 119(1): p. 1-9.
Itasaki, N., et al., Actin bundles on the right side in the caudal part of the heart
tube play a role in dextro-looping in the embryonic chick heart. Anatomy and
embryology, 1991. 183(1): p. 29-39.
Lange, S., et al., Subcellular targeting of metabolic enzymes to titin in heart
muscle may be mediated by DRAL/FHL-2. Journal of cell science, 2002. 115(Pt
24): p. 4925-36.
Lapidos, K.A., R. Kakkar, and E.M. McNally, The dystrophin glycoprotein
complex: signaling strength and integrity for the sarcolemma. Circulation
research, 2004. 94(8): p. 1023-31.
Latacha, K.S., et al., Role of actin polymerization in bending of the early heart
tube. Developmental dynamics : an official publication of the American
Association of Anatomists, 2005. 233(4): p. 1272-86.
Knoll, R., et al., The cardiac mechanical stretch sensor machinery involves a Z
disc complex that is defective in a subset of human dilated cardiomyopathy. Cell,
2002. 111(7): p. 943-55.

50

119.
120.

121.
122.

123.

124.
125.
126.

127.
128.

129.
130.
131.

132.
133.
134.
135.

Niimura, H., et al., Sarcomere protein gene mutations in hypertrophic
cardiomyopathy of the elderly. Circulation, 2002. 105(4): p. 446-51.
Sheikh, F., et al., An FHL1-containing complex within the cardiomyocyte
sarcomere mediates hypertrophic biomechanical stress responses in mice. The
Journal of clinical investigation, 2008. 118(12): p. 3870-80.
Taber, L.A., Biomechanics of cardiovascular development. Annual review of
biomedical engineering, 2001. 3: p. 1-25.
Nagueh, S.F., et al., Altered titin expression, myocardial stiffness, and left
ventricular function in patients with dilated cardiomyopathy. Circulation, 2004.
110(2): p. 155-62.
al., G.G.e., Cell-Cell Interactions and the Mechanics of Cells and Tissues
Observed in Bioartificial Tissue Constructs, in Mechanobiology of Cell-Cell and
Cell-Matrix Interactions, H.B. Wagoner-Johnson A, Editor. 2011, Springer: New
York. p. 75-103.
Belkin, A.M. and M.A. Stepp, Integrins as receptors for laminins. Microscopy
research and technique, 2000. 51(3): p. 280-301.
Ratcliffe, A. and L.E. Niklason, Bioreactors and bioprocessing for tissue
engineering. Annals of the New York Academy of Sciences, 2002. 961: p. 210-5.
Vandenburgh, H.H., et al., Mechanical stimulation of organogenic cardiomyocyte
growth in vitro. The American journal of physiology, 1996. 270(5 Pt 1): p.
C1284-92.
Horton, R.E., et al., Engineering microenvironments for embryonic stem cell
differentiation to cardiomyocytes. Regenerative medicine, 2009. 4(5): p. 721-32.
Shimko, V.F. and W.C. Claycomb, Effect of mechanical loading on threedimensional cultures of embryonic stem cell-derived cardiomyocytes. Tissue
engineering. Part A, 2008. 14(1): p. 49-58.
Jacot, J.G., J.C. Martin, and D.L. Hunt, Mechanobiology of cardiomyocyte
development. Journal of biomechanics, 2010. 43(1): p. 93-8.
Reis, L.A., et al., Biomaterials in myocardial tissue engineering. Journal of Tissue
Engineering and Regenerative Medicine, 2014: p. n/a-n/a.
Di Donato, M., et al., Effects of the Dor procedure on left ventricular dimension
and shape and geometric correlates of mitral regurgitation one year after
surgery. The Journal of thoracic and cardiovascular surgery, 2001. 121(1): p. 916.
Robinson, K.A., et al., Extracellular matrix scaffold for cardiac repair.
Circulation, 2005. 112(9 Suppl): p. I135-43.
Beltrami, C.A., et al., Structural basis of end-stage failure in ischemic
cardiomyopathy in humans. Circulation, 1994. 89(1): p. 151-63.
Gepstein, L., Derivation and potential applications of human embryonic stem
cells. Circulation research, 2002. 91(10): p. 866-76.
Williams, J.W., Jr., et al., in Percutaneous Heart Valve Replacement. 2010:
Rockville (MD).

51

136.

137.

138.

Lonn, L., T. Larzon, and J.C. Van Den Berg, From puncture to closure of the
common femoral artery in endovascular aortic repair. The Journal of
cardiovascular surgery, 2010. 51(6): p. 791-8.
Fishbein, G.A. and M.C. Fishbein, Arteriosclerosis: rethinking the current
classification. Archives of pathology & laboratory medicine, 2009. 133(8): p.
1309-16.
Mitchell, R.N. and P. Libby, Vascular Remodeling in Transplant Vasculopathy.
Circ Res, 2007. 100(7): p. 967-978.

52

CHAPTER TWO: PROJECT MOTIVATION, SPECIFIC AIMS, AND
SIGNIFICANCE

2.1 Introduction and Clinical Relevance:
Myocardial infarction (MI), the principal complication associated with
cardiovascular disease, affects over 1,000,000 individuals annually.[1] Incidences of acute
MI are increasingly survivable, however, the associated transient ischemia causes tissue
damage, scar formation, and initiates a degenerative progression toward congestive heart
failure (CHF) in more than one fourth of affected patients.[2-5] Consequently, the prevalence
of CHF is currently estimated at 5.7 million afflicted, and total expenditures for CHF
treatment are expected to increase from 44.6 billion dollars in 2015 to 97 billion dollars by
the year 2030.[6] It is clear that CHF represents a vast economic burden and should be
regarded as a significant public health concern.
CHF develops as a result of global cardiac remodeling (i.e. left ventricular dilation
and wall thinning) that occurs in response to the death of cardiomyocytes (CM) during MI.
These CM are not regenerated, but are instead replaced by largely non-contractile,
collagenous scar tissue.[5,

7-9]

Mechanically speaking, the scar is a poor substitute for

functional cardiac muscle, as it disrupts the continuity of the contractile syncytium of the
myocardium. Persistence of the scar over time leads to maladaptive, compensatory CM
hypertrophy, fibrosis, contractile dysfunction, and dilated cardiomyopathy en route to
CHF.[3, 10-14] To prevent CHF, prospective therapies must aim to replace the infarct
scar with functional cardiac muscle.
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2.2 Current Standards of Care and Limitations:
Coronary artery bypass grafting, percutaneous coronary intervention, ventricular
reconstruction, and left ventricular assist devices either focus solely on revascularization
or do not adequately restore functionality to infarct-damaged tissue.[15] Heart
transplantation falls short as a solution, as demand for donor hearts far outpaces supply,[16,
17]

Success of stem cell therapy for MI in the form of intramyocardial (transendocardial) or

intracoronary delivery of stem cells has been anecdotal. Several clinical trials have yielded
findings that suggest marginal improvement in cardiac function, but none have shown any
sustained improvement beyond 18 months. This is most likely due to poor cell engraftment
and integration with host tissue, extensive apoptosis, and absence of cell differentiation.[1820]

Tissue engineering approaches may address the need for effective cell delivery by
providing a stable environment for regenerative cells in the infarcted area. [2, 7, 21, 22] Early
efforts to generate a biomimetic, functional, tissue-engineered construct have shown
promise with thinner grafts (<1 mm),[23,

24]

but thicker grafts (7 mm to 15 mm) are

necessitated because the infarct scar is nearly transmural in many cases. Long-term
survival and functionality of thicker, more clinically relevant-sized grafts implanted in
animal models, however, has been hindered by insufficient vascularization within the grafts
themselves, as well as lack of perfusion by the host’s blood supply.[21] In order to replace
the infarcted area with a functional graft of such thickness and sustain its constituent cells,
vasculature is necessary to transport nutrients and wastes further than diffusion alone can
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(≈100 μm).[4, 7, 25] As of yet, no tissue engineering approach exists which has addressed and
overcome these limitations.
The overarching goal of this project is to develop a biomimetic, acellular, and
vascularized graft for replacement of infarct scar tissue. The graft is to be in the form of a
“vascularized flap” to allow for surgical manipulation and implantation via anastomosis
(similar to CABG) of the graft’s major vessels to the recipient vasculature.
It is hypothesized that this vascularized-flap graft, which will consist of a
DCELLed myocardial ECM scaffold derived from the left ventricular wall of porcine
hearts and relevant cardiac cell types derived from autologous adult stem cells, will
integrate with the host cardiac conduction system and produce systolic force upon
implantation. In doing so, it will replace the lost functionality of cardiac muscle damaged
by MI and avert (or possibly reverse) the remodeling which precipitates CHF. Our
approach, as envisioned in a clinical scenario, is depicted in Figure 2.1.
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Figure 2.1: Overview of proposed translational approach and clinical scenario: Patient suffers a
myocardial infarction, has subcutaneous adipose tissue harvested, and adipose stem cells are isolated
from the tissue; patient receives optimal medical management during the rest of the process until graft
implantation. Cells are cultured with the aim of growing large numbers for later repopulation by
reseeding of the myocardial scaffold generated from xenogeneic sources (i.e. a pig). The seeded
construct is placed into a bioreactor wherein it is exposed to stimuli which mimic the cardiac
environment in order to differentiate stem cells and condition the construct into a functional graft.
The graft, consisting of autologous cells and nonimmunogenic scaffold, is implanted in the patient as a
functional replacement for infarct scar tissue.

2.3 Specific Aims:
Four related and overlapping aims have been established toward achieving the
overall goal of this research, and they are directed at understanding: 1) how to generate a
DCELLed scaffold with the necessary features to overcome existing limitations of tissue
engineering approaches; 2) the role and fate of DCELLed scaffolds in cardiac tissue
engineering; 3) bioreactors, stem cells, and strategies for producing functional grafts; and
4) desired outcomes and benefits of infarct scar replacement with functional grafts.
Aim 1 (Chapter 3): To develop and characterize a decellularized, vascularized scaffold
for use in myocardial tissue engineering
Hypothesis: Acellular left ventricular porcine myocardium will serve as an ideal
supporting material for tissue engineered myocardial grafts due to its low immunogenicity,
potential as an excellent “niche” for inducing differentiation of stem cells toward cardiac
phenotypes, and its network of preserved, patent vascular channels.
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Approach: Scaffolds will be generated using a combination of reagents, including
detergents, chelators, bases, and enzymes to remove all cellular proteins from porcine
myocardium. In doing so, scaffolds should: 1) have all potentially immunogenic proteins
and molecules removed, 2) retain the biochemical structure, composition, architecture, and
relative quantities of all ECM proteins (e.g. collagens type I, III, and IV, elastin,
fibronectin, and laminin), and 3) provide a means of nourishing reseeded regenerative cells
(i.e. an inherent vasculature).
Innovation: In addition to the properties listed above, the myocardial scaffold will
preserve the native vasculature of the xenogeneic tissue and its connection to the coronary
artery and cardiac vein to allow for convenient surgical manipulation and implantation.
This will be in the mode of a “free flap transfer” with anastomoses of the above vessels to
specific locations, providing a strategy for graft implantation that can be adopted quickly
in the clinic.
Aim 2 (Chapter 4): To characterize the host response to scaffolds and optimize their
in vivo degradation rate
Hypothesis: Scaffolds which resist in vivo degradation for longer than 8 weeks will
provide implanted cells sufficient stability and time to integrate with host tissue, improving
functional outcomes. Treatment with a specialized cross-linking agent will mitigate the
severity of the immune response to implanted scaffolds.
Approach: As shown in previous studies, treatment of scaffolds with penta-galloyl
glucose (PGG), a plant-derived antioxidant and matrix-binding polyphenol, will protect
scaffolds from calcification, mitigate immune rejection, and prevent excessive matrix
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metalloprotease-driven degradation. Myocardial scaffolds will be treated with two
different concentrations of PGG and implanted subdermally in rats. At 4, 8, and 12 weeks,
scaffolds will be explanted and examined histologically and immunohistochemically to
characterize the host response, as well as the extent of degradation; results will be
compared to non PGG-treated scaffolds.
Innovation: Tissue engineers who employ scaffolds as a significant component of
their prospective therapy have struggled with questions surrounding the fate of scaffolds
once implanted (i.e how long should they persist, should they be remodeled, and how long
should remodeling take in order to assure the optimum therapeutic benefit?). Our approach
aims to answer these questions, determine the in vivo degradation rate of the scaffold, and
to elucidate the precise nature of the host response to the scaffold (i.e. inflammatory vs.
remodeling) including delineation of the source(s) of any stem cells that may be involved.
Aim 3: To condition cell-seeded myocardial constructs in vitro into functional grafts
Hypothesis: Exposure to conditions mimicking the physiological environment of
the myocardium will induce stem cell differentiation and maturation of cell-seeded
constructs into functional myocardial grafts.
Approach: A bioreactor will accommodate constructs seeded with hADSCs,
fibroblasts, and endothelial progenitor cells. It will allow for precise control of physical
and biochemical conditions (pressures, electrical stimulation, and media compositions).
Constructs will be exposed to these conditions for 4 weeks to direct differentiation of stem
cells toward electrically integrated and synchronously contracting cardiomyocytes.
Resultant grafts will be examined for evidence of physiologic maturation using histology,
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gene and protein expression, and by measuring excitation thresholds, calcium transients,
fractional shortening, and force generation; results will be compared to unstimulated
control constructs.
Innovation: Using bioreactors to deliver the stimuli necessary to differentiate and
condition stem or progenitor cells into cardiac cells helps produce more functional
myocardial grafts. The precise application of these stimuli in terms of what combination
of stimuli to use, how to coordinate them, and the magnitude and frequency of their
application will be determined by the studies outlined in this aim.
Aim 4: To develop an animal model of infarction and demonstrate feasibility of
surgical replacement of infarct scar with tissue-engineered constructs
Hypothesis: A porcine model of infarction and surgical approach to construct
implantation must be developed and optimized.
Approach: Coronary artery ligation in pigs will be used as an infarct model, and
electrocardiography (EKG), echocardiography (ECG), blood chemistry, and histology will
ascertain induction of MI. For implantation, the scaffold’s major vessels will be
anastomosed to the host vasculature, and the flap-like portion of the scaffold will be affixed
to the exposed viable myocardium with fibrin glue and sutures.

Two rounds of

implantation will be conducted: the first to evaluate the degree of hemostasis and vascular
integrity, and the second to evaluate the subacute host response. For the former, pigs with
healthy hearts will be implanted with a scaffold and observed for 1 hr. For the latter, pigs
at 4 weeks post-MI will undergo infarct scar resection and replacement with a scaffold and
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be allowed to survive for 1 week. EKG, ECG, histology, immunohistochemistry, and
electrophysiology methods will be used to evaluate the responses.
Innovation: This aim will demonstrate the feasibility of the proposed surgical
implantation method while allowing for identification of challenges and aspects of the
procedure in need of revision. This will set the stage for a larger, full-scale study of the
efficacy of tissue-engineered myocardial grafts in the future.

2.4 Project Significance:
Building upon recent advances in stem cell biology and tissue engineering, the
proposed research will develop a meaningful therapy and further it toward application in
the clinic. We expect the outcomes of this translational approach to have a positive impact
upon efforts to treat a growing population of patients suffering from complications of
coronary heart disease. Also, it could represent a significant step toward better
understanding of the complex interaction between cells and extracellular signals in the
cardiac environment. This research will not only enable clinicians to prevent or reverse
the progression towards CHF—undoubtedly saving lives and improving the quality of life
for recipients of this therapy—but also contribute to the advancement of the cardiac tissue
engineering field.
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CHAPTER THREE: DEVELOPMENT AND CHARACTERIZATION OF AN
ACELLULAR MYOCARDIAL SCAFFOLD ENRICHED WITH PATENT
VASCULAR NETWORKS AND BIOCOMPATIBLE CELL NICHES

3.1 Introduction:
The prevailing paradigm in the field of tissue engineering advocates the combined
use of cells and scaffolds for therapeutic application to the target tissue. Among the
biomaterial scaffolds under investigation, none have recently gained as much attention as
acellular tissue matrices. These DCELLed extracellular matrix (ECM) scaffolds have been
successfully generated by subjecting tissues from a number of sources to various
combinations of chemical, enzymatic, and physical agitation, breaking up and removing
cells and cellular proteins in the process.[1, 2] The remaining ECM acts as an agreeable
“niche” for reseeded cells, complete with the appropriate binding sites, mechanical
properties, and architecture necessary to induce formation of a tissue-engineered construct
that is physiologically comparable to native tissue. The function of ECM proteins does not
differ among species, and thus their structure has been highly conserved over the course of
evolution. As such, these proteins should not perturb the host immune system when
implanted in an allogeneic or even xenogeneic capacity.[3] Another major advantage
offered by DCELL is that the resulting scaffold is left with an intact vascular network, a
design which nature has perfected and would be painstaking, if not impossible, to duplicate
from the bottom-up. This vascular network can be used to sustain cells seeded onto
DCELLed scaffolds once the resulting constructs are implanted.
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Porcine hearts are also approximate in size to human hearts, which is important
considering that hearts with different ventricular volumes will experience different
pressures, and thus, have different wall stresses and amounts of constituent collagen to bear
those stresses.[4] In terms of mechanics, this means that scaffolds generated with porcine
hearts are macromechanically equipped to withstand forces in the human cardiac
environment, as well as micromechanically amenable to attachment and proper
mechanotransduction of seeded cells.
Whole heart and myocardial patch DCELL has been demonstrated by a number of
groups.[5-11] Typically, remnants of the DCELL process are composed of extracellular
matrix (ECM) proteins native to the myocardium and the native vascular network. Few
studies, however, have attempted a comprehensive, parallel analysis of both the vascular
and myocardial matrices focusing on DCELL efficacy, elastic moduli and burst pressures
of the intrinsic coronary arteries, patency of capillary perfusion, exact amounts of
collagen and elastin, and identification of important basement membrane proteins, among
others. In our view, complete and efficient DCELL of such complex tissues appeared
problematic and required a comparative analysis of several DCELL methods.
An optimal DCELL technique for this application should fulfill the following
criteria: 1) remove all potentially immunogenic proteins and molecules, rendering the
implant biocompatible; 2) preserve the biochemical structure, composition, architecture,
and relative quantities of all matrix proteins including basement membrane, thus
generating an agreeable biological and biomechanical “niche” for reseeded cells; 3)
provide a means of nourishing reseeded regenerative cells by preserving the natural
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vasculature; and 4) allow for convenient surgical manipulation, implantation, and
reconnection to the host vasculature.
To this end, we DCELLed porcine myocardium and its constituent vasculature
using four different procedures comprising combinations of sodium dodecyl sulfate
(SDS) and sodium hydroxide (NaOH) in a comparative study of their ability to remove
cells and cell remnants and preserve the features of the native ECM. The scaffold was
uniquely shaped as a “flap” so that the native vasculature could be used in a three-fold
manner: first, to facilitate DCELL by perfusion, second, to serve as a conduit for
recellularization with appropriate cells, and third, to allow for surgical manipulation and
implantation via anastomosis of the graft’s vessels with the recipient vasculature (similar
to coronary bypass surgery). We systematically evaluated both the myocardial and
coronary arterial ECM and investigated their ability to support the attachment and
survival of relevant cardiac cell types.

3.2 Methods and Materials:
3.2.1 Decellularization of Porcine Myocardium:
Whole hearts were obtained from healthy, adult pigs at a local abattoir.
Immediately following harvest, 50 mM ethylenediaminetetraacetic acid (EDTA) in warm
phosphate buffered saline (PBS) was injected into the left coronary artery branch at the
aortic trunk to prevent clotting in the vasculature, and the hearts were transported on ice
for immediate processing. A 1 cm thick, 6-8 cm wide, and 12 cm long “flap” of
myocardium was excised from the left-anterior ventricular wall, with care not to sever the
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coronary artery or cardiac vein, and these vessels were cannulated with barbed Luer
connectors (Cole-Parmer) secured with zip-ties in order to facilitate perfusion (Figure
3.1). Larger, open-ended vessels severed during excision of the flap were closed with 4-0
silk suture (Ethicon). The flaps were then subjected to combined perfusion and
immersion of solutions in a continuous-flow DCELL system. The system comprised a
series of fluid reservoirs and a multi-channel peristaltic pump (Masterflex, Cole-Parmer)
which circulated 2 L of solution through and around each scaffold. The inflow reservoir
was elevated 90 cm above the cannulated ends of vessels, generating a hydrostatic
pressure of about 80 mmHg and a flow rate of about 200 ml/min (largely dependent on
tissue resistance). A solution of 30 mM EDTA in PBS (pH=7.5) was perfused for 12 h to
clear any remaining clotted blood from the vasculature, followed by 1% SDS and 0.1 M
NaOH solutions in sequence and in various durations for 10-15 days, while solutions
were changed every 2 days. The four separate DCELL treatment groups (n=4 scaffolds
per group) were as follows: Group 1: 2 days SDS followed by 8 days NaOH, Group 2: 5
days SDS followed by 5 days NaOH, Group 3: 10 days SDS followed by 2 days NaOH,
Group 4: 15 days SDS. DCELL efficacy was gauged by monitoring changes in scaffold
color and mass. Following completion of the DCELL process, scaffolds were immersed
and rinsed overnight in 70% ethanol and 3 changes (one overnight) of PBS on an orbital
shaker. For post-SDS DCELL studies, Group 4 scaffolds (n=3) were further subjected to
treatments of either 24 h perfusion with DNAse/RNAse (Worthington Biochemical)
solution (720 mUnits/mL each) in PBS containing 5 mM magnesium chloride at pH 7.5,
perfusion of 0.1 M NaOH for 2 hours, or 3 days perfusion of PBS.
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Figure 3.1: A pedicled “flap” of A) native myocardium excised from the left ventricular wall of the porcine
heart and a representative image of the decellularized (Decelled) scaffolds resulting from perfusion
decellularization. The cannulae used to connect the vasculature to the perfusion system are shown secured
with orange zip ties. Red arrows indicate the open end of the coronary artery prior to cannulation (Native)
and the inlet to the coronary artery after cannulation (Decelled). Similarly, blue arrows indicate the same
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features for the cardiac vein. Arrows also indicate the direction of anteriograde blood and decellularization
solution flow. Areas designated by circles indicate origins of specimens of decellularized coronary arterial
extracellular matrix (CA ECM) and decellularized myocardial extracellular matrix (MYO ECM) used in
histological, immunohistochemical, DNA, biochemical, mechanical, and cell-seeding analyses. Time-course
plot B) of the mean recorded masses of scaffolds exposed to 4 different decellularization methods. Results
of a C) PicoGreen® quantitative assay for DNA are shown which compare the DNA content of both
decellularized MYO ECM and CA ECM samples generated with various decellularization treatments to that
of native myocardium and native coronary arteries, respectively. DNA content of D) MYO ECM samples
from scaffolds generated with the Group 4 decellularization treatment and subsequent exposure to various
reagents as measured by PicoGreen® assay. DNA content of Group 4 and native myocardium represented
in D are carried over from C for comparison (*: indicates statistical significance from all other groups,
p<0.0001). Images of DAPI-stained sections E) from MYO ECM and CA ECM of decellularized porcine
myocardial scaffolds from Group 4 and Group 3, showing residual nucleic acids (blue, white arrows; 10X,
bar=100 μm). Images of H&E-stained sections F) from MYO ECM and CA ECM of scaffolds from Group
4 and Group 3, showing residual “pools” (black arrows) of nucleic acids (blue; 10X, bar=100 μm).

3.2.2 Histology and Immunohistochemistry:
Samples of myocardial ECM (“MYO” in Figure 3.1A) and coronary arterial
ECM (“CA” in Figure 3.1A) were examined by histological staining with Hematoxylin
and Eosin (H&E), Gomori’s trichrome, Movat’s pentachrome, and Verhoeff-Van
Gieson’s stains. Immunohistochemical (IHC) analysis was performed on formalin-fixed
and paraffin-embedded sections using heat-mediated antigen retrieval (10 mM citric acid
buffer at 95-100 °C for 10-15 minutes) followed by incubation with antibodies to
collagen IV (2 µg/mL, Abcam), laminin (4 µg/mL, Abcam), actin (2 µg/mL, Abcam),
cardiac myosin heavy chain (4 µg/mL, Abcam), or fibronectin (4 µg/mL, BD
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Biosciences) and application of Vectastain DAB kit (Vector Labs) reagents for detection.
For pore size determination, images (n=25) of H&E-stained sections of MYO ECM from
each group were analyzed using ImageJ software (NIH) to determine the mean diameter
of pores in both longitudinal (n=210) and transverse (cross-sectional) (n=278) directions.

3.2.3 DNA, Collagen and Elastin Quantification:
DNA content of MYO ECM (n=8) and CA ECM (n=10) and samples of similarly
located native tissues (myocardium: n=8, coronary artery: n=10) was measured using a
Quant-IT PicoGreen® kit (Invitrogen). Lyophilized samples of MYO ECM (n=8), CA
ECM (n=8), native myocardium (n=8), and native coronary artery (n=8) were analyzed
for desmosine content by radioimmunoassay (RIA) and for hydroxyproline content by
amino acid analysis as previously reported,[12] and collagen and elastin content were
calculated as previously described.[13, 14]

3.2.4 Mechanical Properties:
Rectangular 2.5 x 1 cm specimens of DCELLed porcine MYO ECM (n=4) were
either left with the epicardium attached or had the epicardium removed (n=4). Similar
samples (n=4) of native porcine myocardium with and without the epicardium were
prepared for comparison. Specimens were secured to a frame with 10 N load cell (MTS
Systems), submerged in PBS at 37 °C, and preconditioned for 10 cycles between 0-15%
strain at a rate of 3.0 mm/min. After 2 minutes rest, they were subjected to 3 cycles to
40% strain at 3.0 mm/min. Tangential slopes of each stress-strain curve between 35-40%
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strain were averaged and taken as the Young’s modulus. Samples of native porcine
coronary arteries (n=8) and DCELLed CA ECM (n=8) isolated from DCELLed porcine
myocardial flap scaffolds were subjected to burst pressure measurements as previously
described.[15]

3.2.5 Evaluation of Scaffold Vasculature:
A native porcine heart (obtained as above) was injected with 50 mM EDTA in
warm PBS at the left coronary arterial branch from the aortic trunk to clear the
vasculature of any clots. The left coronary artery and superior portion of the cardiac vein
were cannulated with barbed Luer connectors (Cole Parmer). A cannulated, acellular flap
scaffold was embedded in concentrated (126 mg/mL) Knox gelatin to seal any openended vascular channels created during the excision portion of the DCELL process. Red
and blue-pigmented polymethyl methacrylate (PMMA) from Batson’s #17 Anatomical
Corrosion Kit (Polysciences Inc.) were sequentially injected into the vasculature of both
the native heart and scaffold. Red PMMA was infused anteriogradely through the
coronary arterial inlet, and blue PMMA retrogradely through the cardiac vein inlet. After
polymerization, a cast of the vasculature was obtained by tissue maceration. Vascular
casts were imaged on a dissection microscope and ImageJ software was used to measure
the diameters of blood vessels.
For injection and imaging of fluorescent dyes, fluorescein isothiocyanate (FITC)–
dextran and rhodamine B isothiocyanate (RITC)–dextran (Sigma) were simultaneously
injected into the scaffold vasculature (FITC-dextran anteriogradely through the arterial
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inlet and RITC-dextran retrogradely through the venous inlet). The scaffolds were
immediately imaged macroscopically using an in vivo imaging system (IVIS® Lumina
XR, Caliper Life Sciences). The system generated images of photon density on a
greyscale which were artificially colored using the accompanying Living Image®
software (Caliper Life Sciences).
Carbon black spherical particles of 2-12 μm in diameter (Sigma) were passivated
via overnight incubation in 100% fetal bovine serum (FBS, Atlanta Biologicals), washed
2X in PBS, suspended in PBS at a concentration of 2x106 particles/mL, and injected into
the vascular inlets of a Group 4 scaffold. Movat’s pentachrome stain was used to
examine 5 μm-thick sections of MYO ECM distal (at the apical end of the scaffold) to the
inlet cannulae.

3.2.6 Cell Seeding and Analysis:
Cylindrical, 5 mm-diameter punch biopsies (n=4) of MYO ECM were taken from
DCELLed porcine myocardial scaffolds from Group 4, sterilized in 0.1 % peracetic acid
(Sigma) in PBS for 1 h, washed 3X in sterile PBS, and lyophilized. For initial
cytotoxicity studies, approximately 5x106 rat dermal fibroblasts (Cell Applications) at
passage 11 were seeded onto the dry scaffold samples and cultured statically for either 7
or 14 days. At each time point, seeded scaffold samples were stained for viability using a
Live/Dead kit (Invitrogen).
For seeding of neonatal rat cardiomyocytes (Lonza), 1 mm3 samples of MYO
ECM from Group 4 scaffolds (n=3) were sterilized with peracetic acid and washed as
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described above, seeded with 2 x 106 cells at passage 2, and cultured statically for 7 days.
Samples were analyzed by immunofluorescence with primary antibodies to connexin43
(2 μg/mL, Abcam), actin (2 μg/mL, Abcam), cardiac myosin heavy chain (4 μg/mL,
Abcam), and α-sarcomeric actinin (2 μg/mL, Abcam), secondary antibodies AlexaFluor
488 and 594 (4 μg/mL, Invitrogen), and 4',6-diamidino-2-phenylindole (DAPI) nuclear
counterstain.

3.2.7 Statistical Analysis:
Statistical analysis was performed using JMP software (SAS Institute Inc.). Oneway analysis of variance (ANOVA) and Fisher’s least significant difference method for
post-hoc comparison of mean values (with α=0.05) were used. All quantitative data are
represented as mean ± standard deviation. Error bars represent ± standard error.

3.3 Results
3.3.1 Removal of Cellular Components:
Scaffold color and mass loss were indicative of effective muscle cell removal, as
scaffolds initially of red-brown color became progressively paler throughout the DCELL
process before becoming white and translucent (Figure 3.1) and wet masses decreased
with time. Notably, NaOH treated scaffolds displayed a higher rate of mass removal than
SDS treated scaffolds (Figure 3.1B). Upon switching from SDS to NaOH as called for
by each treatment, the mass removal rate increased by more than a factor of three. The
treatment for Group 4 (SDS alone) removed 49.6±1.4% of the original tissue mass, while
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the other three treatments, which all incorporated varying lengths of NaOH exposure,
resulted in an average 58.8±1.3% removal of the initial mass (p=0.0006). These results
indicate that NaOH is a more rapid and more efficient DCELL agent as compared to
SDS.
Histological analysis of MYO and CA ECM (Figure 3.2A) illustrated removal of
cell nuclei and cytoplasmic proteins from native tissues, leaving voids in the resulting
scaffold. IHC analysis confirmed complete removal of actin and cardiac myosin heavy
chain muscle proteins from both tissues (Figure 3.2B). Data in Figure 3.6 also reflect
effective DCELL, as the disparity between the weight percentages of matrix proteins in
DCELLed and native tissues was caused by removal of cell proteins.
Quantification of DNA showed that all DCELL treatments which employed NaOH
(Groups 1-3) cleared 95-98% of DNA from myocardial and arterial tissues. However,
DNA content was not significantly different in Groups 1-3. The treatment in Group 4
(SDS alone) reduced DNA content by 33.2% in the myocardium and only 27.5% in the
coronary arteries (Figure 3.1C). H&E- and DAPI-stained sections of Group 4 scaffolds
showed positive staining for nucleic acids which had “pooled” in sub-epicardial and subintimal areas of the MYO and CA ECM, respectively, while Group 3 scaffolds were
completely devoid of nucleic acids (Figure 3.1E and F). Quantification of DNA in
MYO ECM from Group 4 scaffolds perfused with additional solutions, described as postSDS procedures, including DNAse/RNAse or NaOH, resulted in further reduction of
DNA content (Figure 3.1D).
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Figure 3.2: Histological images of A) native porcine myocardium and decellularized (Decelled) porcine
myocardial ECM (MYO) stained with H&E and sectioned in the longitudinal and transverse (cross-sectional)
directions with respect to cardiomyocytes, depicting the cylindrical voids left in their absence (40X, bar=20
μm); H&E-stained native porcine coronary artery and decellularized porcine coronary arterial ECM (CA;
10X, bar=100 μm). Decellularized sections are representative of all four treatment groups. Cell nuclei (blue),
cytoplasmic proteins (dark pink), and collagen (light pink) are shown. B) Immunohistochemical (IHC)
staining of native and decellularized (Decelled) porcine myocardium (MYO) for actin and cardiac myosin
heavy chain (cardiac MHC; 40X, bar=20 μm). IHC of native and decellularized porcine coronary artery
(CA) for actin (10X, bar=100 μm). Decellularized sections are representative of all four treatment groups.
IHC positive staining = brown. Inserts = IHC negative controls. L = lumen and black arrows indicate the
internal elastic lamina.
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Figure 3.3: Histology of native porcine myocardium and decellularized (Decelled) porcine myocardial ECM
(MYO) from Group 4 scaffolds (40X, bar=20 μm) and native porcine coronary artery and decellularized
porcine coronary arterial ECM (CA) from Group 4 scaffolds (10X, bar=100 μm) stained with Movat’s
pentachrome, which shows nuclei (dark red), collagen (yellow-orange), elastin fibers (maroon), and
cytoplasmic proteins (red). Native porcine myocardium and decellularized porcine myocardial ECM from
Group 4 scaffolds (40X, bar=20 μm) and native porcine coronary artery and decellularized porcine coronary
arterial ECM from Group 4 scaffolds (20X, bar=50 μm) stained with Gomori’s trichrome, which shows nuclei
(dark purple), collagen (blue-green), elastic fibers (purple), and cytoplasmic proteins (red). Native porcine
myocardium and decellularized porcine myocardial ECM with epicardium from Group 4 scaffolds (20X,
bar=50 μm) and native porcine coronary artery and decellularized porcine coronary arterial ECM from Group
4 scaffolds (10X, bar=100 μm) stained with Verhoeff-Van Gieson’s (VVG) stain for visualization of nuclei
(grey/black), elastin fibers (black), and collagen (pink). Images of decellularized sections for all stains are
representative of all four treatment groups. L = lumen and black arrows indicate the internal elastic lamina.
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3.3.2 Preservation of Matrix Architecture and Mechanical Integrity:
H&E-stained histological sections cut in the longitudinal and transverse planes of
DCELLed MYO ECM reflected retention of the native myocardial structure and
organization (Figure 3.2A). Taken together, images from these two planes illustrated the
cylindrical voids left within scaffolds following removal of cardiomyocytes. Quantitative
analysis of the pores in these images showed they had mean dimensions of about 20 x 40
μm among all treatment groups (Table 1). Histological sections of DCELLed CA ECM
displayed elliptical and oblong pores vacated by smooth muscle cells and fibroblasts,
intact internal elastic lamellae, and little delamination of the vessel tunics (intima, media,
adventitia; Figures 3.2, 3.3, 3.4, 3.5). Uniaxial tensile testing of DCELLed MYO ECM
samples showed that scaffolds from all groups had a higher elastic modulus than that of
native tissue (p<0.0001). Group 1 scaffolds (with epicardium attached) had a
significantly greater modulus than scaffolds from other groups (p=0.0011). Separation of
the epicardium from MYO ECM samples was not found to have a significant effect upon
the modulus (Figure 3.6C).
Tubular segments of DCELLed CA ECM from all groups exhibited burst
pressures which were not significantly different from those of native coronary arteries
and exceeded 2000 mmHg (Figure 3.6D).
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Figure 3.4: Immunohistochemistry (IHC) of native porcine myocardium and decellularized porcine
myocardial ECM, showing the degree of preservation of collagen IV (Coll IV), laminin, and fibronectin in
Group 2, Group 3, and Group 4 (40X, bar=20 μm). IHC positive staining = brown. Inserts = IHC negative
controls.
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Figure 3.5: Immunohistochemistry (IHC) of native porcine coronary artery and decellularized porcine
coronary arterial ECM, showing the degree of preservation of collagen IV (Coll IV), laminin, and fibronectin
in Group 2, Group 3, and Group 4 (20X, bar=50 μm). IHC positive staining = brown. Inserts = IHC negative
controls.
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3.3.3 Preservation of ECM Proteins and Basal Lamina:
Gomori’s trichrome, Movat’s pentachrome and Verhoeff-Van Gieson’s-stained
sections illustrated the preservation of collagen and elastin following DCELL in both
MYO ECM and CA ECM (Figure 3.3). Notably, elastin was diffuse in the CA ECM
(Figure 3.3) but was also observed in the epicardium and microvascular channels within
the MYO ECM (Figure 3.7). These results were consistent among scaffolds from all
treatment groups and indicate excellent preservation of collagen and elastin. To evaluate
preservation of basement membrane components, we performed IHC for collagen IV,
laminin, and fibronectin. These were all present within native tissues and localized to the
peri-cellular interstitium (Figure 3.4 and 3.5). IHC of sections from Group 4 confirmed
excellent retention of collagen IV, laminin, and fibronectin in both the MYO and CA
ECM following DCELL (Figures 3.4 and 3.5, Table 2). Scaffolds from groups exposed
to NaOH (Groups 1, 2, and 3), however, displayed a trend of increasingly diminished
staining of these proteins as length of NaOH exposure increased (Figures 3.4 and 3.5,
Table 2). IHC of sections from Group 1 scaffolds displayed sparse labeling of collagen
IV in comparison to other groups and little to no labeling of either laminin or fibronectin.
Images of these sections are not shown due to their similarity to images of sections from
Group 2 scaffolds.
Quantification of collagen and elastin content using total hydroxyproline and
desmosine analysis showed that MYO and CA ECM were composed mainly of collagen
and elastin, with slight differences among the various groups (Figure 3.6). Elastin
content was significantly different only between Group 2 and Group 4 in the MYO ECM
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(p=0.0005; Figure 3.6A) and between Group 2 and Group 3 in the CA ECM (p=0.0432;
Figure 3.6B). Both types of matrices from all DCELLed treatment groups had mean
collagen and elastin weight percentages which were significantly different from those of
native tissue (p<0.0001; Figure 3.6A and B). The ratio of mean collagen weight
percentage to mean elastin weight percentage for native myocardium was 19.5. This
ratio increased significantly in samples of DCELLed MYO ECM from all treatment
groups, and, among treatment groups, was only significantly different between Groups 1
and 4 (p=0.0457, Table 3). This same ratio was 4.3 in native coronary arteries, and it was
not significantly different from that of CA ECM in any of the groups (Table 3).

Figure 3.6: Biochemical quantification of collagen and elastin content of A) decellularized myocardial ECM
samples generated with four different decellularization treatments as compared to that of native myocardium
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(*: indicates statistical significance from all other groups, p<0.0001; **: p=0.0275; ***: p=0.0005). Collagen
and elastin content of B) decellularized coronary arterial ECM samples generated with four different
decellularization treatments as compared to that of native coronary arteries (*: indicates statistical
significance from all other groups, p<0.0001; **: indicates significance from all groups except Group 3,
p<0.0001; ***: p=0.002; #: p=0.0419; ##: p=0.0432; ###: p=0.0009). C) Young’s elastic moduli of
decellularized myocardial ECM samples generated with four different decellularization treatments as
compared to that of native myocardium (*: indicates statistical significance from all other groups, p<0.0001;
**: indicates statistical significance from all other groups in “without epicardium” group, p=0.0011). Groups
of samples with and without the epicardium attached were tested. D) Burst pressures of decellularized
coronary arterial ECM segments generated with four different decellularization treatments as compared to
that of native coronary arteries.

3.3.4 Preservation of Vascular Integrity and Patency:
Simultaneous injection of FITC- and RITC-conjugated dextran into arterial and
venous vascular inlets showed extensive perfusion of scaffolds with fluorophores (Figure
3.7A and B). An overlaid image of both emission spectra demonstrated that the
fluorophores had actually mixed within the same vessels (Figure 3.7C), and an overlaid
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image of the fluorescent channel with a white-light photograph of the scaffold (Figure
3.7D) illustrated localization of fluorophores to the scaffold vasculature. Corrosion casts
of a scaffold from Group 4 demonstrated retention of structure and patency of both
macro- and microvasculature following DCELL. Intact capillaries 5-8 μm in diameter
were observed in casts of native myocardium as well as DCELLed scaffolds (Figure
3.7). Carbon microspheres injected through the vascular inlets of a scaffold from Group
4 were observed to accumulate within capillaries in histological sections of distal portions
of the scaffold (Figure 3.7M and N). Microvasculature was also routinely observed in
histological sections, and was illustrated by staining of internal elastic lamina or laminin
via VVG and IHC, respectively (Figure 3.7K and L).
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Figure 3.7: Top Left Panel: Macroscopic images of a decellularized porcine myocardial scaffold from
Group 4 following injection with A) fluorescein isothiocyanate (FITC, red) through the arterial inlet and B)
rhodamine isothiocyanate (RITC, blue) through the venous inlet. C) Merged image of images A and B
showing colocalization of fluorescent dyes within arteries and veins. D) Merged image of image C and a
white-light image of the scaffold displaying fluorescent dyes confined to the vasculature. Bottom Left
Panel: Corrosion casts of the vasculature of E, F) native left-ventricular porcine myocardium and a G, H)
decellularized porcine myocardial scaffold from Group 4, showing preservation of both G) macro- and H)
microvasculature following the decellularization process. A 500 μm-diameter needle was included in the
frame as a scale reference (black bar in E-H=500 μm). Right Panel: Representative images across all
decellularization treatments of I) H&E- and J) VVG-stained sections of decellularized vasculature from
scaffolds showing the coronary artery (CA) and adjacent cardiac vein (CV; 2.5X, bar=500 μm). Micrographs
of K) VVG staining and L) IHC for laminin in sections of microvasculature from Group 4 scaffolds showing
preservation of elastin (black) and laminin (brown) around vessels, respectively (40X, bar=20 μm).
Micrographs M, N) of decellularized myocardial scaffold vasculature from Group 4 following injection of
2-12 μm–diameter, carbon particles via the vascular inlets. Sections were from sites distal (apical portions
of scaffold) to inlets, and black carbon particles are shown localized to small vessels (M: 10X, bar=100μm;
N: 20X, bar=50 μm).

3.3.5 Cytocompatibility:
Samples of MYO ECM from scaffolds exhibited excellent cytocompatibility to
fibroblasts after 7 and 14 days in culture (Figure 3.8A). Rat neonatal cardiomyocyteseeded samples labeled for connexin43, actin, cardiac myosin heavy chain (MHC), αsarcomeric actinin, and DAPI appeared viable and positive for these markers. Although
no tests of functionality were performed, cells appeared to interconnect and self-organize
on the scaffolds (Figure 3.8B).
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Figure 3.8: A) Images of decellularized porcine myocardial ECM from Group 4 scaffolds seeded with rat
dermal fibroblasts (FB) and cultured for either 7 (top) or 14 (bottom) days. Cells were labeled with Live/Dead
reagents at each time point. Live cells were labeled with calcein AM (green) and dead cell nuclei were
stained with ethidium homodimer (EthD-1, red; 20X, bar=50 μm). B) Immunofluorescence (IF) images of
decellularized porcine myocardial ECM from Group 4 scaffolds seeded with neonatal rat cardiomyocytes
(CM) and cultured for 7 days. Scaffolds were stained for α-sarcomeric actinin, cardiac myosin heavy chain
(MHC), actin, connexin43 and DAPI (40X, bar=20 μm).

3.4 Discussion
3.4.1 Evaluation of Decellularization Efficiency:
In this study, we have taken a systematic and thorough approach to developing a
naturally vascularized, acellular myocardial flap, addressing the key features and
characteristics of the myocardial matrix, the major arteries and veins, and the intrinsic
microvasculature. Several groups have successfully DCELLed myocardium in either
whole or excised portions of both rat and pig hearts using a wide range of chemical
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agents and physical methods.[5-11, 16] Many reported on characteristics (e.g. acellularity,
biochemical composition, vascularity, thickness) of the resulting scaffolds and their
applicability to tissue engineering efforts. However, with regard to optimization of a
DCELL method, these studies vary in the comprehensiveness of their analysis.
Our choice of chemical agents for DCELL was predicated upon previously
published results from studies which used SDS [2, 6, 8, 11] and upon our previous experience
with NaOH as a DCELL agent. The latter has long been used in “hot alkali” methods for
elastin isolation (indicating its suitability for preserving elastin),[13] and we previously
observed extensive removal of DNA and collagen from carotid arteries treated with 0.1
M NaOH at 37˚C.[15] In several pilot studies, we used this same concentration of NaOH
to decellularize myocardium at room temperature, and did not observe any noticeable
degradation of the collagenous matrix components (data not shown). We surmised that
the lower temperature reduced protein degradation kinetics so as to remove cellular
proteins without causing extensive damage to the collagenous ECM. Thus, it was of
interest to investigate the combinatorial effect of SDS’s ability to solubilize plasma
membranes and denature proteins with NaOH’s affinity for solubilizing protein and
degrading nucleic acids.[2]

3.4.2 Removal of Cellular Material:
Despite its reputation as an effective DCELL reagent,[1, 2, 8, 11, 17] it has been
suggested by some that SDS may leave cellular remnants when used in DCELL of MYO
ECM. However, there is scant evidence furnished by the authors in support of this
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contention.[9] Our own histology and IHC results demonstrated that every DCELL
treatment we investigated, including that which used solely SDS following EDTA (Group
4), was effective in disrupting cell and nuclear membranes and in completely removing
intracellular proteins from both the MYO ECM and CA ECM. Measurements of the
dimensions of pores within our DCELLed scaffolds are consistent with those previously
reported.[7] DNA quantification was carried out to provide an additional measure of
acellularity, and with the exception of the Group 4 treatment, all DCELL methods left
only small amounts of residual DNA. Although quantitative assays, as well as H&E- and
DAPI-stained sections, confirmed that Group 4 scaffolds contained visible amounts of
residual DNA (Figure 3.1), none of the corresponding histological stains or IHC showed
muscle proteins or other apparent cellular remnants (Figure 3.2). Furthermore, the
nucleic acids in these sections were not observed in small, concentrated areas (which
would be indicative of intact nuclei), but rather seemed faint and diffuse, occasionally
“pooling” within pores of the matrix. This was especially evident in areas adjacent to
denser portions of the matrix, such as the epicardium, adventitia, and internal elastic
lamina, where resistance to diffusion of large molecules is potentially greater.
In replicating a similar SDS-based protocol developed by Ott et al., Akhyari and
colleagues showed only a 43% reduction of native DNA content.[11, 16] Weymann et al.
DCELLed an intact porcine heart using perfusion of 4% SDS over 12 h, concluded with
perfusion of PBS for 24 h, and reported an 82% reduction in DNA content.[8] While SDS
was effective in lysing the nuclear membranes, it likely did not interact with this newly
extra-nucleated, or free DNA. This lack of interaction is explainable, given that SDS is a
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strongly anionic molecule and DNA is negatively charged along its phosphate backbones.
NaOH, by contrast, is exceedingly effective in breaking down DNA, as it causes both
denaturation[18] and hydrolysis of the molecule.[19]
To reduce content of residual DNA within Group 4 scaffolds, we prepared a new
set of scaffolds using the Group 4 treatment and compared the effects of three prospective
post-SDS “washing procedures” upon levels of residual DNA. The DNAse/RNAse and
NaOH (2 hours) treatments were effective in removing some residual DNA, but did not
achieve the very low levels of residual DNA observed in groups with significant
exposure to NaOH (2 days or more). Despite this, we demonstrated that minor additions
to our Group 4 treatment could result in further removal of DNA to acceptable limits.

3.4.3 Preservation of Basal Lamina Components:
Basement membrane proteins contain important cell binding moieties, and any
alteration of their conformation by chemical or physical means during DCELL could
render them nonfunctional.[16, 20] Laminin is a vital link in the chain which binds the
cardiomyocyte cytoskeleton to the collagenous ECM components, thereby facilitating
transfer of mechanical forces and stimuli between the two.[21, 22] It has multiple domains
which allow it to simultaneously bind integrins, proteoglycans, and collagen IV, making
laminin the all-purpose “glue” of the basement membrane.[4, 23] Attachment to laminin
has also been shown to be necessary for cardiomyocyte survival in vitro, indicating its
ability to mediate important cell signaling pathways. [24, 25] Collagen IV assembles into
an open network overlaying the predominant structural ECM proteins.[18] It serves as the
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linkage between fibrillar collagens and both laminin and fibronectin. Fibronectin acts as
an important intermediary between cardiomyocytes and the basal lamina, binding
integrins, proteoglycans, and collagens.[23] Although these are minor components within
the ECM, they will likely play a major role in the attachment, mechano-transduction,
differentiation, maintenance of phenotype, and ultimately, functionality of reseeded cells.
In our studies, DCELL treatments which employed NaOH altered and/or removed
basement membrane proteins. While collagen IV and fibronectin appeared less affected
by this exposure, laminin was aggressively degraded by NaOH (full degradation at 48 h
exposure to 0.1 M NaOH). Scaffolds from Group 4 (SDS alone) retained all basement
membrane proteins we attempted to identify by IHC.

3.4.4 Preservation of Collagen and Elastin:
Quantitative analysis showed that collagen and elastin were the predominant
components of both myocardial and coronary matrices within scaffolds from all groups.
Aside from studies which reported Western blotting results[16] and qualitative or semiquantitative results,[5-10] to our knowledge, no other attempts were made to quantify these
important matrix proteins. Elastin plays an important mechanical role in normal cardiac
tissue, as it facilitates passive recoil of the matrix following muscle contraction and
distension of the collagenous components within both the MYO and CA ECM.[23, 26]
Akhyari et al. reported that DCELL with a similar method reduced elastin content relative
to native tissues,[16] but our data show that elastin content is largely preserved,
particularly within the CA ECM.
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3.4.5 Evaluation of Mechanical Properties:
Overall, the elastic moduli of MYO ECM and CA ECM did not differ
significantly from native tissues, which suggests that DCELL procedures assessed in this
study did not alter their mechanical properties. The elastic moduli we report here (0.40.9 MPa) for DCELLed MYO ECM is somewhat lower than that reported by other
groups, but this does not indicate that our scaffolds are by any means mechanically
deficient. This disparity can be attributed in part to differences in mechanical testing
methods (e.g. strain rate, modulus calculation method, preconditioning, preloading, and
cross-sectional area measurement techniques for calculation of engineering stress). Our
mechanical testing procedure was most comparable to that described by Eitan et al. in
terms of preconditioning and strain rate, but it was not clear as to which specific portion
of the stress-strain curve was used for calculation of their reported elastic modulus.[10]
Our myocardial matrix is also considerably less stiff than another acellular porcine MYO
ECM generated with an SDS-based protocol, which had a reported modulus of 5.219
MPa (strain rate was 6.0 mm/min – twice the rate used in the current study).[6]
Importantly, both the above DCELL protocols employed trypsin extensively
(Sarig et al.: 0.05% (w/v) for 96 hr and Wang et al.: 0.01% for 2.5 weeks).[7, 9] Trypsin is
a serine protease known to partially degrade elastin, an observation confirmed by our
own work with this enzyme (data not shown). Acellular myocardial matrix generated by
the first trypsin protocol[9] was reported to be completely devoid of elastin, and while
recently published results from the second group confirm the presence of elastin
histologically, no quantitative data was provided.[7
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3.4.6 Vascular Integrity and Patency:
Corrosion casts of scaffolds demonstrated that our DCELL procedure leaves the
inherent vasculature intact to the extent of preserving the patency of microvasculature
and capillaries. Simultaneously anterio- and retrogradely injected fluorescent dyes were
able to move freely through the scaffolds’ vascular tree and mix with one another. In
addition, carbon microspheres appeared within distal microvascular channels following
their injection into the scaffold’s main vascular inlets. These observations confirm that
the microvasculature and capillary beds linking the arterial and venous circulation are left
intact by our DCELL process. Using a similar perfusion SDS-based protocol, Ott et al.
presented evidence of vascular preservation with corrosion casting results, but also by
heterotopically connecting the vasculature of their whole, DCELLed rat heart to the aorta
of a recipient rat and observing perfusion of the scaffold with host blood.[11]
Microvasculature is absent in trypsin-exposed scaffolds, possibly complicating
subsequent efforts to maintain viability of reseeded cells and limiting feasibility of
reperfusion or graft integration upon implantation.[9, 16]

3.4.7 Cytocompatibility and Cardiomyocyte Cell Seeding:
Several groups have already established DCELLed MYO ECM as an acceptable
substrate for supporting reseeded cells.[5, 6, 9-11, 16] Relevant cardiac cell types seeded onto
samples of DCELLed MYO ECM from scaffolds in Group 4 attached, maintained a
cardiac phenotype, and remained viable for up to 14 days in static culture. These data
support the cytocompatiblity of our scaffolds and their suitability for maintaining
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cardiomyocyte cell phenotype, although more definitive studies must be conducted to
substantiate the latter claim.

3.4.8 Analysis of Optimal Decellularization:
The acellular myocardium is an outstanding matrix scaffold with promising tissue
engineering applications for in vitro testing, as well as for in vivo regeneration. Our
results suggest that a rational design and selection of DCELL methods for myocardium
needs to take into account several criteria which serve the intended final application.
These criteria were used to comment on some of the positive and negative effects of each
of the DCELL reagents we investigated, including EDTA (Table 4).
Our comparative study shows that scaffolds DCELLed with SDS alone exhibit
excellent preservation of major and minor ECM components but are not fully DNA-free
despite extended perfusion with SDS, which removed all detectable cell proteins. PostSDS treatments with nucleases may reduce DNA content further and thus provide
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acceptable scaffolds for implantation. NaOH, on the other hand, is very effective at
removing all traces of DNA but also removes some of the basement membrane
components. Currently, there is no definitive evidence to support residual exogenous
nucleic acid content as being a critical determinant of the success or failure of implanted
scaffolds or constructs.[27] Producing a DNA-free scaffold is neither the sole, nor
necessarily the most important, criterion for determining whether a scaffold is optimal,
and it must be weighed against other criteria in judging a scaffold’s suitability for tissue
engineering applications. There is evidence, however, that basement membrane proteins
play an important role in cell survival, attachment, and interactions with the ECM.[16, 23-25]
Thus, in selecting a scaffold for regenerative medicine applications, we lend more
credence to preservation of native ECM characteristics than we do to absolute removal of
DNA. For this reason, our future work will be conducted using scaffolds from Group 4
which have been treated to further remove residual DNA. Other scaffolds we generated
are also suitable materials for tissue engineering. Some may see merit in using them,
especially since their lower DNA content may assuage fears of immunogenicity or other
unforeseen negative effects. Ongoing studies focus on cell-seeding and preconditioning
of constructs made from our scaffolds, and on implantation studies to assess
biocompatibility and feasibility of implantation techniques.

3.5 Conclusions:
To the best of our knowledge, this is the first study which has carried out a
comprehensive, parallel analysis of both the vascular and myocardial matrices in a
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myocardial flap containing intact coronary arteries, veins, and associated
microvasculature. DCELL of such complex tissues was challenging and required a
comparative analysis of detergent versus alkaline DCELL methods. Our scaffolds are
porous, retain collagen and elastin content and structure, exhibit excellent mechanical
properties, and are cytocompatible. Moreover, scaffolds retain laminin, fibronectin, and
collagen IV. We’ve also preserved the vasculature’s integrity and patency down to the
capillary scale, as shown by several assays. Together with our demonstration of
cytocompatibility and support of cardiomyocyte survival, these results indicate that our
scaffold is ideally suited for repopulation with relevant cardiac cell types as a tissueengineered construct for myocardial repair. Given its composition, intact vasculature
tree, mechanical properties, and geometry, we believe constructs produced from this
scaffold have the potential to functionally integrate with healthy host myocardium and to
be nourished by direct anastomotic connection with the host’s own vasculature. We also
believe such constructs may be useful as physiologically accurate models for in vitro
studies of cardiac physiology and pathology.

3.6 Updates to These Methods:
It is noteworthy that our process of tissue preparation and DCELL changed from
those depicted in Figure 3.9 since these studies were conducted. To make preparation of
the tissue for DCELL less labor-intensive, we elected to decellularize the entire porcine
heart via retrograde perfusion of the aorta to generate scaffolds for use in future studies
(Figure 3.10C). We designed a new vessel to accommodate an entire porcine heart using
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SolidWorks software, and machined three of these containers with the help of Clemson
University Machining and Technical Services (Figure 3.10B and D). The critical point
of this method involved preventing the outflow of solutions from the heart at too high of
a rate. It was necessary to maintain pressure within the left ventricle so that the main
path travelled by solutions was into the coronary arteries, through the microvasculature,
and out through the veins. As such, the pulmonary veins at the posterior of the heart
needed to be closed to prevent solutions from preferentially flowing rapidly through the
left ventricle, into the left atrium, and out of these severed veins. We sealed the veins
with suture or a plugged cannula secured with zip-ties (in the case of large openings).
Upon achieving complete DCELL of the organ, regions of interest were dissected and
used for experiments in Aims 2, 3, and 4. The reagents used and the sequence in which
they were used did not change, however, and characteristics of scaffolds generated with
this new method were identical to those presented here (data not shown).
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CHAPTER FOUR: EVALUATION OF THE HOST RESPONSE TO IMPLANTED
MYOCARDIAL SCAFFOLDS

4.1 Introduction:
In myocardial tissue engineering, the optimal therapeutic approach is one of
delivering a graft containing functional, autologous CM that will integrate electrically and
mechanically with existing healthy myocardium. Delivery of a sufficient number of new
CM to replace CM lost in an MI requires a thick graft, nourished by an organized
vasculature. The optimal scaffold must not only support and nourish the replacement CM,
it must also resist significant degradation by the host until these CM can integrate with
native CM and until the graft’s vasculature can form connections with native vasculature
of the host. The important questions then become 1) how long do these processes take,
and 2) what is an acceptable degree of degradation?
Since our scaffold is composed of ECM, which is normally in a constant state of
turnover via degradation and synthesis, it is expected that some degree of remodeling will
occur in our implanted grafts. Over time, host CM, endothelial cells, vascular smooth
muscle cells, and especially macrophages and cardiac fibroblasts will likely infiltrate the
myocardial grafts and degrade the scaffold ECM while replacing it with endogenous, fully
remodeled ECM that incorporates the delivered cells into the tissue. Groups who have
implanted ECM or other biologic scaffold-based grafts in the myocardium have observed
cell and vascular integration as early as 4 days and consistently at 4 weeks and beyond. [16]

Despite the rapidity with which integration can occur, scaffolds should not be considered
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dispensable before the 3-week period encompassing the acute and subacute host responses
has elapsed.[7, 8] Furthermore, in light of the thickness of the grafts and the potentially
inhospitable environment into which they will be placed, the scaffolds should remain
largely intact for up to 8 weeks to ensure that their constituent cells have ample time to
integrate with host tissue and vascular supply.
To learn more about the possible host response to our scaffolds, we implanted them
in an in vivo model that represented a very active immune site, so that if the material was
immunogenic, we would be certain to observe a response.

The model, subdermal

implantation in juvenile rats, does so because the integumentary system boasts a strong
presence of immune cells, including Langerhans cells and dendritic cells, and because the
adaptive immune system in these juvenile animals is sufficiently developed and, overall,
vigorous.[9]

4.2 Biocompatibility Study 1:
4.2.1 Methods:
4.2.1.1 In Vitro Cytotoxicity Assessment:
The indirect cytotoxicity of scaffolds was evaluated according to methods adapted
from ISO standard 10993-5.

Possible extractables were eluted from high density

polyethylene (HDPE; negative control) and scaffolds via incubation of (n=6), 5 x 5 mm
samples of each material in culture media (DMEM with 10% FBS) at 37 °C for 7 days.
NIH 3T3 fibroblasts were then seeded into two 24-well plates at 50,000 cells/well (n=3
wells/condition) and cultured for 3 days in standard media prior to being cultured with
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extraction media containing possible cytotoxic eluates for 7 days. Upon 7 days of culture
with extraction media, cell viability was examined using a tetrazolium-based MTS assay
(Promega) and a Live/Dead® assay (Invitrogen). In each assay, measurements collected
from the cells exposed to extracts were compared to those of cells cultured in either
negative (normal media) or positive (70% ethanol) conditions to quantify the extent of
cytotoxicity.

4.2.1.2 Scaffold Sample Preparation for Implantation:
DCELLed scaffolds were prepared according to the original method of dissection
and DCELL as described in Chapter 3. Following DCELL, a 10 mm-diameter biopsy
punch was used to cut pieces of scaffold, and the resulting cylinders were cut in half to
create the final samples used for implantation. Prior to implantation, the samples were
sterilized by immersion and gentle agitation in 0.1% (w/v) peracetic acid in PBS for 1 h,
followed by rinsing in 4 changes of sterile PBS. Peracetic acid has been demonstrated to
be an effective antibacterial and antimicrobial agent by means of oxidation, and has been
used successfully in our lab as a non-degradative wet sterilization method.[10-12]

4.2.1.3 Subdermal Implantation Procedure:
In accordance with an approved animal use protocol, 16 juvenile Sprague-Dawley
rats were anesthetized with buprenorphine at 0.03-0.05 mg/kg and acepromazine at 0.5
mg/kg administered subcutaneously. A small incision was made in the center of the dorsal
area of each rat about 2 cm inferior to the scapulae, and, using blunt dissection, two pockets
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were created between the dermis and fascia lateral to the incision (one pocket in each
direction). A scaffold sample was placed into each pocket, and the incision was closed
using staples. Rats were allowed to recover and were housed individually for the remainder
of the study.

4.2.1.4 Explantation and Histological Evaluation:
At both 4 and 8 weeks post implantation, (n=8) rats were euthanized via CO2 gas
(Euthanex system) followed by bilateral pneumothorax. Scaffold samples and small
amounts of their adjacent host tissues were excised and fixed in 10% neutral buffered
formalin and processed for histological examination.
Parafin-embedded samples were sectioned at 5 µm and stained by H&E and
immunohistochemistry (IHC) for CD68, a marker for monocytes/macrophages, and CD8,
a marker for cytotoxic T-lymphocytes.

4.2.2 Results:
4.2.2.1 In Vitro Cytotoxicity Assessment:
Preliminary testing of the scaffolds revealed no evidence that they contained
cytotoxic leachables. Two methods, Live/Dead staining (Figure 4.1A) and an MTS assay
(Figure 4.1B) were used to measure cytotoxicity. Results were reported as comparisons
to measured values from fibroblasts grown in normal cell culture media. Neither assay
demonstrated a significant difference in viability between cells exposed to extract media
from scaffolds and cells grown with normal media. The assays were proven to be effective
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in measuring cytotoxicity by the inclusion of both a positive and negative control in the
experimental design. The positive control resulted in a great increase in cell death, and the
negative control saw no significant deviation from the normal control in the Live/Dead
assay.

Rather unexpectedly, cells from the negative control displayed a significant

reduction (40%) in cell viability compared to normal cells as measured by MTS assay,
although this reduction was not to the extent observed with the positive control (60%).
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Figure 4.1: In vitro cytotoxicity assessment: Live/Dead® A) and MTS® B) assays for cytotoxic effects
of myocardial scaffolds. In each assay, the reported value for each group is relative to the measured value
for NIH 3T3 fibroblasts under standard culture conditions (i.e. a value of 1 in A and 100% in B; *: indicates
statistical significance from control, p<0.0001 in A and B; **: indicates statistical significance from control,
p=0.0005 in B).

4.2.2.2 Explantation and Histological Evaluation:
DCELLed myocardial scaffold samples implanted in rats were almost completely
degraded at 8 weeks post-implantation. In a few cases (2 of 8 rats) at this time point, it
was not possible to macroscopically identify any remaining scaffold upon explantation.
H&E staining, as well as IHC for CD8 and CD68, revealed the presence of large
populations of immune cells, including macrophages and lymphocytes, inside the scaffolds
and at the implant-host tissue interface. This was consistent in histological sections of
explants from both time points, seemingly indicative of a chronic inflammatory response
(Figure 4.2). It was also noted that a significant number of cells in the IHC sections did
not stain positively for either marker, indicating that they were not macrophages,
monocytes, or cytotoxic T-lymphocytes.
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Figure 4.2: Histological analysis of explanted scaffolds from Biocompatibility Study 1: Representative
images of H&E staining of decellularized myocardial scaffolds following subdermal implantation in juvenile
rats for 4 weeks show heavy infiltration of leukocytes within and around the scaffolds (S); dashed black line
denotes scaffold-host tissue interface. Representative images of IHC for CD8 and CD68 show T-cells and
monocytes and/or macrophages, respectively, are present within the scaffolds. Representative images of
H&E staining of explanted scaffolds at 8 weeks post-implantation show persistent and, in some cases,
increased presence of leukocytes within and around scaffolds in comparison to scaffolds explanted at 4
weeks. The amount of identifiable scaffold in each sample explanted at 8 weeks was also greatly diminished
with respect to that of samples explanted at 4 weeks (in some cases scaffolds were not identifiable at all).
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4.2.3 Discussion:
In our experience with implanted scaffolds, we had not observed an inflammatory
response of this magnitude.[13-15] Furthermore, as discussed previously in this document,
the expected response to an acellular scaffold should not involve an aggressive or
protracted immune response. We hypothesized that this response could have been due to
insufficient rinsing of the scaffold prior to implantation (instead of perfusing wash
solutions through the scaffold as was done with DCELL solutions, scaffolds were simply
immersed in wash solutions with agitation on an orbital shaker), and therefore to the
presence of residual SDS from DCELL or peracetic acid from sterilization methods.
To test for residual SDS, we retroactively performed an assay to quantify the SDS
concentration (described in further detail in methods section for Biocompatibility Study 2)
in lysates of leftover, unimplanted scaffolds. It was found that the SDS concentration in
the pre-implanted scaffolds was 2.14 +/-1.17 µg/cm3 tissue. In searching for some context
as to whether this concentration was sufficient to induce cytotoxicity, we came across a
study which focused upon determining whether SDS used to decellularize pulmonary
valves could be removed from the tissues, and correlated residual SDS concentrations with
cytotoxicity and metabolic activity as measured by lactate dehydrogenase (LDH) and MTS
assays, respectively.[16] The authors found that after 5 wash cycles with PBS, they could
reduce the SDS concentration to under 50 µg/mL, and that this concentration did not result
in any cytotoxicity or reduction in metabolic activity. Yet another study cited the threshold
toxicity concentration (defined as a 10% decrease in cell viability) of SDS as 0.047 mM,
or roughly 13.6 µg/mL (in this case, specific gravity dictates 1 mL=1 cm3).[17] Given that
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the SDS concentration within our scaffolds was nearly 25-fold and 6-fold less these figures,
respectively, we ruled out residual SDS as the cause of any heightened immune response.
Similarly, previous studies conducted by our lab involving peracetic acid
sterilization of implanted scaffolds did not result in any negative outcomes associated with
immune or inflammatory responses.[11] In these cases, simple repetitive washing of the
scaffolds with PBS on an orbital shaker (identical to the method used here) was sufficient
to remove peracetic acid.
In the absence of any other obvious explanation for the response we observed, it
was worth delving deeper into the results of similar studies, both internal and external to
our lab. Previous scaffolds we implanted were not only generated from vastly different
tissues (thus, of different structure and composition), but were also either fixed with PGG
or seeded with ADSC, both of which have been shown to mitigate the immune response.[13,
14, 18]

Our conventional thinking about host responses to implants has been informed by
observations of responses to non-biological, and thus, less bioactive materials. It is narrowminded to assume that the host response to a material composed of ECM proteins should
proceed in the same manner. Instead, the host uses the only real means at its disposal to
respond to the presence of this material – leukocytes (e.g. lymphocytes, monocytes, and
macrophages). Together, these cells dictate the nature of the response to the material and
direct its remodeling through mechanisms traditionally associated with inflammation.[19, 20]
One could argue that fibroblasts also play a role in the host response to biologic
scaffolds because they are capable of both synthesizing and degrading (via secretion of
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matrix metalloproteases; MMPs) ECM components.[21]

Their synthesis of MMPs,

however, is largely mediated by signaling from TNF-α and TGF-β1 – cytokines produced
by leukocytes, so it is unlikely that fibroblasts could direct the remodeling or degradation
of a biological scaffold on their own.[22]
In addition, there is further evidence in the literature to suggest that what we viewed
as an aggressive inflammatory response was simply a normal response to a non-crosslinked
biologic scaffold. While our previous studies with PGG-treated scaffolds showed limited
involvement of macrophages in the host response, several studies conducted by the
Badylak group demonstrated a prominent role of various subsets of macrophages,
neutrophils, and monocytes in the response to implantation of non-chemically modified
scaffolds.[20, 23-25]
It has been established that macrophages are possessed of significant plasticity,
changing, or “polarizing”, to fit the conditions of the local environment. While there are
multiple phenotypes (M1, M2a, M2b, and M2c), polarization generally refers to the polar
extremes of either an M1 (classically activated, proinflammatory) or M2 (alternatively
activated, immunomodulatory and remodeling) phenotype.[23, 24, 26] Enough is known about
these two distinct populations that they can be identified by certain markers: inducible
nitric oxide synthase (iNOS), CD80, and CCR7 for M1, and CD206, CD163, and Fizz1/Ym
for M2.[23, 27] In general, it has been observed that desirable outcomes with implanted
biological scaffolds (i.e. remodeling into appropriate, functional tissue as opposed to scar
tissue formation) correlate with a shift from the M1 to the M2 polarity as the host response
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progresses.[20] With this in mind, it became of interest to identify the types of macrophages
present within the implant site at different time points.
An additional observation from this first study was that not all cells which had
infiltrated the scaffolds stained positively for markers of monocytes, macrophages, and
lymphocytes. This is not surprising given that we have previously found that other types
of scaffolds (DCELLed porcine carotid arteries and DCELLed porcine pericardium)
implanted in this same model attracted cell infiltrates that stained positive for vimentin,
prolyl-4-hydroxylase, and alpha-smooth muscle actin in addition to macrophages.[13, 14]
In light of the questions surrounding the outcomes of this study, we planned a
subsequent study to investigate means to forestall complete degradation of the scaffold and
to more closely examine the identities, functions, and origins of cells at the implant site in
order to gain a better understanding of the host response and the ultimate implant fate.

4.3 Aims for Biocompatibility Study 2:
In the eventual clinical adaptation of this approach, we believe that extending the
in vivo lifespan of the scaffold so as to partly preserve it up to 12 weeks or beyond will
lead to more favorable outcomes with respect to myocardial graft integration and
incorporation of constituent cells. To test if this was possible, we employed penta-galloyl
glucose (PGG), an ECM protein-binding, plant-derived polyphenol, as a cross-linking
agent to impart the scaffolds with greater resistance to degradation by the host. Indeed,
previous studies conducted by our laboratory demonstrated that treatment of scaffolds with
PGG protected them not only from excessive matrix metalloprotease-driven degradation,
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but also prevented calcification while mitigating the severity of the immune response
(Figure 4.3).[15]
Figure 4.3: Effects of PGG as assessed by
histology and cytokine array: Histology and
IHC performed on decellularized carotid
artery

scaffolds

following

subdermal

implantation in rats for 4 weeks. Scaffolds
treated

with

PGG

show

decreased

susceptibility to calcification and deposition
of osteogenic proteins in comparison to
scaffolds not treated with PGG (nontreated),
as reflected by alizarin red staining for
calcium (Azn Red), and IHC for osteopontin
(OPN) and alkaline phosphatase (ALP).
PGG-treated

scaffolds

also

displayed

immune-modulatory characteristics, as fewer
CD68 positive cells were identified within
them than in nontreated scaffolds (as assessed
by IHC), and less TNF-α was observed in
PGG-treated scaffolds in a cytokine array
(graph).
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We expected that myocardial scaffolds treated with PGG would demonstrate
improved resistance to degradation over non-treated scaffolds, and the degradation profile
of PGG-treated scaffolds would be sufficiently gradual to allow regenerative cells
delivered within them in the future to integrate with host cells and provide functional
benefits. If at least a portion of the scaffold remained at 8 weeks post-implantation, this
expected outcome was considered met.
This study was also intended to analyze the host biological response to the
implanted myocardial scaffold, specifically in terms of macrophage polarization. The
results allowed us to determine whether this biomaterial elicited a classical inflammatory
response or a more constructive, remodeling response. Given PGG’s purported antiinflammatory properties, we expected to observe a significant reduction of inflammatory
cells within and around the implant site of PGG-treated scaffolds as compared to nontreated scaffolds.

Similarly, we expected to observe a greater ratio of M2 to M1

macrophages and greater recruitment of stem cells, indicative of a more regenerative
response, in the PGG-treated scaffolds.
Cellular infiltration, vascularity, and collagen content were analyzed in order to
evaluate the structure of the tissue that was formed as a result of the host response. We
also intended to determine the phenotype of the previously unidentified cells by staining
for common markers of fibroblasts, smooth muscle cells and mesenchymal and
hematopoietic stem cells, which could be recruited to the site in order to remodel the
scaffold.

109

4.4 Biocompatibility Study 2:
4.4.1 Methods:
4.4.1.1 Quality Control Characterization of Scaffolds: DNA Quantification, SDS
Quantification, and alpha-1, 3-galactose Screening:
4.4.1.1.1 DNA Quantification:
Picogreen and Oligreen assays for double-stranded DNA (dsDNA) and singlestranded (ssDNA), respectively, were carried out on (n=6) samples from randomly selected
areas of the DCELLed scaffolds used in this implantation study. Briefly, samples were
completely digested in 1 mL of papain digestion buffer and run against a standard curve
generated from known concentrations of a supplied DNA standard in order to determine
the DNA content of each sample.

4.4.1.1.2 SDS Quantification:
In addition to acellularity, it was also important to demonstrate the removal of SDS
from scaffolds following DCELL. Residual SDS in an implanted scaffold could be
cytotoxic to the immediate host cells and elicit an aggressive inflammatory response if its
concentration was sufficiently high and/or persistent. The same digested scaffold samples
(n=6) described above in DNA quantification methods were also used in this assay. The
assay was derived from a previously published method and designed around a phase
separation principle.[28] It involved an aqueous phase comprised of slightly alkaline PBS
(pH=8.0) and toluidine blue dye, as well as a chloroform organic phase, and the two phases
were combined in a single test tube. A small volume (5-10 µL) of digested scaffold was
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added to the aqueous phase, the two phases were mixed by inversion, and the mixture was
incubated at room temperature. The critical mechanism of the assay was the binding of
toluidine blue to SDS. This complex was able to traverse the interface between the two
phases due to the amphiphilic nature of SDS. The SDS-toluidine blue complex then
collected in the chloroform phase, and a volume of this phase was pipetted into a 96-well
plate for spectrophotometric analysis of absorption at 600 nm. The optical density of each
sample of unknown SDS concentration was compared against a standard curve of samples
of known SDS concentration, and the concentration of unknown samples was extrapolated
(Figure 4.5B).

4.4.1.1.3 Screening for alpha-1, 3-galactose:
The alpha-1, 3-galactose, or alpha-gal, carbohydrate is found in all non-primate
mammals, and therefor triggers an aggressive immune response when introduced into
humans. This is particularly concerning given that porcine tissue contains this antigen,
which must be removed from scaffolds intended for xenogeneic implantation in humans,
lest an immune response lead to implant rejection and failure.[29] Since alpha-gal is
normally occurring in rats, its presence in the scaffold would not be detrimental to this
particular implantation study. However, with implantation in humans as a future goal for
this scaffold material, it was prudent to demonstrate the removal of alpha-gal from the
tissue as a result of the DCELL process.
Removal of alpha-gal was demonstrated using standard immunohistochemistry
techniques. Instead of a primary IgG or IgM antibody, biotinylated isolectin B4 generated

111

in the griffonia simplicifolia shrub was used to label alpha-gal. Avidin/biotinylated
enzyme complex (ABC; Vector Labs.) with horseradish peroxidase was applied to tissue
sections, followed by the enzyme substrate, 3, 3'-diaminobenzidine (DAB). As a result of
this detection system, brown color was developed wherever alpha-gal was located.

4.4.1.2 Scaffold Preparation and PGG fixation:
Scaffolds were prepared by the method of whole heart DCELL and individual
samples were prepared as previously described. Scaffolds were exposed to differing
concentrations of PGG (Omnichem Ajinomoto, Belgium), 0.15% and 0.3% w/v in 50 mM
phosphate buffer, pH=5.5, containing 20% isopropanol for 24 h, or were left untreated as
a control. Scaffolds were then rinsed with PBS and sterilized for implantation as described
above in the first implantation study.

4.4.1.3 Subdermal Implantation in Rats:
Forty-five male, juvenile Sprague-Dawley rats were randomly assigned between
three groups: 1) non PGG-treated (NT), 2) 0.15% PGG-treated, 3) or 0.3% PGG-treated
(n=5 rats/group/time point). The corresponding scaffolds were subdermally implanted into
each rat. Anesthesia, surgical procedure, implantation (2 scaffolds/rat), closure, and
recovery proceeded in the same manner as previously described.
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4.4.1.4 Explantation and Semi-quantitative Histological Analysis:
At 4, 8, and 12 weeks post-implantation, animals were euthanized as previously
described, and the scaffolds and immediate surrounding tissue were excised and examined
histologically to characterize the host response, as well as the rate and extent of
degradation. Following standard formalin-fixation and paraffin embedding, 5 µm-thick
sections were prepared and stained via H&E and Masson’s trichrome methods. Sections
were imaged using an inverted Zeiss Axiovert microscope and accompanying AxioVision
software. Micrographs were obtained of high powered fields (400X magnification) at the
scaffold/host tissue interface (10 images/section; n=30 images/condition). Characteristics
of the local host response, such as cellularity (cell infiltration), foreign body/multinucleated
giant cell proliferation, vascularity, and collagen content were analyzed semiquantitatively
using ImageJ software (NIH) to quantify these components of interest in the field of view)
(Figure 4.7).
Macrophage polarization was assessed by immunofluorescence double-staining of
formalin-fixed, paraffin-embedded, 5 µm-thick section. Sections were deparaffinized and
heat mediated antigen retrieval with 10 mM citric acid at ph=6.0 was performed. Primary
antibodies for known markers of M1 and M2 macrophages, C-C chemokine receptor type
7 (CCR7, Cell Applications; 1:250 dilution) and CD206 (Santa Cruz Biotechnology; 10
µg/mL), respectively, were applied and sections incubated overnight at 4 °C. Nuclei were
counter-stained with DAPI. Sections were imaged using an inverted Zeiss Axiovert
microscope equipped with mercury lamp, and accompanying AxioVision software.
Micrographs were obtained of high powered fields (400X magnification) at both the
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interior of the scaffold (3 images/condition) and the scaffold-host tissue interface (3
images/condition). ImageJ software was once again used to process the images and count
numbers of positively-stained cells for each marker (Figure 4.10). Resulting data was used
to compare the response in different groups and time points.

4.4.1.5 Statistical Analysis:
Wherever possible, analysis of variance (ANOVA) was performed to identify
differences in population means and to test for significant effects of overall factors (i.e.
time point and treatment). Post-hoc comparisons between means of individual conditions
(treatment and time point) were performed using Fisher’s least significant difference test
(LSD). In all tests, a p-value of 0.05 or less had to be calculated to attain statistical
significance.

4.4.2 Results:
4.4.2.1 DNA Quantification:
PicoGreen and OligGreen assays of pre-implanted scaffold lysates displayed
approximately 92% and 84% reductions in dsDNA and ssDNA from native levels,
respectively (Figure 4.4, p<0.0001 in both cases).
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DNA Content of Pre-implanted Scaffolds
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Figure 4.4: Screening of myocardial scaffolds for DNA content: Results of PicoGreen® and OliGreen®
quantitative assays for double-stranded (dsDNA) and single-stranded (ssDNA) DNA, respectively, in
samples of native porcine myocardium and myocardial scaffolds prior to implantation (*: indicates statistical
significance from native, p<0.0001).

4.4.2.2 SDS Quantification:
As shown in Figure 4.5A, the residual SDS content of scaffolds at different steps
of the washing process following complete removal of cells was determined. SDS
concentration is reduced significantly to innocuous levels following the first wash step and
remains stable for the duration of the washing procedure. While the measured value in the
final step in Figure 4.5A is very near zero, these were not the data from the samples used
in the actual study; they only serve as a demonstration that SDS can be removed from
scaffolds. SDS concentration within scaffolds used for Biocompatibility Study 2 was
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found to be 2.402+/- 0.867 µg/cm3 tissue, which was not significantly different from the
value measured for Biocompatibility Study 1.

Figure 4.5: Screening of myocardial scaffolds for SDS content: A) Results of a quantitative assay for SDS
content in samples of myocardial scaffolds from each of the stages of rinsing following decellularization with
SDS. The rinsing process is reflected by moving from left to right on the ordinate (ddi H2O = distilled,
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deionized water, EtOH = ethanol). B) Image of the well plate used in the SDS assay, depicting toluidine blue
bound to SDS from the organic phase of test reactions. Upper wells are from scaffold samples, with each
successive rinsing step represented from left to right. Lower wells are samples of known SDS concentration,
which increased from right to left, used to generate a standard curve.

4.4.2.3 Screening for alpha-1, 3-galactose:
Examination of histological sections of pre-implanted scaffolds stained for the
presence of alpha-gal showed that the antigen had been completely removed from the tissue
during DCELL (Figure 4.6). This was the case in both the arterial and myocardial matrices
of scaffolds, although only samples of the myocardial matrix were used in this study.
Sections of explanted scaffolds stained for this antigen displayed diffuse positive staining,
indicating that endogenous alpha-gal had been deposited by the infiltrating rat cells (data
not shown).

Figure 4.6 (below): Screening of myocardial scaffolds for alpha-1, 3-galactose: A) Micrographs of native
A-D) and decellularized E-H) porcine myocardium and constituent coronary artery stained via
immunohistochemistry (IHC) for evidence of the alpha-gal epitope, showing its removal as a result of the
decellularization process. IHC positive staining = brown; A, B, E, F 10X, bar=100µm; C and D 40X,
bar=20µm; G and H 20X, bar=50µm.
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4.4.2.4 Semi-quantitative histological analysis of cellularity, foreign body giant cell
proliferation, vascularity, and collagen content:
H&E and Masson’s trichrome staining of histological sections of explanted
scaffolds provided ideal images for analysis of these characteristics using ImageJ software
(Figure 4.7). Individual components of interest were readily identifiable to the naked eye,
as well as to the software.

Figure 4.7: Histological evaluation of explanted scaffolds from Biocompatiblity Study 2: Micrographs
of explanted scaffolds stained with hematoxylin and eosin (H&E) A and B) and Masson’s trichrome C and
D). The former show collagen and cytoplasm (pink), nuclei (navy blue), and red blood cells (bright red),
while the latter show collagen (royal blue), multinucleated foreign body giant cells (FBGCs) and cytoplasm
(red), and nuclei (maroon). ImageJ was used in conjunction with H&E images to count nuclei and blood
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vessels (black arrows in B), and with Masson’s images to count FBGCs (black circles in C) and measure the
area of collagen within the field of view (All images 40X).

4.4.2.5 Cell infiltration, Figure 4.8A:
ANOVA identified a significant effect of group. PGG-treated groups were not
significantly different from one another, but both had significantly fewer infiltrating cells
than the NT control (0.15%, 0.3% < NT; p<0.0001). ANOVA also identified a significant
effect of time point. Significantly less cell infiltration was observed at 12 weeks than at 4
or 8 weeks, and cell infiltration was not significantly different between 4 and 8 weeks (12
< 4, 8; p<0.0001).

4.4.2.6 Vascularity, Figure 4.8B:
ANOVA identified a significant effect of group. 0.3% PGG-treated and NT groups
were not significantly different from one another, but both had significantly more
vasculature than the 0.15% PGG group (0.15% < 0.3%, NT; p<0.0001). The amount of
vasculature between PGG-treated groups was not significantly different until 12 weeks,
with a significant uptick in the 0.3% PGG group. ANOVA also identified a significant
effect of time point. Significantly less vasculature was observed at 12 weeks than at 4 or
8 weeks (although this effect does not hold for the 0.3% PGG group, which had
significantly more vascularity than the other groups at this time point). Vascularity was
not significantly different between 4 and 8 weeks (12 < 4, 8; p=0.0012).
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Figure

4.8:

quantitative

Semianalysis

of histological images
of explanted scaffolds
from Biocompatiblity
Study 2: A) Number of
nuclei as counted by
ImageJ

per

high

powered field (HPF), or
each micrograph taken
at 40X (400X total)
magnification; images
were those described in
Figure 4.7. Scaffolds
were treated with either
0.15% PGG or 0.3%
PGG, or not treated
(NT) with PGG at all
prior to implantation.
Scaffolds in each of the
groups were explanted
at either 4 weeks (4
Wk), 8 weeks (8 Wk), or 12 weeks (12 Wk) post-implantation; #: indicates statistical significance from all
other groups except one another and 0.15% PGG, 4 Wk, p<0.0001; *: indicates statistical significance
between specified groups, p=0.0008. ANOVA indicated there was a statistically significant effect of
treatment; cell infiltration in 0.15% PGG and 0.3% PGG < NT, p<0.0001. ANOVA indicated there was a
statistically significant effect of time point; cell infiltration in 12 Wk < 4 Wk and 8 Wk, p<0.0001. B)
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Number of blood vessels as counted manually per HPF; images were those described in Figure 4.7.
Explanted scaffolds were grouped according to the same conditions as described in A; #: indicates statistical
significance from all other groups except one another and 0.3% PGG, 4Wk and 12 Wk, p<0.0001; *: indicates
statistical significance between specified groups, p=0.0006; **: indicates statistical significance between
specified groups, p<0.0001. ANOVA indicated there was a statistically significant effect of treatment;
vascularity in 0.15% PGG < 0.3% PGG and NT, p<0.0001. ANOVA indicated there was a statistically
significant effect of time point; vascularity in 12 Wk < 4 Wk and 8 Wk, p=0.0012.

4.4.2.7 FBGC count, Figure 4.9A:
ANOVA did not identify a significant effect of group (p=0.1725). There were no
significant differences between groups within the same time point. 0.3% PGG and 0.15%
PGG groups were the closest to being significantly different from one another (p=0.1507).
ANOVA identified a significant effect of time point. Fewer FBGC were observed at each
successive time point in every group (4 > 8 > 12; p < 0.0001). While there appeared to be
a trend of decreasing FBGC presence in the NT group, none of the means at different time
points within this group were significantly different. In contrast, both of the PGG-treated
groups experienced a significant decrease in FBGC presence between 4 weeks and 12
weeks.

4.4.2.8 Collagen Content, Figure 4.9B:
ANOVA identified a significant effect of group. Scaffolds from PGG-treated
groups contained significantly more collagen than the NT group, and the 0.15% group
contained significantly more collagen than the 0.3% group (0.15% > 0.3% > NT;
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p<0.0001). ANOVA also identified a significant effect of time point. A significant
increase in collagen content was observed at each successive time point in every group (4
< 8 < 12; p < 0.0001).
Figure

4.9:

quantitative

Semianalysis

of histological images
of explanted scaffolds
from Biocompatiblity
Study 2: A) Number of
foreign body giant cells
(FBGC)
manually

as
per

counted
high

powered field (HPF), or
each micrograph taken
at 40X (400X total)
magnification; images
were those described in
Figure 4.7. Scaffolds
were treated with either
0.15% PGG or 0.3%
PGG, or not treated
(NT) with PGG at all
prior to implantation.
Scaffolds in each of the
groups were explanted
at either 4 weeks (4 Wk), 8 weeks (8 Wk), or 12 weeks (12 Wk) post-implantation; *: indicates statistical
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significance between specified groups, p≤0.0214 in all cases. ANOVA indicated there was no statistically
significant effect of treatment, p=0.1725. ANOVA indicated there was a statistically significant effect of
time point; FBGC number in 12 Wk > 8 Wk > 4 Wk; p < 0.0001. B) Collagen content per HPF as measured
by ImageJ; images were those described in Figure 4.7. Explanted scaffolds were grouped according to the
same conditions as described in A; *: indicates statistical significance between specified groups, p≤0.0481
in all cases (not all significant differences are shown). ANOVA indicated there was a statistically significant
effect of treatment; collagen content in 0.15% PGG > 0.3% PGG > NT, p<0.0001. ANOVA indicated there
was a statistically significant effect of time point; collagen content in 4 Wk < 8 Wk < 12 Wk, p<0.0001.

Figure 4.10: Evaluation of explanted scaffolds from Biocompatiblity Study 2 by immunofluorescence:
Micrographs of explanted scaffolds stained with antibodies to CD206 (green) and CCR7 (red); nuclei were
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counterstained with DAPI (blue). ImageJ software was used to count cells that stained positively for each
protein, and data were analyzed to characterize the nature of the host response to scaffolds.

4.4.2.9 Semi-quantitative histological analysis of macrophage polarization:
The ratio of cells which stained positively for CD206 to cells that stained positively
for CCR7 in areas within the scaffold is shown in Figure 4.11A. Initially, at 4 weeks after
implantation the macrophage population overwhelmingly favored polarization toward an
M1 phenotype, but the ratio reverted significantly back in favor of M2 macrophages as
implantation time increased. The ratio overwhelmingly favored M2 macrophages at later
time points in both PGG-treated groups, but did not change significantly over time in the
NT group (although it did favor M2 macrophages and did show a trend of increasing M2
polarization). ANOVA to test for overall effects was not possible because small sample
size did not provide sufficient degrees of freedom.
The ratio of cells which stained positively for CD206 to cells that stained positively
for CCR7 in areas immediately surrounding the scaffold is shown in Figure 4.11B. At 4
weeks post-implantation, the NT group already showed that much of the macrophage
population consisted of M2 macrophages, while macrophages in the PGG-treated groups
tended be split between the two phenotypes or slightly favored the M1 phenotype. Over
time, just as they did at the interior of the scaffold, the macrophages in the PGG-treated
groups shifted drastically toward an M2 phenotype. In the NT group, the ratio remained
in favor of M2 but decreased significantly at the 8 and 12 week time points. ANOVA to
test for overall effects was not possible because small sample size did not provide sufficient
degrees of freedom.
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The percentage of total macrophages (CD206+ and CCR7+ cells) which stained
positively for CD206 within the scaffold is shown in Figure 4.12A. There was an overall
trend of increasing M2 percentage with time regardless of treatment with PGG. The NT
group had a slightly greater percentage of M2 macrophages than the PGG-treated groups
at 4 weeks, but this was only weakly significant (p<0.0845). As seen in Figure 4.12B, this
same trend applied to cells at the scaffold-host tissue interface. In fact, in NT scaffolds M2
macrophages predominated throughout all time points, whereas PGG-treated scaffolds
displayed a dramatic M1 to M2 shift in between 4 and 8 weeks post-implantation.

Figure 4.11 (below): Semi-quantitative analysis of immunofluorescence images of explanted scaffolds
from Biocompatiblity Study 2: A) Ratio of CD206+ (M2) macrophages to CCR7 (M1) macrophages at the
interior of scaffolds per high powered field (HPF), or each micrograph taken at 40X (400X total)
magnification, as counted by ImageJ; images were those described in Figure 4.10. Scaffolds were treated
with either 0.15% PGG or 0.3% PGG, or not treated (NT) with PGG at all prior to implantation. Scaffolds
in each of the groups were explanted at either 4 weeks (4 Wk), 8 weeks (8 Wk), or 12 weeks (12 Wk) postimplantation; *: indicates statistical significance from all other groups, p<0.0003; **: indicates statistical
significance from all other groups except for 0.15% PGG at 12 weeks, p=0.0322. B) Same ratio as described
above, but determined from cells observed in tissues immediately surrounding the scaffolds; images were
those described in Figure 4.10. Explanted scaffolds were grouped according to the same conditions as
described in A; *: indicates statistical significance from all other groups except for 0.15% PGG at 8 and 12
weeks, p<0.0001; **: indicates statistical significance from all other groups except for 0.15% PGG at 12
weeks, 0.3% PGG at 12 weeks, and NT at 4 weeks, p=0.0002; #: indicates statistical significance from other
groups at same time point, p<0.0029.
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Figure 4.12: Semi-quantitative analysis of immunofluorescence images of explanted scaffolds from
Biocompatiblity Study 2: A) Percentage of total macrophages positive for CD206+ (M2 macrophage
marker) in each image of the interior of scaffolds as counted by ImageJ; the remainder were positive for
CCR7 (M1 macrophage marker). Images were high powered fields (HPF), or micrographs taken at 40X
(400X total) magnification; images were those described in Figure 4.10. Scaffolds were treated with either
0.15% PGG or 0.3% PGG, or not treated (NT) with PGG at all prior to implantation. Scaffolds in each of
the groups were explanted at either 4 weeks (4 Wk), 8 weeks (8 Wk), or 12 weeks (12 Wk) post-implantation;
$: indicates weak statistical significance from other groups at same time point, p<0.0845; #: indicates
statistical significance from other groups at same time point, p<0.0061; *: indicates statistical significance
between specified groups, p=0.0164; **: indicates statistical significance between specified groups,
p=0.0168.

B) Same percentage as described above, but determined from cells observed in tissues

immediately surrounding the scaffolds; images were those described in Figure 4.10. Explanted scaffolds
were grouped according to the same conditions as described in A; #: indicates statistical significance from
other groups at same time point, p<0.0001; ##: indicates statistical significance between specified groups,
p<0.0352; *: indicates statistical significance between specified groups, p<0.04; **: indicates statistical
significance between specified groups, p=0.0003.

4.4.3 Discussion:
4.4.3.1 General Observations:
In summary, PGG treatment decreased cell infiltration as compared to NT
scaffolds, and cell infiltration decreased over time among all treatment groups. Vascularity
appeared to correlate almost exactly with this trend.

FBGC presence decreased

significantly over time in the PGG-treated groups, and displayed a trend of doing so in the
NT group. Collagen content significantly increased over time in all groups, and PGG
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treatment significantly increased the cumulative amount of collagen formed at the implant
site with respect to the NT group.
It was clear that PGG-treated scaffolds degraded less over time, and that treatment
of scaffolds with higher concentrations of PGG exaggerated this effect. This was not only
evident macroscopically at explantation, but also microscopically in sections of the NT
scaffold, as scaffold remnants were considerably more difficult to identify in that group
than in the PGG-treated groups. Scaffold remnants were readily identifiable in PGG
groups, even at 12 weeks after implantation. This was not surprising given that our group
previously showed PGG treatment of collagenous scaffolds decreased the activity of
MMPs when in implanted scaffolds, and demonstrated PGG treatment reduced the
susceptibility of collagen and elastin to collagenase and elastase degradatio.[11, 18]
Despite the trend of decreasing vascularization in scaffolds over time, closer
histological inspection of all groups at 12 weeks post-implantation seemed to indicate a
great number of vessels within and around the implant site. Numbers of vessels in these
areas also seemed to be increased relative to the distal, surrounding dermis, although we
collected no quantitative data in support of this observation. Along with an angiogenic
effect, the implant site was also rich with collagen. We did not stain for collagen type III
or prolyl-4-hydroxylase, so we cannot claim this was newly synthesized collagen. There
was, however, a noticeable, localized difference in shades of blue and pink staining in
Masson’s and H&E stains, respectively. This seemed to suggest a difference in the
structure, and therefore, in both type and age of these areas of collagen.
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From previous studies conducted in our lab, we know PGG slows the degradation
of scaffolds, presumably through the physical action of crosslinking ECM proteins; but
also by modulating the activity of immune cells. The observation that neovascularization
and angiogenesis in the implant area was reduced with PGG treatment seemed to correlate
with the observed reduction in the number of infiltrating leukocytes, as they likely arrived
at the site via the vasculature.
FBGC presence was not significantly different between the groups, but it was
interesting to see their numbers decline significantly over time, especially in the PGG
treated groups. There was also a slightly greater number of FBGC in the 0.3% PGG group
than in the 0.15% PGG group (although not significant). Taken together with the late
increase in vascularity observed in the 0.3% PGG group, this might suggest that fixation
with a greater concentration of PGG leads to a more chronic inflammatory response, or at
least a delay in the host’s ability to respond to the presence of the implant.
Increased collagen content with PGG treatment could be reflective of either better,
more organized remodeling of the implant or the formation of dense, collagenous scar
tissue at the site. Formation of collagenous tissue could also have less to do with scarring
and be more the product of appropriate remodeling for the implant site given its proximity
to the dermis, which is mostly collagenous. Alternatively, higher collagen content in the
PGG-treated groups, especially earlier on, could be the result of scaffolds’ increased
resistance to degradation. Thus, the collagen being measured in these groups may not be
newly synthesized endogenous collagen, but simply stubborn remnants of the scaffold.
This theory is contradicted by the fact that the group treated with a greater concentration
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of PGG did not have the greatest collagen content, as one would assume the higher
concentration would cause more crosslinking and impart greater resistance to degradation.
In addition, most of the scaffold area in histological sections was highly cellularized, so
the image analysis method used to measure collagen content would not have recognized
these areas of scaffolds as collagenous.

4.4.3.2 Macrophage Polarization:
Macrophages in both the scaffold interior and at the scaffold-host tissue interface
displayed a shift in polarization from the M1 phenotype to the M2 phenotype. This effect
was less pronounced in the NT group, however, as the population seemed to remain
roughly split between the two phenotypes over the course of the study. This shift occurred
primarily between 4 and 8 weeks following implantation. After 8 weeks, the macrophage
population remained predominantly of the M2 phenotype.
It is difficult to say how these M2 macrophages arrived at the scaffold interior.
There were very few M2 macrophages at 4 weeks in the PGG groups’ interface, but their
number drastically increased at 8 weeks in the scaffold interior. There were also relatively
high numbers of M2 macrophages at 4 weeks in the NT group’s interface, but no drastic
increase in M2 macrophages at 8 or 12 weeks in the scaffold interior. Taken together, these
observations seemed to indicate that M2 macrophages arrived at the scaffold interior via
the many newly formed vessels in the area. However, if one considers that both vascularity
and cell infiltration were decreasing over time in all groups, it suggests that M2
macrophages did not simply arrive at the scaffold interior as M2 macrophages, but either
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arrived as monocytes and differentiated into M2 macrophages, or existing M1
macrophages in the area shifted to an M2 phenotype. Again, given the decreases in both
cellularity and vascularity over time, the latter seemed the more likely scenario.
Several studies investigating the response to implanted biological scaffolds – with
or without a cellular component – have associated adverse outcomes (chronic
inflammation, loss of implant functionality, and scar tissue formation) with a macrophage
population of predominantly M1 phenotype.

Conversely, responses that involved

macrophage populations shifting from M1 phenotype to predominantly M2 phenotype
were correlated with positive, constructive responses (recruitment of stem cells, formation
of functional tissue).[20]
While the results of this study indicated that a shift from M1 to M2 phenotype
occurred in macrophages at the implant site, it was difficult to make conclusions about the
overall outcome based upon the tissue which was formed. Because of the implants’
subdermal location, the highly vascularized collagenous tissue they were transformed into
could be appropriate in such a site. On the other hand, it was not clear that this tissue was
not granulation or scar tissue. The resultant tissue will need to be studied in more detail to
determine the exact matrix constituents, their source, and the identities of cells before
conclusions can be made regarding its fitness for the implant site.
There is evidence that chemical cross-linking of biologic scaffolds (via
carbodiimides or glutaralehyde) limit the ability of macrophages to respond to and remodel
the material, leading to a pro-inflammatory, M1-dominated response.[20, 24] One study
which focused on carbodiimide-crosslinked scaffolds noted an M2 to M1 shift between 2
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and 4 weeks post-implantation, and a persistence of this condition out to 16 weeks.[24] Our
results with PGG-crosslinked scaffolds in this study contradicted these findings,
demonstrating an M1 to M2 shift after 4 weeks of implantation. We have no particular
insight as to the cause of this disparity, other than the differing crosslinking mechanisms
of the two chemicals, PGG and carbodiimide, must have caused different changes in
structure of the scaffolds, leading to differences in the way cells responded to the material.
Additionally, we have shown previously that PGG reduced the infiltration of
macrophages into scaffolds composed primarily of collagen when those scaffolds were
implanted in the same model used here.[18] This result would seem to support the above
claims that chemical crosslinking inhibits macrophage response, but the explanted
scaffolds in this case were stained only against CD68, a pan-macrophage marker (not
specific for polarization), so we could not comment as to whether this resulted in an M1dominated macrophage response.

Interestingly, PGG treatment did reduce cellular

infiltration of scaffolds in the current study, but this did not result in a predominantly M1
response, as the above study involving crosslinking predicted.
Limitations of this study included a lack of staining to identify specific phenotypes
of non-monocytes, non-macrophages, and non-lymphocytes; a lack of methods to assess
whether endogenous matrix was synthesized and, if so, what specific matrix components
were produced. This study also would have benefitted from the use of another method to
measure M1 and M2 macrophage presence, such as qRT-PCR to determine gene
expression of iNOS (M1) and arginase (M2).
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4.4.4 Conclusions:
Studying the host response to biologic scaffolds is as much a matter of curiosity as
it is practicality. By virtue of their composition, these materials cannot be “inert”, as the
conventional definition of biocompatibility would have us believe is a requisite for safety
upon implantation. Instead, they are “bioactive” and can be degraded or transformed to
serve whatever purpose the host determines is most beneficial. This response is mediated
by cells of the immune system, which normally participate in inflammation and wound
healing. Because these cells are traditionally associated with these processes, and because
these processes commonly have a negative connotation, it is our first instinct to perceive
the responses to biological scaffolds in a negative manner. But, when we understand that
these cells constitute the only available apparatus for remodeling or repurposing an
implanted material, we can focus on discovering the mechanisms at work behind the
immune cell-mediated host response and developing a better understanding of the
characteristics of the remodeled tissue. This will serve to better inform our thought
processes and opinions on the safety and effectiveness of therapies, particularly tissue
engineering therapies, which are predicated upon the use of biological scaffolds.
The studies discussed above were designed to examine the host response to the
myocardial scaffolds whose generation was described in Chapter 3. We aimed to gain
insight into how and why the scaffold would be remodeled, and to apply this to knowledge
to our overall translational approach. In particular, we wanted to know how long the
scaffold would persist before it was degraded, and understand what type of local
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microenvironment would be presented to cells that might eventually be delivered to
damaged hearts using the scaffold as a vehicle.
Our results allowed us to answer these questions in a general sense. We learned
that fixation with PGG can extend the lifetime of scaffolds up to, and possible beyond, 12
weeks – presumably a sufficiently long period for delivered cells to integrate with host
tissue in future implantations of recellularized scaffolds. We also learned that while the
response to this scaffold does involve some elements of the classical inflammatory
response (FBGCs), over time the environment becomes less pro-inflammatory as
evidenced by the predominance of M2 macrophages. Lastly, although we were unable to
thoroughly describe the functionality, or “appropriateness”, of the tissue ultimately formed,
it was clear that this scaffold encouraged angiogenesis, which is a very desirable quality
for our purposes in generating functional, vascularized muscle.
Moving forward, we will be able to use either PGG-treated or non-treated scaffolds
in these therapies, depending upon the desired degradation profile. The response to
scaffolds may also prove to be drastically different at the eventual target site, the heart, and
when there is an autologous cellular presence within the scaffolds, as would be the case
with myocardial grafts.[30]
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CHAPTER FIVE: DEVELOPMENT OF A PLATFORM FOR IDENTIFYING
DRIVING FACTORS IN THE DIFFERENTIATION OF STEM CELLS
TOWARD A CARDIOMYOCYTE PHENOTYPE

5.1 Introduction:
In its infancy, Vacanti and Langer described tissue engineering as an
interdisciplinary effort to create “functional substitutes for damaged tissue”.[1] As the field
grew, more groups continued to develop scaffolds and attempted to repopulate, or “seed”,
them with cell types relevant to the tissue being replaced.[1-3] It was soon recognized that,
regardless of the source or type of cells used, static seeding and culture methods were
insufficient to produce organized, highly populated constructs with well-differentiated and
functional cells, and the importance of incorporating extracellular factors such as
mechanical, electrical, and biochemical stimuli was realized. In order to mimic the
structure and function of native tissue more closely, tissue engineers began seeking a means
to allow their constructs to mature, or be “conditioned”, by these extracellular stimuli, and
they developed bioreactors for this purpose. Bioreactors are specially designed, selfcontained systems which provide for the adjustment and control of specific conditions (e.g.
pH, oxygen concentration, nutrient supply, mechanical forces, and electrical impulses) to
simulate the dynamic surroundings and processes which support the functions of native
tissue.[2, 4]
As critical as delivering the correct stimuli to cells may be, choosing a source of
stem cells with the appropriate characteristics may be even more important. Large
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quantities of cells are necessary to produce recellularized tissue-engineered grafts, so these
cells must be either abundant at the source or proliferative to the extent necessary to
repopulate scaffolds at the cell density of native myocardium (200 million cells/cm3).[5]
These cells must also be compatible with the recipient’s immune system and be of the
proper phenotypes (i.e CM, cardiac fibroblasts, vascular smooth muscle cells, and
endothelial cells) which comprise the myocardium (or possessed of the ability to
differentiate into them). In view of these criteria, the cell source of choice should be
autologous cells (i.e. from the recipient patient) which are clonally expanded, differentiated
ex vivo, and implanted as a component of a tissue-engineered therapy.
Recently, the approach of using IPSC generated from fibroblasts, BM-MSC, or
other terminally differentiated adult cells has been popularized. This approach can be used
in myocardial tissue engineering strategies as an autologous therapy if the somatic cells
used to generate IPSC are harvested from the patient for whom the tissue-engineered graft
is intended.

This method uses transfection of either retroviral vectors or episomes

containing plasmid DNA or other vectors to first dedifferentiate the somatic cells into
IPSC.[6]
These cells can then be differentiated into a CM phenotype followed by specialized
low attachment/suspension culture techniques to generate embryoid bodies and subsequent
treatment with WNT signaling molecules.[7,

8]

There are also protocols that use the

principle of induced pluripotency, but differentiate somatic cells in to CM in a more direct
process, without an intermediate step wherein IPSCs are generated.[9]
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A major disadvantage of using IPSCs is that concerns remain over their stability
once dedifferentiated, specifically whether the epigenetic reprogramming strategies, either
retroviral or molecular, might cause unintended changes in expression or regulation of
other genes. This could lead to undesirable consequences once the pluripotent cells are
differentiated and implanted, such as tumor formation.[10-12] While they may seem highly
conjectural, these concerns could derail progress of any therapies based on IPSCs toward
clinical translation.
After consideration of available cell sources and their respective pros and cons, we
identified ADSCs as the most ideal fit in view of the criteria presented above. These cells
are highly abundant within subcutaneous fat, with about 100-300 x 106 cells/100-500 g of
adipose tissue.

More importantly, harvest of this tissue is accomplished through a

minimally invasive liposuction procedure, which can generate between 100 mL to 3 L of
lipoaspirate per procedure. Processing of lipoaspirate to isolate ADSC is also a wellestablished process that can be automated and even performed in the operating room.[13, 14]
The ability of ADSC to differentiate into CM, EC, and VSMC lineages has not been
widely demonstrated. However, it has been well-established that they can become
osteoblasts, chondrocytes, and adipose cells. Given this demonstrated multipotency, it’s
not far-fetched to believe they can differentiate into CM, EC, or VSMC if subjected to the
right conditions. Additionally, in vitro cultures of ADSC have shown a reduction in major
histocompatibility complex expression with progressive passages, possibly suggesting they
could be used allogeneically.[14] This mode of use would need to be proven safe in separate
clinical trials, as it is possible that expression of these complexes is only suppressed in
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vitro, and could return once the cells are transplanted into a new host. Furthermore, a
comprehensive post-hoc analysis of their effectiveness in an array of clinical trials for MI
treatment was recently conducted, and many of the results appeared promising.[15]
The studies described in the next few sections were aimed at evaluating the
potential of select stimuli that mimic the cardiac environment to cause differentiation of
ADSC toward a CM phenotype. They were designed as part of the overall project aims,
and in accordance with the tissue engineering paradigm of using bioreactors to apply
stimuli to scaffolds seeded with stem cells. As will be detailed in the introduction to each
study, evidence from the literature was also used to construct detailed aspects of these
experiments and the methods and systems used within.

5.2 Pilot Study: Differentiation of hADSC Cultured Statically on Decellularized
Myocardial Scaffolds:
5.2.1 Introduction:
There is little evidence in literature of a robust protocol for differentiation of
hADSC or MSC into CM. Successful studies are anecdotal, especially in human cells, and
the efficiency of differentiation protocols is low (≈50% of original cells were differentiated
at best).[16,

17]

Some studies demonstrated that varying the surface chemistry of the

substrate for cell growth, such as coating with laminin, can have a positive effect.[16] Others
have shown that varying surface topography of the substrate can also have a
cardiomyogenic effect. In addition, effects of both these variables on differentiation have
been enhanced by the concurrent application of 5-aza-2-deoxycitidine (AZT), a DNA-

142

demethylator.[16, 18] In brief, AZT inhibits the action of DNA methyltransferase enzyme,
leaving portions of the genome unmethylated and therefore more accessible to binding by
transcription factors that may be upregulated as a result of signaling cascades activated by
changes to the substrate or the application of other stimuli.[19]
These studies supported the idea that a possible mechanism for inducing cell
differentiation was simply the characteristics of the substrate (i.e. structure and
composition), so we were interested in studying the effect of our DCELLed myocardial
scaffold, which was shown to preserve proteins that mediate cellular attachment (e.g.
laminin, collagen IV, and fibronectin) and therefore play a role in mechanotransduction.
By virtue of this characteristic, they may have the potential to affect differentiation of cells
grown on scaffolds, even in the absence of dynamic mechanical stimuli.

5.2.2 Methods:
5.2.2.1 Scaffold preparation, cell seeding, AZT stimulation, and cell culture:
Human adipose-derived stem cells (hADSC) were seeded onto DCELLed, sterile
myocardial scaffolds (prepared by whole heart DCELL and peracetic acid sterilization as
previously described) at 3x106 cells/scaffold and cultured for 7 days. In addition, hADSCs
were seeded in standard, 6-well, tissue-culture plastic plates at 50,000 cells/well and
cultured during the same period; this group served as a negative control for the effect of
the scaffold. At this point, scaffolds and well plates were either treated with 9 µM AZT
for 24 h or left untreated (n=1 for scaffolds; n=6 for well plates). Cells in all conditions
were then cultured for an additional 3 weeks before being processed for analysis via
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histology, immunofluorescence and IHC, quantitative reverse transcription-polymerase
chain reaction (qRT-PCR), Western blotting, and ELISA to evaluate gene and protein
expression of the CM markers alpha-actinin, connexin 43, troponin T, troponin I, beta
myosin heavy chain, and desmin.

5.2.2.2 Isolation of mRNA and protein:
Cells on scaffolds and culture plates were harvested and processed to isolate mRNA
and cellular protein using Trizol™ reagent (Invitrogen). For cell on scaffolds, scaffold
samples (n=1) were first flash frozen in liquid nitrogen, fractured into small pieces using a
Biopulverizer (BioSpec, Bartlesville, OK) and then processed according to the Trizol
isolation process for mRNA and protein.
For cells on well plates, culture media was aspirated and wells (n=3) were rinsed
with warm, sterile PBS. One mL of Trizol reagent was added to each well and the wells
were incubated for 5 min at room temperature. A cell scraper (BD Biosciences) was used
to scrape cells free of the culture surface, and the solution was collected in a sterile,
nuclease-free tube. To lyse cells, the solution was aspirated and forcefully passed through
a 26-guage needle several times. The sample was processed according to the Trizol
isolation process for mRNA and protein.

5.2.2.3 Histology, immunofluorescence, and IHC staining:
Following standard formalin-fixation and paraffin embedding, 5 µm-thick sections
were prepared and stained with H&E.
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Formalin-fixed, paraffin-embedded, 5 µm-thick sections were deparaffinized and
heat mediated antigen retrieval with 10 mM citric acid at ph=6.0 was performed. Primary
antibodies for alpha-actinin, troponin T, connexin 43, and desmin (Abcam; 4 µg/mL) were
added to sections and incubated overnight at 4 °C. At this point, sections were labeled with
the correct secondary antibody for the application (i.e fluorescently conjugated for IF or
biotinylated for IHC). Sections were counterstained with dilute (1:1) hematoxylin in
distilled, deionized water (IHC) or with DAPI (IF).

5.2.2.4 Western blotting:
In order to normalize the amount of protein in samples used for Western blotting, a
bicinchoninic acid (BCA) assay (Pierce) was used to quantify protein concentration in the
samples isolated as described above. To prepare samples for electrophoresis prior to
blotting, the sample volume necessary to obtain 20 µg of protein was calculated, and
diluted in reducing buffer containing 1 µL β-mercaptoethanol (βME)/20 µL.
Electrophoresis and transfer were run at standard conditions. Blots were labeled with
primary antibodies to desmin, troponin T, and connexin 43 (Abcam, 1 µg/mL, 1 µg/mL,
and 0.128 µg/mL) and detected using secondary antibody and other reagents supplied in a
BM Chemiluminescence Western Blotting Kit (Roche). Blots were imaged on a BioRad
ChemiDoc system and bands were analyzed for relative intensity (densitometry) and
molecular weight using the accompanying Image Lab software.
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5.2.2.5 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
The concentration of isolated mRNA was measured using a NanoDrop 2000
benchtop spectrophotometer (Thermo Scientific), and a total of 1 µg of mRNA was
reverse-transcribed using M-MLV reverse-transcriptase enzyme and other reagents
supplied in an Ambion RT kit (Invitrogen). Resultant complimentary DNA (cDNA) and
SYBR Green Master Mix (Invitrogen) were used to prepare reactions for qRT-PCR.
Reverse transcription and PCR reactions were run on a RotorGene cycler (Qiagen).
Relative expression of markers was calculated using the 2-ΔΔCt method.[20]

5.2.2.6 Enzyme-linked immunosorbent assay (ELISA):
ELISA for troponin I was performed on samples of protein isolated as described
above. Samples were prepared to contain 10 µg protein, and were run using reagents and
instructions supplied by a cardiac Troponin I ELISA kit (Calbiotech). The blue color
evolved by addition of the supplied detection reagent was measured spectrophotometrically
at 450 nm.

Sample concentrations of troponin I were calculated according to the

relationship between known concentration and OD established by the supplied standard
curve samples.

5.2.3 Results:
5.2.3.1 Histology, immunofluorescence, and IHC staining:
H&E staining of seeded scaffolds showed the presence of hADSCs, mainly
concentrated several layers-thick on the outer surface, although some pockets of cells were
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identified within the scaffolds (Figure 5.1 middle). Immunostaining for the above markers
on scaffolds revealed cellular expression of alpha-actinin, connexin 43, and desmin
(Figure 5.1 top and middle). Correspondent staining of hADSC grown on culture plastic
appeared less intense (Figure 5.1 bottom). Upon inspection of these images, AZT
treatment did not appear to affect the expression of the proteins in cells on scaffolds, but
seemed to cause increased expression of CX43 and troponin T in cells grown on culture
plastic. Sections were imaged using an inverted Zeiss Axiovert microscope equipped with
mercury lamp, and accompanying AxioVision software.
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Figure 5.1. Analysis of Differentiation of hADSC Cultured Statically on Decellularized Myocardial
Scaffolds by IHC and IF : At top, Images of IHC-stained sections of scaffolds seeded with hADSCs and
cultured for 4 weeks show expression of the indicated proteins. At 7 days, cell-seeded scaffolds and culture
plates were either treated with 5-aza-2-deoxycytidine (+AZT) or not (-AZT). At middle, IF images of the
same scaffolds show positively stained sections (green) counterstained with DAPI (blue) and H&E-stained
sections display tissue morphology of seeded scaffolds. At bottom, IF images of cells on culture plastic
stained in the same manner. IHC positive staining=brown; all images 40X, bar=20µm.

5.2.3.2 Western blotting:
When assayed for relative expression of the same markers by Western blotting,
however, intensity of the bands produced by cells on culture plastic was greater than that
of cells on scaffolds (Figure 5.2). This relationship held regardless of treatment with AZT.
Treatment with AZT significantly increased protein expression of troponin T and desmin
in cells grown on culture plastic, and there was a trend suggesting the same effect in cells
grown on scaffolds, although low sample numbers did not permit analysis for statistical
significance.
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Figure 5.2: Analysis of Differentiation of hADSC Cultured Statically on Decellularized Myocardial
Scaffolds by Western blotting: Western blotting and densitometry calculations of the resulting bands
quantify relative expression of specific proteins in hADSCs seeded and cultured statically on scaffolds and
hADSC cultured with standard methods on cell culture plastic. Cells in each condition were also either
treated with 5-aza-2-deoxycytidine (+AZT) or not (–AZT); *: indicates statistical significance from
corresponding –AZT, p=0.0471.

5.2.3.3 qRT-PCR:
Gene expression as measured by qRT-PCR showed that CX43 and troponin T were
slightly upregulated in hADSCs on scaffolds as compared to hADSCs grown on culture
plastic, while desmin and beta myosin heavy chain were both downregulated, all in the
absence of treatment with AZT (Figure 5.3B). In fact, treatment with AZT did not appear
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to increase expression of any of the markers of interest when directly comparing cells
grown on the two different substrates. When the effect of AZT was studied within cells
grown on the same substrate, AZT significantly increased expression of troponin T and
βMHC, and showed a trend of increased expression of desmin in cells on culture plastic
(Figure 5.3A). AZT treatment also showed a trend of increased expression of desmin and
βMHC in cells grown on scaffolds. It did not significantly descrease expression of the
other markers in either case.
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Figure 5.3: Analysis of Differentiation of hADSC Cultured Statically on Decellularized Myocardial
Scaffolds by qRT-PCR: A) Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
performed on RNA isolated from hADSC-seeded and cultured statically on scaffolds and hADSC cultured
with standard methods on cell culture plastic. Cells in each condition were also either treated with AZT or
not treated. Expression is reported as the fold change in expression of each gene in each group relative to
expression in its non AZT-treated counterpart (represented with a value of 1); *: indicates statistical
significance from non AZT-treated control, p=0.002; **: indicates statistical significance from non AZTtreated control, p=0.029. B) qRT-PCR performed on RNA isolated from the same conditions as above.
Expression is reported as the fold change in expression of each gene in the scaffold group relative to
expression in the culture plastic group (represented with a value of 1). Cells in each condition were also
either treated with AZT or not; *: indicates statistical significance from culture plastic group, p=0.045; **:
indicates statistical significance from culture plastic group, p=0.0314; #: indicates statistical significance
from culture plastic group, p=0.039; ##: indicates statistical significance from culture plastic group,
p=0.0573.

5.2.3.4 Enzyme-linked immunosorbent assay (ELISA):
ELISA for troponin I found none of this marker was present in cells grown on
culture plastic regardless of treatment with AZT. In contrast, cells grown on scaffolds were
found to express troponin I, and treatment with AZT appeared to enhance expression of
this marker, although statistical significance of this effect could not be established (Figure
5.4).
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Figure 5.4: Analysis of Differentiation of hADSC Cultured Statically on Decellularized Myocardial
Scaffolds by ELISA: Enzyme-linked immunosorbent assay (ELISA) was used to quantify expression of
troponin I in protein isolated from hADSCs seeded and cultured statically on scaffolds (S) or on cell culture
plastic (P). Cells in each condition were also either treated with 5-aza-2-deoxycytidine (+AZT) or not (–
AZT); hADSCs cultured with standard methods on cell culture plastic (P) did not contain measurable
amounts of the protein.

5.2.4 Discussion:
The markers studied here all play critical roles in the functionality of CM (as
discussed in sections 1.5.5.1 and 1.5.5.2). CX43 is a gap junction protein through which
calcium ions are transported in order to facilitate propagation of an excitation stimulus.
This makes coordinated muscular contraction of the myocardium possible.[21, 22] Troponin
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T and I are components of the troponin complex, which forms part of the larger
tropomyosin complex. The troponin complex is found near the heads on myosin filaments
and normally impedes their binding to actin filaments unless the complex is bound by a
calcium ion.[23] Thus, this complex represents an important intermediary in the mechanism
of sliding filament muscle contraction. Desmin is an important intermediate filament
protein which links the contractile apparati of CM with one another at Z-disks and to other
components of the cell, including the nucleus and mitochondria.

Collectively, this

maintains the structural and mechanical integrity of CM during contraction, and aids in
both force transmission and longitudinal load bearing.[24, 25] It may also play a role in
connecting the sarcomere to the ECM within desmosomes, thus forming a mechanical
linkage between the ECM and sarcomere useful in mechanotransduction. Similar to
desmin, alpha-actinin plays a mechanical role by anchoring the actin filaments in CM to
the Z-disc.[26]
In light of their functions, it is clear to see why we chose these proteins as the focus
of this initial differentiation experiment. Since we were studying the effect of the substrate
on the differentiation of bound cells, it was incumbent upon us to select markers with an
established role in the attachment and mechanotransduction pathways of CM.
When cultured on scaffolds, hADSCs expressed cardiac genes and proteins
regardless of treatment with AZT (which was expected to increase marker expression),
implying that the myocardial scaffold might possess some intrinsic characteristics that
cause this expression. These characteristics likely include the composition (collagen,
elastin, fibronectin, basement membrane proteins) and architecture (pore size, ECM
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organization), which together provide signals to hADSC through mechanotransduction that
may upregulate the gene and protein expression of these markers.[27]
There was also some evidence that treatment of cells grown on either substrate with
AZT might have increased expression of these markers, but more supporting data must be
collected before this claim can be made. When deciding whether to include AZT as part
of a differentiation protocol, some consideration must be given to nonspecific and
widespread deleterious changes the chemical could produce in the genome and its structure.
AZT has been commonly studied as an anti-cancer treatment, mainly because it has the
ability to induce cytotoxicity by causing DNA damage (i.e. strand breaks)[28] Dosages and
concentrations used in these studies were on par with those used here, so some of these
effects could be imparted on hADSCs seeded on scaffolds. These effects, and consequently
the use of AZT, may be undesirable outside of the context of cancer treatment or other
more suitable applications.
It was noteworthy that hADSCs grown on culture plastic (i.e. “undifferentiated”
cells) expressed CX43, troponin T, and desmin in at least a minimal level. In retrospect,
we found that some groups who have carried out extensive analysis of the expression
profile of hADSCs found that CX43 is normally expressed in these cells. Since they have
been theorized to be of a perivascular phenotype, they may employ CX43 in intercellular
signaling with endothelial and smooth muscle cells as part of their normal function.[13]
It would be more beneficial in the context of an experiment such as this, which is
focused on differentiation of cells, to measure a marker that is not constitutively expressed
in the initial, undifferentiated phenotype. However, given the importance of CX43 to CM
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function, it will still be critical to demonstrate its expression in the differentiated cell
population. As such, we will continue to measure it in future differentiation experiments
with the aim of demonstrating the development of a CM phenotype.
That said, in order to posit differentiation of these cells in experiments where
dynamic stimuli will be applied, increased expression of these markers must be observed
with respect to unstimulated control cells, as well as expression of other cardiac markers
in the stimulated cells with little to no expression in the control cells (i.e. differential
expression suggesting a change in phenotype). This effect was best illustrated in this study
by ELISA for troponin I, which was only present in cells grown on scaffolds. In addition,
there was some indication that culture of hADSCs on scaffolds resulted in increased
expression of a few of these markers with respect to cells grown on culture plastic, as seen
in the IF staining. Aside from those specific results, this study largely demonstrated the
opposite outcome, specifically Western blots which showed greater expression of CX43,
troponin T, and desmin in cells cultured on plastic as opposed to scaffolds. It’s possible
that this result was skewed by the presence of solubilized matrix proteins in samples of
seeded scaffolds. This extracellular protein could have contributed to the total 20 µg of
protein which is normally run in all samples to normalize them so they may be
quantitatively compared. Consequently, the protein samples from the seeded scaffolds
might have contained a smaller proportion of cellular protein compared to those samples
isolated from cells grown on tissue culture plastic. So, while samples from both groups
were found to contain the proteins of interest, samples from the cells on culture plastic
might not have contained more of those proteins if there had been a correction for the
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extraneous extracellular proteins. A control will need to be devised to account for the
presence of these proteins in future experiments wherein the undifferentiated control group
consists of cells grown on culture plastic.

5.2.5 Conclusion:
Use of myocardial scaffolds as a substrate for hADSC growth precipitated
expression of cardiac genes and proteins regardless of treatment with AZT (which was
expected to increase marker expression). Although evidence of increased expression of
these markers in cells on scaffolds with respect to cells on culture plastic was less abundant,
the structure and composition of myocardial scaffolds could be an inductive mechanism
for cardiomyogenic differentiation of hADSCs.
This study focused only on the effect of the DCELLed myocardial scaffold as a
substrate in differentiating hADSCs into CM. Its findings, while of interest, neglected
variables such as electrical and mechanical stimuli which we believe are necessary to
achieve full differentiation of stem cells into a CM phenotype. The system described in
the next section of this chapter was designed with the idea of incorporating such factors in
mind.

5.3 hADSC Differentiation with Flexcell System:
5.3.1 Introduction:
To date, many groups have recognized the need for reproducing the physiological
stimuli observed in the cardiac macro- and microenvironments in order to generate more
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biomimetic constructs or grafts. Eschenhagen and colleagues demonstrated the beneficial
effects of the application of mechanical strain on engineered heart tissue, noting increased
CM alignment, sarcoplasmic protein organization, and concomitant enhancement of
contractile force generation in the stretched constructs.[29] The effects of electrical
stimulation have been studied and reviewed extensively by Vunjak-Novakovic’s group,
among others, who have shown that culturing myocardial tissue-engineered constructs in
the presence of electrical fields with defined parameters can encourage development of
electrical connectivity and excitability of CM, as evidenced by increased expression of
connexin 43, lowered excitation thresholds, and increased stimulus capture rates.[30, 31] Few
groups, however, have taken these two most defining stimuli of the cardiac environment
and applied them simultaneously to cell-seeded constructs.[32] Even fewer have recognized
the natural interplay between them in the excitation-contraction coupling of the
myocardium and attempted to mimic this within a bioreactor by carefully synchronizing
timing, duration, and characteristics of electrical impulses and mechanical forces.[33-35]
Wang et al. recently investigated the effects of coordinated electrical and
mechanical stimuli on DCELLed myocardium scaffolds reseeded with rat mesenchymal
stem cells. They observed positive immunostaining for the cardiac markers myosin heavy
chain, sarcomeric α-actinin, cardiac troponin T, connexin43, and N-cadherin but did not
analyze gene and protein expression of the cells within their constructs following culture
and stimulation. Most importantly, they did not observe contractile behavior in their
constructs, nor did they find any direct evidence of electrical activity or connectivity
between the constituent cells.[35] It is likely this is due to their use of too few seeded cells;
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the roughly 833,000 cells/cm3 density of their constructs did not allow for the necessary
proximity of cells to produce intercellular connectivity.
As discussed in previous sections, cells within a tissue-engineered graft should be
functional (contractile and able to integrate with the host cardiac conduction system) upon
implantation. Otherwise, the graft does not help alleviate the mechanical dysfunction
which leads to remodeling and CHF. Thus, characterizing changes in stem and progenitor
cells which have been exposed to physiological stimuli in bioreactors becomes a key
milestone in developing feasible approaches to engineering new myocardium with
therapeutic potential.

5.3.2 Methods:
5.3.2.1 System Design:
This platform was designed to integrate the mechanical and electrical stimulation
of cells seeded on DCELLed myocardial scaffolds, and to allow for precise control of the
characteristics of these two stimuli. Design inputs included: 1) means of applying a
uniaxial tensile force of up to 140 mmHg to a cell-seeded construct, with the ability to
control characteristics of the waveform 2) means of applying at least 2 V electrical stimulus
to seeded constructs, with the ability to control other characteristics of the waveform 3)
means to coordinate the timing of delivery of these two stimuli to the construct, and in such
a manner so as to allow for changing how the two waveforms overlap in successive
experiments 4) allow for conventional culture of seeded constructs in a standard incubator
with standard media, and facilitate convenient changing of media every 2-3 days 5)
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accommodate a sufficient number of experimental replicates to achieve statistical
significance among experimental groups in measured endpoints.
A commercially available system sold by Flexcell International Corp. served as the
basic component around which this platform was designed (Figure 5.5). The system was
sold under the name FX-5000™ Compression System, and was comprised of a main
controller housing with pressure regulators, valves, and transducers used to precisely
control the flow of compressed air into a baseplate upon which four 6-well plates were
attached (Figure 5.5B and C). The bases of the 6-well plates were hermetically sealed
against rubber gaskets on the baseplate by means of telescoping bolts that clamped the well
plates to the baseplate (Figure 5.5E).
The system functioned by pumping compressed air into the space beneath the
baseplate and the well plates above, forcing the membrane at the bottom of each well
upward (Figure 5.6F). The result was that the membrane moved upward like an inflating
balloon when air was pumped into the baseplate and returned downward to a flat position
when air pressure was released. This movement was very similar to the motion of the left
ventricular free wall during diastole and systole, and was used to simulate just that. The
accompanying Flexcell software was used to create a pressure waveform modeled after the
left ventricular pressure waveform observed during the cardiac cycle (Figure 5.6A). A
pressure transducer was used to measure the real-time pressure applied to the silicone
membrane, and the data was fed to a custom-written LabView program. This program was
designed to deliver an electrical pulse which was triggered when the pressure reading
reached a specific value input by the user (Figure 5.6A an C). In other words, the LabView
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program was used to tightly control the relative temporal delivery of both mechanical and
electrical stimuli to samples contained within the well plates. This fact allowed us to
simulate the excitation-contraction behavior of cardiac muscle in an effort to expose
hADSCs to proper physiological stimuli and induce their differentiation into CM.

162

163

Figure 5.5: Design of Flexcell system: A) Schematic illustration of main components of the Flexcell system.
B) An incubator containing the modified Flexcell® system comprised of tubing, baseplate, and 6-well plates
with silicone membranes pumps air into the baseplate shown in C, where E) telescoping bolts are used to
seal the edges of F) modified 6-well plates against a rubber gasket. D) Flexcell controller (2 bidirectional,
software-controlled valves inside) and data acquisition (DAQ) modules, which collectively enable all
measurement and output of physical signals in the system, are shown.
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Figure 5.6: Detailed operation of Flexcell system: A) Screenshot of display from computer used to
control the Flexcell system. The window at back left is the Flexcell software, running the programmed
regimen and displaying pressure waveform data collected by the Flexcell controller’s pressure transducers.
The window at front right is the LabView program, displaying pressure waveform data from a pressure
transducer which was tapped into the positive pressure line running to the Flexcell baseplate. This data was
acquired by one data acquisition (DAQ) module and fed into the LabView program; this program triggered
an electrical pulse, output by a second DAQ module, every time the pressure fell within a user-defined
range (in this case, at the rising edge of each pressure wave). A, C) This trigger is illustrated by two virtual
LEDs in the LabView display (dashed yellow ovals), which indicate the status of the pulse by lighting up
with an “ON” or “OFF”. E,F) Pressure from air pumped into the baseplate (blue arrows in F) with 6-well
plate sealed atop it causes upward deflection of the silicone membrane in each well. Scaffolds are shown in
F with horizontal ends fixed in place at the sides of each well. When the membrane deflects upward under
pressure, a resultant uniaxial tensile force (black arrows with yellow outline in E and F) is applied to the
scaffold. F) Heat map illustration of the potential field and graph of electrical potential vs. position
generated from a Comsol™ model based upon the well and electrode dimensions and the applied electrical
pulse. The region of interest (R.O.I.), or the area of scaffold where the effects of mechanical stimuli and
electrical stimuli will both be applied to seeded cells, is indicated with a dashed box. B, D) Auxiliary setup
for plates receiving only electrical stimuli; these plates could not be kept in the same incubator as those
receiving mechanical stimuli because said incubator was set at a higher temperature to offset the cooling
effect of running compressed air through the baseplate. D) The LabView program responsible for
delivering the electrical stimulus to electrical only plates; the characteristics of the pulse (amplitude,
frequency, duration) were controlled to match those of the electrical pulse produce by the program in A and
C.
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5.3.2.2 Modified Flexcell Well Plate Design:
We modified Flexcell Bioflex® 6-well plates by attaching customized, plastic well
inserts to the lid of each plate using a combination of cyanoacrylate glue and silicon sealant
in order to provide a watertight seal (Figure 5.7A, B, F, H). The inserts were designed to
accommodate a 1-2 mm thick, 3.5 cm x 2 cm rectangular scaffold sheet that had been
seeded with cells. Inserts held the sheets stretched directly above the silicone membrane
by providing fixation points for the edges of each sheet at the periphery of the well on
opposing sides (Figure 5.7E and Figure 5.6F). Once stretched across the diameter of the
well, each sheet was clamped between the bottom of the insert and a ring which fastened
to the insert via a snap hook mechanism (Figure 5.7E). This ensured that as the membrane
deflected upward under pressure, the seeded scaffolds were subjected to a uniaxial tensile
force (Figure 5.6E). A lock-in-groove feature was included between the rings and inserts
to prevent slippage of the sheets over time due to cyclical application of tensile force
(Figure 5.7C and D).
The inserts also incorporated fixtures for two cylindrical, 3 mm-diameter, carbon
electrodes which were positioned parallel to each other but perpendicular to the direction
of the tensile force (Figure 5.7F, G, and H). The electrodes (one positive, one negative)
were wired to electrical adapters through a network of wires attached to the lid of the plate
(Figure 5.7G). The wiring and inserts were both attached to the undersides of the plate
lids to facilitate media changes in the wells.
Plates were connected to the electrical signal output from the LabView program,
and the pulses delivered to them resulted in the development of an electrical field within
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each well, the direction of which was parallel to that of the tensile force applied to the
scaffolds (Figure 5.6F). Scaffolds lay directly below the electrodes such that cells seeded
on them were exposed to the electrical field.
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Figure 5.7: Design of Flexcell plates and well inserts: A) CAD rendering of a well insert and the B) 3Dprinted ABS plastic part produced from the same SolidWorks file. C) Protrusions from the bottom of the
well inserts were designed to lock with grooves on the accompanying locking ring shown in D. E) Scaffold
sheets were secured near the bottoms of wells at both ends by stretching the sheets across the well inserts and
then placing a locking ring over them. Sheets were clamped between the two parts and held securely by
means of the lock-in-groove feature described above; compression was maintained by 4 snap-hooks (black
arrows) that retained the locking ring in close apposition. F) Fully-assembled lid of a Flexcell plate used for
groups receiving electrical stimulation, with well inserts attached by super glue and silicone sealant. G)
Carbon electrodes (black rods) were used to create an electrical potential within each well, and are shown
connected to larger wires (yellow and green) via thin platinum wire (black arrows). The ends of the electrodes
fit inside hollowed-out channels, allowing them to slide up and down with the motion of the scaffold as it
was mechanically stretched. For groups that did not receive mechanical stimulus, electrodes were not
attached and plates were not wired. H) Each circuit, consisting of a positive and negative electrode, was
wired to a single connector (black part at left) that conducted electrical impulses produced by a data
acquisition module.

5.3.2.3 Experimental Setup:
We surmised there were 4 major stimuli that determined the nature and degree of
hADSC differentiation into CM: mechanical stimulation (M), electrical stimulation (E),
substrate properties (S; scaffold vs. no scaffold/silicone membrane only), and
pharmacological stimuli (P; AZT-treated). We used the Flexcell system’s ability to
accommodate many samples (n=24) to our advantage in achieving this aim – to discover
which of these stimuli had the greatest impact on hADSC differentiation, and to determine
if there was any synergistic effect between them in this respect. For the first experimental
run using the Flexcell system, 4 different conditions were tested: 1) M+E+S, 2) M+S; 3)
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M+S+P; 4) E+S (referred to hereafter as E+M, M, M+AZT, and E, respectively). We used
one, 6-well plate per condition (n=6), and hADSC were seeded onto each scaffold via
injection through a small-diameter needle at various points in the area between the two
electrodes. Upon completion of 3 weeks of culture under the conditions listed above, the
scaffolds were collected in order to characterize the extent of hADSC differentiation into
CM.
At the conclusion of culture in this system, sections of seeded scaffolds from each
well were divided up and processed for various methods of evaluation: 1) fixation in 4%
paraformaldehyde for histology and immunofluorescence/IHC; 2) isolation of protein and
RNA via homogenization and Trizol® reagent for Western blotting and qRT-PCR,
respectively; 3) preservation in cell culture media for tests of cell/tissue functionality and
viability, including Live/Dead assay and live cell calcium imaging using Fluo-4.
Statistical analysis techniques, including multivariate analysis of variance
(ANOVA) and post-hoc contrast analysis of means via Fisher’s least significant difference
test, were used to determine main effects and interactions of the 4 stimuli tested on the
measured outcomes.

5.3.2.4 Preparation of Scaffolds:
Scaffolds were prepared by first dissecting 2.0 x 3.8 cm rectangular segments of
DCELLed myocardial scaffold generated via whole heart DCELL. Then, 1-2 mm thick
layers of these segments were sheared off using a scalpel to generate scaffold sheets.
Sheets were washed 3X (1 h, 3 h, 1 h) before being sterilized with 0.1% peracetic acid in
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PBS at pH 7.4 (2X; 30 min, 1 h). Sheets were then washed with sterile PBS 3X (1 h, 3 h,
1 h) in preparation for cell seeding.

5.3.2.5 Cell Seeding and AZT stimulation:
Each sheet was incubated overnight at 37 °C in DMEM with 10% FBS.
Immediately prior to seeding, the excess media was removed from the sheets and they were
incubated another 2 h at 37 °C in an attempt to slightly dehydrate the scaffolds. The
rationale was that cell solution would be more likely to penetrate a slightly dehydrated
scaffold than one that was swollen with media, increasing the effective density of seeded
cells. We used a cell culture scale-up apparatus, the CellSTACK® (Corning), to produce
sufficient numbers of cells for this study. Once the sheets were secured to the inserts, a
suspension of hADSCs was injected at several random points in the center of each sheet,
and a total of 3.1 x 106 cells were seeded onto each sheet. The remainder of the cell
suspension solution was drop-seeded onto the upper surface of each sheet, and the seeded
scaffold sheets were placed in wells with no media and incubated for 4 h at 37 °C to allow
cells to attach to the sheet. About 6.5 mL of media was placed in each well and the sheets
were cultured statically for another 20 hours. At this point, scaffolds in the M+P+S
(M+AZT) group were treated with 9 µM AZT and cultured for an additional 24 h, while
the other groups were only statically cultured during this time.
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5.3.2.6 Construct Attachment and Stimulation Parameters:
Seeded myocardial scaffolds were placed across the space between the two
extensions of each well insert, and clamped into place using the rings as previously
described (Figure 5.7E).
In its final configuration, a 3.6 cm2 rectangular area of hADSC-seeded myocardial
scaffold received user-controlled, synchronized, and cyclic mechanical and electrical
stimulation (Figure 5.6F). This area would serve as the region of interest (R.O. I.) for all
methods performed to assess differentiation. These stimuli were adjusted to mimic those
of the native cardiac environment as closely as possible, with a cyclic pressure waveform
(0-120-0 mmHg amplitude in 350 msec with 450 msec static at 0 mmHg, 1.17 Hz or ~70
BPM) and a 5V (2.78 V/cm), 20 msec-width, square-wave electrical pulse applied at the
rising edge of every pressure wave.
Prior to stimulating scaffold sheets with the above protocol, we thought it prudent
to allow the newly seeded cells sufficient time to attach to the scaffold, and to ramp-up the
mechanical stimulus in a stepwise manner so the cells could acclimate to the stress. This
was accomplished by applying waveforms similar in period and frequency to the one
described above, but with amplitudes of 40 mmHg and 80 mmHg for 24 h each. The results
of this analysis will determine which stimulus or combination of stimuli should be used to
differentiate seeded cells most effectively in the bioreactor phase of this aim.
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5.3.2.7 Isolation of mRNA and protein:
An approximate 1 cm2 area of each scaffold was cut from the R. O. I. and mRNA
and protein were isolated as previously described.

5.3.2.8 Histology, immunofluorescence, and IHC staining:
An approximate 0.5 cm2 area of each scaffold was cut from the R. O. I. and fixed
in 10% neutral buffered formalin. These sample were histologically process and stained
via IHC for alpha-actinin (Abcam; 4 µg/mL) as previously described. Sections were
counterstained with dilute (1:1) hematoxylin in distilled, deionized water. Sections were
imaged using an inverted Zeiss Axiovert microscope and accompanying AxioVision
software.
An approximate 0.5 cm2 area of each scaffold was cut from the R. O. I. and fixed
in 4% paraformaldehyde for 2 hours at 37 ºC. Following adequate fixation, samples were
rinse 3X in PBS and stored in PBS. For IF staining, samples were cut into thin (<1 mm
wide) strips and placed into wells of 96-well plates, where they could be subjected to heat
mediated antigen retrieval and the various steps of the IF staining process. They were
incubated overnight at 4 °C with primary antibodies to actin and CX43 (Abcam; 4 µg/mL),
and nuclei were counterstained with DAPI. Samples were imaged using an inverted Zeiss
Axiovert microscope equipped with mercury lamp and accompanying AxioVision
software.

174

5.3.2.9 Live/Dead Assay:
An approximate 0.5 cm2 area of each scaffold was cut from the R.O.I. and placed
in wells of a 24-well plate which contained complete culture medium (DMEM with 10%
FBS and 1% antibiotic/antimycotic) until they could be assayed. When ready, the samples
were cut into thin strips as describe above, rinsed 2X with warm PBS, submerged in a
Live/Dead working solution containing calcein AM and ethidium homodimer-1, and
incubated for 20 min at 37 ºC. Samples were imaged using an inverted Zeiss Axiovert
microscope equipped with mercury lamp and accompanying AxioVision software.

5.3.2.10 Calcium Staining Assay:
An approximate 0.5 cm2 area of each scaffold was cut from the R.O.I. and placed
in wells of a 24-well plate which contained complete culture medium (DMEM with 10%
FBS and 1% antibiotic/antimycotic) until they could be assayed. When ready, the samples
were cut into thin strips as describe above using sterile surgical instruments and then placed
back into their respective wells containing media. An equal volume of 2X Fluo-4 Direct™
calcium reagent loading solution (Life Technologies) was added to the well and the plate
was incubated at 37 ºC for 45 min. Samples were imaged using an inverted Zeiss Axiovert
microscope equipped with mercury lamp and accompanying AxioVision software.
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5.3.3 Results:
5.3.3.1 Isolation of mRNA and protein:
Appreciable amounts of mRNA and protein were obtained from the scaffolds,
indicating a significant cellular presence on all of the scaffolds following the 3 week culture
and stimulation period (data not shown). There were sufficient amounts of each to perform
the qRT-PCR and Western blotting for all markers of interest (up to 10), however those
assays were not carried out prior to publication of this document.

5.3.3.2 Live/Dead Assay:
Examination of Live/Dead staining of scaffolds revealed that all groups contained
live cells along with some dead cells (Figure 5.8). Some cells were observed to have nuclei
which stained red, indicating they were dead, while their cytoplasm concurrently stained
green, indicating they were alive. Importantly, cells displayed an elongated morphology,
and appeared to align with one another in a direction parallel to that of both the applied
tensile stress and electrical field. More cells were visible in the E and E+M groups than in
the other groups. It was also difficult to find cells spread evenly throughout the scaffold.
They were not visible on every strip that was prepared and stained, and it appeared they
were mostly confined to the surface of scaffolds.

176

Figure

5.8:

Analysis

of

hADSC

differentiation with Flexcell system:
Images of cells contained within scaffold
sheets exposed to the indicated stimuli and
stained with Live/Dead™ assay reagents
(calcein AM/live (green) and ethidium
homodimer-1/dead (red)).

Stimuli were

part of dynamic differentiation regimens
within the Flexcell system. Small areas of
the sheets were cut into thin (< 1 mm wide)
segments and stained with these reagents;
second image from top 10X, bar=100µm;
all other images 2.5X, bar=500µm.
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5.3.3.3 Calcium Staining Assay:
Fluo-4 Direct™ Calcium reagent stained intracellular Ca+2 within all groups
(Figure 5.9). The same elongated morphology and consistent orientation along directions
of applied tensile force and electrical field observed with Live/Dead staining were observed
in this assay. Small nodules or pockets of calcium could be discerned throughout the
entirety of the cells’ length, with clear voids which were presumably the locations of nuclei.
It was unclear if the staining extended into the cytoplasm or was concentrated at the cell
membrane. Similar to the Live/Dead assay, more cells were observed in the E and E+M
groups than in the other two groups.

Figure 5.9 (below): Analysis of hADSC differentiation with Flexcell system: Fluo-4 Direct™ Calcium
reagent shows binding to intracellular calcium (green) of cells contained within scaffold sheets exposed to
the indicated stimuli. Stimuli were part of dynamic differentiation regimens within the Flexcell system.
Small areas of the sheets were cut into thin (< 1 mm wide) segments and stained with this reagent; left column
10X, bar=100µm; right column 40X, bar=20µm.
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5.3.3.4 Histology, immunofluorescence, and IHC:
IF staining for actin and CX43 showed positive staining only in the E group. Actin
staining was definitive, but CX43 staining (green dots) was less intense and could have
been background autofluorescence (Figure 5.10A, C, and E). Portions of scaffolds from
all groups were stained in the same manner, but an area of positively staining cells for
either marker could not be found in these groups, even though some sporadic nuclei were
identified. It was noted that the area of cells depicted as staining positively here was found
on a very thin piece of tissue. Again, cell morphology was elongated, cells were oriented
in the same direction, and some appeared in close enough proximity to allow for contact
with one another.

Figure 5.10 (below): Analysis of hADSC differentiation with Flexcell system:

A, C, E)

Immunofluorescence staining of cells contained within scaffold sheets exposed only to an electrical stimulus.
Cells showed positive staining for actin (red), but staining for connexin 43 (green) was less definitive. DAPI
(blue) was used as a nuclear counterstain. Groups exposed to other stimuli from the Flexcell system are not
shown because positive staining for either marker was not present. Small areas of the scaffold sheets were
cut into thin (< 1 mm wide) segments and stained; A 20X, bar=50µm; C and E 40X, bar=20µm. B, D, F)
Histological sections of cells contained within scaffold sheets exposed only to an electrical stimulus shown
stained by immunohistochemistry (IHC) for alpha-actinin. Groups exposed to other stimuli from the Flexcell
system are not shown because of difficulties encountered in obtaining histological sections containing cells.
IHC positive staining = brown; B 10X, bar=100µm; D and F 40X, bar=20µm.
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Sections from the E group stained positively for the presence of alpha-actinin as
demonstrated by IHC (Figure 5.10B, D, and F). These sections were known to contain
cells because previous H&E staining of serial sections had shown the presence of cells
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(data not shown). We could not determine whether cells from other groups expressed this
marker because we were unable to obtain sections from them that contained any cells. In
contrast to IF, IHC allowed for examination of how cells fit into scaffold interstices. Many
of them appeared to align in the predominant direction of collagen fibers (Figure 5.10F).
One dense group of cells looked as if it was ensconced in a network of newly synthesized,
or otherwise heavily remodeled, matrix; this area of matrix appeared very different from
others (Figure 5.10B and D).

5.3.4 Discussion:
Results of this experiment were not the complete battery they were intended to be;
there was no quantitative data on protein or gene expression because Western blotting and
qRT-PCR were not completed prior to publication of this document. Despite this, amounts
of mRNA and protein isolated from scaffolds will be sufficient for these methods to be
completed in the future, and they will allow more substantive conclusions to be made.
Live/Dead staining and calcium staining confirmed the presence of live cells on
scaffolds from all groups. Calcium staining was much more diffuse, but it could be
coincidental given that cell density on scaffolds was very heterogeneous, and portions of
the R.O.I. used for calcium staining might have contained more cells than portions used
for Live/Dead staining. The particular appearance of calcium in these cells was intriguing
because of how diffuse it appeared, spread throughout the cells. The fact that the images
shown here were taken from specimens with significant depth, as opposed to histological
sections with only 5 µm of depth, is advantageous because close inspection of high
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powered images revealed some nodules in the plane of focus while others (apparently still
within the same cell) were slightly out of focus. This could be taken to mean that calcium
was dispersed through the entire volume of the cell cytoplasm, as one would expect in a
CM. Regardless of this observation, staining of calcium stores alone was far from
definitive evidence that these cells had acquired a CM phenotype. This is because calcium
is rather ubiquitous, and is involved in processes (e.g. second messengers in signal
transduction and enzyme cofactors) not necessarily specific to CMs. It is regularly stored
within mitochondria and the endoplasmic reticulum (the sarcoplasmic reticulum in muscle
cells).[36] It would have been helpful to have performed the same staining on both a positive
and an undifferentiated control as references for how intracellular calcium deposits should
appear in those situations (unfortunately, there is also a lack of other studies which have
used Fluo-4 to label calcium in these instances). Another more definitive test would
involve stimulating the cells with agonists to calcium uptake, such as heptanol and
carbachol, and monitoring the response.[36, 37] Similarly, the provision of an electrical
stimulus would provoke a spike in intracellular calcium concentration in a CM-like cell.

5.3.4.1 Histology, immunofluorescence, and IHC:
Although positive staining for actin was observed, this particular antibody was not
specific to cardiac muscle alpha actin, so other isoforms could be labeled here. The signal
did not localize to bands, as is sometimes seen in staining of CM. CX43 staining was
sparse, with widely dispersed dots that might be construed as positive staining (CX43
normally appears as dots at intercellular junctions). Alpha-actinin staining of cells was
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similar to what we observed with the static differentiation study – positive staining along
the body of the cells, but no distinctive banding from concentration at Z-disks as in CMs.
Since we identified cells in all groups with Live/Dead and calcium staining, we
were somewhat surprised that we could not do the same with other cardiac specific markers
such as those discussed above. We did observe some nuclei (as stained by DAPI) in these
groups, but no accompanying staining for the markers of interest. This would seem to
suggest that these few cells simply did not express these markers. While that may well
have been the reality, one conflicting observation was that positively stained cells shown
in Figure 5.10 were found on a very thin piece of scaffold (probably only 0.25-0.5 mm
wide) relative to other pieces (0.5-1.0 mm wide). By virtue of being thin, the solutions
used in the IF protocol may have come into closer proximity with the cells, enhancing their
action and resulting in more intense staining. In contrast, thicker pieces of scaffold may
have created a physical barrier to the entry of these solutions, resulting in poor staining.
Our purpose behind employing the proceeding method, by which pieces of scaffold
were stained without paraffin embedding, dealt with the drawbacks we encountered with
the method used to obtain IHC results. With paraffin-embedded and sectioned samples,
we found it difficult to obtain sections with any cells. The cells were contained in pockets
so dispersed that many of our 5 µm sections failed to capture any. With the exception of
the E only group, we could not obtain sections with cells from any of the other groups,
even when we staggered our sections 50 µm apart between every 2 or 3 serial sections.
Since our R.O.I. was relatively small – 3.6 cm2 – and we had to use portions of it for other
assays, we could not afford to be inefficient with our samples. We decided that the best
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approach to immunostaining was to use small portions of scaffold for each antibody, and
to use IF to stain the samples without embedding. This enabled us to stain more of the
sample by avoiding the wasted sections associated with paraffin or cryo-embedding. Not
insignificantly, this strategy also maximized our chances of identifying all pockets of cells
that might stain for our markers of interest.

5.3.4.2 Design Iterations and Challenges:
The development of this system was not without its challenges, and, as a result,
went through several iterations before taking on a final form. In several tests of the system
following this experiment, it was observed that the pH of the media from wells run on the
Flexcell baseplate was slightly alkaline, as the phenol red indicator shifted from an orangered to a red-purple color. When measured with a pH meter following several days of
culture within the system, media from these wells had a pH of around 7.9. Since we were
using normal DMEM media buffered by bicarbonate and ambient CO2, we surmised that
the local CO2 concentration within the wells was somehow too low.

A plausible

explanation for this was our use of house compressed air, consisting of room temperature
air with an atmospheric concentration of CO2 (≈0.035%), as the source of air which was
pumped through the Flexcell baseplate.
This was problematic because silicone is a gas-permeable material, so the
compressed air with a much lower CO2 concentration was permeating the membrane and
reducing the local CO2 concentration from its desired level of 5%. In turn, this caused the
bicarbonate buffer system equilibrium to shift toward alkalinity. Additionally, the lower
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temperature of the compressed air was found to reduce the temperature of the culture media
from 37 °C to as low as 31 °C. This, too, could have shifted the effective range of the
buffer but, more importantly, may have also reduced enzyme activity and metabolic
processes within the cells.
A simple solution would have been the addition of 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES) to the media since its buffering mechanism is not
dependent upon CO2, but it was found that HEPES has been shown to produce free radicals
when an electrical potential in excess of 0.8 V is applied to the molecule. This precluded
its use in our system, as we were using much greater electrical potentials than this figure
and free radicals can produce oxidative damage in cells, possibly impacting their viability
or their responses to the experimental treatments.
We therefore elected to change the source of the air pumped through the Flexcell
to air from the incubator so that it possessed the correct CO2 concentration and temperature.
However, we found that since this air was also heavily humidified, it presented a risk of
damage to the vacuum pump and the Flexcell pump in our system. It then became
necessary to remove the water vapor from the incubated air by means of an inline dryer.
This dryer used a silica desiccant that became saturated and required changing every 8-12
hours. Once implemented, it was found that this system normalized the pH of the media
to around 7.5, but the temperature of the media did not recover to 37 °C as expected. To
correct this, the ambient temperature of the incubator was iteratively increased and the
temperature of the media was measured until a temperature setting was determined which
produced the desired media temperature of 37 °C.
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After these changes were made, the system functioned as intended and the culture
conditions were all holding steady at their proper levels. But, over the course of three
experiments, the Flexcell controller proved to be unreliable, suffering hardware
malfunctions in the midst of two of them. This portion of the system was critical to the
experiment, and its frequent downtime severely hindered progress in this study. The
redesigned system is depicted in Figure 5.11.
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Figure 5.11: Modification of Flexcell system: A) Schematic illustration of main components of the second
generation Flexcell system. In order to better regulate temperature and pH, the system was modified to
circulate air from within the incubator through the Flexcell controller and baseplate; the functions of all other
components remained unchanged. B) An incubator containing tubing, baseplate, and a compressed air
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storage tank; the tank and as much tubing as possible were kept inside the incubator to reduce condensation
of water vapor from the humidified incubator air. C) An in-line dryer filled with silica gel dessicant was
used to dehumidify air drawn from the incubator by a D) vacuum pump. This was done to protect the vacuum
pump and Flexcell controller against possible damage from the buildup of condensate.

5.3.4.3 Cell Seeding Challenges:
The challenges presented by insufficient cell density to obtaining and evaluating
results in this experiment prompted us to change our cell-seeding methods in a subsequent
experiment. This new experiment also incorporated the changes to the system design
enumerated above. We hypothesized that seeding lyophilized (freeze-dried) scaffolds
would encourage more cell infiltration because the cell suspension would be drawn into
the porous, dehydrated scaffold in the same manner that a dry sponge draws in water. To
test this, scaffolds sheets were prepared and sterilized via the same methods as the previous
experiment. Sheets were then placed in sterile petri dishes and lyophilized by first freezing
at -80 ºC, followed by application of continuous vacuum at 1.6 mBar.
We used a cell culture scale-up apparatus, the CellSTACK® (Corning), to produce
sufficient numbers of cells for this study. Each lyophilized sheet was injected with 25 µL
of cell suspension at a concentration of 3.8 x 106 cells/mL at 20 evenly spaced points by
means of a custom-designed and 3D-printed array of needle holes.

The array was

positioned over the center of each sheet and a 26 gauge needle was passed through each of
the holes successively until a uniform grid of points was injected. Following injection,
each sheet was then placed into a petri dish containing 11 mL of cells suspended in media
at a concentration of 4.9x105 cells/mL. Sheets were incubated in this cell suspension
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overnight until they had rehydrated and swelled to their original volume. Based upon the
surface area of each sheet and the concentration of the surrounding cell solution, each sheet
was coated at a cell surface density of at least 5.6x103 cells/cm2.
These seeded scaffolds were mounted on Flexcell plates and run on the redesigned
Flexcell system for 3 weeks. Subsequent Live/Dead staining and mRNA and protein
isolation indicated that there were no cells on any of the scaffolds, even in the E only group
scaffolds cultured in an incubator with normal settings. After some careful consideration
of possible causes, it was determined that injected cells did not remain inside scaffolds.
Our understanding of this was that the lyophilized scaffolds initially repelled media until
their outer surface could become hydrated. Because of this, the injected media was
expelled from the interior of the scaffold and the cells along with it. Since scaffolds were
immediately submerged in cell suspension following injection, there was not sufficient
time for serum proteins in the culture media to adsorb to their surfaces. This meant cells
were deprived of any chance to attach to the scaffold, and were washed away once the
scaffolds were placed in cell suspension. Apparently, the scaffolds also failed to attract
any cells whilst bathing in the cell suspension.

5.3.4.4 Perspectives on Dynamic Stimuli in Cardiomyogenic Differentiation:
There have been a number of studies whose results support the positive effects of
dynamic mechanical and electrical stimuli, as well as AZT, on the differentiation of various
populations of stem or progenitor cells into CM-like cells.[18,

35, 38-42]

Our platform

incorporates many of these strategies into one comprehensive system that should produce
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similar results. Some of these results should include increased gene and protein expression
of most or all of the following: alpha-actinin, troponin-T, CX43, desmin, N-cadherin, βmyosin heavy chain, cardiac alpha myosin heavy chain 6, cardiac alpha actin, cardiac
myosin light chain-2α, titin, GATA4, Nkx2.5, and Islet-1. Cells should also display
responsiveness to electrical stimuli, measurable via multi-electrode arrays (MEA) and
calcium transients with the Fluo-4 assay.
Even though many of these markers were not measured in this experiment,
histological methods showed that cells in all but one group demonstrated poor expression
of the markers which were measured. It is still unclear as to whether poor cell seeding,
ineffective assays and methods, or undesirable environmental conditions were the cause.
Low cell density, in particular, was cited by another group who conducted a similar study
as the reason why the cells they were attempting to differentiate did not become electrically
excitable.[35] Cell density, of course, is a function of the cell seeding methods.
Poor outcomes were likely a result of all three factors, but with more efficient cell
seeding strategies and tighter control of the culture conditions, along with improved
reliability of the Flexcell system, this platform should produce results that allow us to
optimize differentiation of hADSCs and subsequent maturation of grafts produced with
them. Finally, with the addition of qRT-PCR and Western blotting results, it is almost
certain that a clearer perspective will emerge as to the success or failure of this initial
experiment.
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5.3.5 Conclusions:
Through several design iterations, we successfully engineered a system with the
desired features outlined in the previous sections of this chapter. It is capable of delivering
mechanical and electrical stimuli in a coordinated manner to cell-seeded myocardial
scaffolds. Based upon the initial results of experiments with this platform, it would be
advisable to revise cell seeding methods so as to deliver as many cells to the scaffolds as
is practical, and to make certain cells are retained within the scaffolds immediately
following the seeding process. Without an abundance of cells in the scaffolds, their
differentiation may be adversely affected, and even evaluation of the effects of the
experiment may become too challenging.
In the future, this system will also serve as an efficient platform for testing the
effects of seeding other cell types (e.g. cardiac fibroblasts, smooth muscle cells, or
endothelial cells), in addition to hADSC, on the differentiation of the latter into CM and
the overall development of the construct into a functional tissue. We can also test the
effects of changing the coordination of the mechanical and electrical stimuli. For example,
the electrical impulse can be alternatively delivered at the peak of the pressure waveform,
simulating an excitation followed by a compression of sorts (the relaxation of applied
tensile force). It might be determined that this method is more effective at producing
differentiation and contractility in hADSC than delivering the stimulus just prior to the
beginning of the pressure waveform.
Other changes that might improve the operation of the system include improving
the reliability of the Flexcell control unit, which malfunctioned during two separate
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experiments involving the platform.

Implementing continuous temperature and pH

monitoring instruments in some of the Flexcell plates could also be a valuable
modification.
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CHAPTER SIX: FEASIBILITY STUDY OF MYOCARDIAL SCAFFOLD
IMPLANTATION IN A PORCINE MODEL

6.1 Introduction:
As discussed in Chapter Two, one of our aims was to evaluate the feasibility of
surgically implanting a tissue engineered myocardial graft in the manner we have
previously described (Figure 6.1). The success of our approach in addressing this problem
hinges on the ability to connect the graft’s vasculature with that of the recipient. Otherwise,
the cells delivered within the graft will likely succumb to ischemia and die.[1] The need for
a vascular supply to the graft was driven by the need for the graft to be thick. Without
sufficient thickness, the graft would be largely ineffective in preventing or reversing
ventricular remodeling. But, a thick graft introduces the complication of diffusional
limitations, so a vasculature becomes necessary to transport nutrients and wastes.
We devised this animal study to demonstrate that tissue-engineered myocardial
grafts (autologous stem cell-seeded myocardial scaffolds) could potentially be used to
revitalize infarcted myocardium by replacing the scar tissue. The goal was to show that
the scaffold could be connected to a patient’s vasculature through anastomosis of its arterial
and venous conduits to the aorta and pulmonary artery, respectively; and that an infarct
scar could be resected and replaced with a portion of the scaffold while this vascular
connection was maintained (Figure 6.1F and G).
In this study, we strove to provide proof of concept for the clinical use of this novel
scaffold. We focused on the scaffold (without seeded cells) to both simplify and avoid
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waste, as the implanted scaffolds did not need to contain cells in order to provide the
information we were seeking. Three sub-studies are proposed which, if successful, will
provide sufficient supporting data for an NIH grant submission (Figure 6.2). More
specifically, the studies aim to prove: 1) that we can generate an infarct model in the pigs,
2) that we can secure the scaffold in place, and 3) that the scaffold will integrate into the
host tissue. Perhaps most importantly, we wanted to show that all of this was possible
without causing harm to the pigs.

Figure 6.1: Overview of an animal model to test clinical implementation of myocardial grafts: This
depiction is representative of the therapy as it is intended to be used in human subjects. A) Intended recipient
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with infarcted heart has subcutaneous adipose tissue harvested and B) adipose stem cells are isolated from
the tissue. Cells are cultured with the aim of growing large numbers for later repopulation by reseeding C)
of the myocardial scaffold D) generated from xenogeneic sources (i.e. a pig). E) The seeded construct is
placed into a bioreactor wherein it is exposed to stimuli which mimic the cardiac environment in order to
differentiate stem cells and condition the construct into a functional graft. F) In the operating room, the
surgeon trims the graft to fit the size of the infarct, resects the infarcted tissue, G) attaches the flap area of
the graft over the resection site, and anastomostically connects the graft’s arterial and venous vessels to the
aorta and the pulmonary artery, respectively.
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Figure 6.2: Overview of preliminary animal study to test clinical implementation of myocardial grafts:
This flow chart illustrates the different groups in the feasibility study. The expected outcomes and methods
to assess them are indicated for each group. In addition, critical decision points are identified wherein specific
outcomes from each group must be observed in order to proceed to the next group. Procedures in each
successive group are more difficult, and thus present more risks.

Pigs were chosen for this study because their cardiovascular anatomy, physiology,
and pathologies are very similar to human aspects. Also, pig models of MI are well
established and widely accepted for testing such procedures.[2-4] Smaller animals such as
mice, rats, and rabbits (the originally proposed subjects for this study) were avoided
because they have smaller anatomical features that would present undue technical
challenges during surgery and recovery that may have directly resulted in poor outcomes.
This is a feasibility pilot study that will form the basis for a larger, more extensive
study. We estimated the number of samples required for each assay to reach statistical
significance once studies are completed at n=3. For proposed studies, the estimated need
is 12 pigs, which will be equally divided between 3 groups (n=3 per group, 3x3=9). Since
survival rate for this type of surgery is estimated at about 70%, we added 3 more pigs to
the study (1 pig/group). For pigs to be of a sufficient size to avoid surgical complications
stemming from the size of anatomical features, we expected they would need to weigh
upwards of 35 kg; pigs were divided into three groups as described above.
After quantitative data sets are obtained, analyses of variance for a completely
random design will be done and means will be compared using Fisher's protected least
significant difference test (LSD).
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We hypothesized that our novel scaffold would allow for efficient integration into
myocardium, and, by virtue of its direct connection to the host vasculature, it would rapidly
become perfused and nourished by host blood, without significant post-op bleeding. We
expected to see positive scaffold integration and adequate perfusion after surgical
connection to the host vasculature.
Confirmation of our hypothesis will serve as the basis for a larger study of
significant clinical relevance, where autologous ADSC will be seeded onto our scaffold,
and, after maturation in vitro, the tissue construct will be implanted into post-infarcted
hearts to help with regeneration and healing (Figure 6.1). From this research we will also
gain valuable insight into surgical techniques and procedures necessary for proper
implantation of such constructs, which will help avoid complications and limit discomfort,
distress, or loss of animals in future studies.

6.2 Pilot Study: In Vitro Test of Surgical Attachment:
6.2.1 Introduction:
Initially, we had planned to conduct these studies in smaller animals to minimize
the costs of surgery and husbandry. We wanted to avoid animals that were extremely small,
such as rats and mice, so settled on using rabbits. Studies using rabbit models of infarction
are prevalent, but few have used the animals to investigate complicated surgical techniques
that might prove necessary with these studies.[5-8] Consequently, we were concerned that
the size of the rabbits’ anatomical features in and of itself would cause surgical
complications that would convolute the outcomes of the study.
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6.2.2 Methods:
6.2.2.1 Porcine Heart Model:
To test the feasibility of the above methods in an in vitro, non-surgical model, an
adult porcine heart obtained from a local slaughterhouse was used as a stand-in for a living
heart that received a myocardial scaffold-graft (Figure 6.3A). The left ventricular free
wall was cut out of a whole, DCELLed porcine heart (Figure 6.3B) and further trimmed
to fit a defect (simulating a resected scar) created in a fresh heart (Figure 6.3C, D, and E).
The defect was not transmural, reflecting a scenario where the surgeon spares a layer of
viable myocardium adjacent the endocardium when resecting the infarct scar.

The

coronary artery and cardiac vein of the scaffold were anastomosed to the ascending aorta
and the coronary sinus, respectively (Figure 6.3F and G). The void was coated with a
layer of Tisseel™ fibrin glue (Baxter), and the flap portion of the scaffold was pressed into
the void (Figure 6.3H and I). A running 4-0 prolene suture was placed at the periphery
of the scaffold and weaved back and forth between the scaffold and the native heart in an
attempt to better seal the severed vessels of the scaffold (Figure 6.4A, B, and C).
The opening of the aortic anastomosis was accessed through the aorta and a syringe
with attached Luer connector was used to cannulate the arterial conduit. The syringe,
which was loaded with water colored with red food dye, was depressed and the solution
was forced into the scaffold vasculature.

Figure 6.3 (below): In vitro test of scaffold implantation method, Part 1: A) Illustration of the graft
implantation method; in the operating room, the surgeon trims the graft to fit the size of the infarct, resects
the infarcted tissue, attaches the flap area of the graft over the resection site, and anastomotically connects
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the graft’s arterial and venous vessels to the aorta and the pulmonary artery, respectively. B-I) Demonstration
of graft preparation and implantation in the laboratory. B) The entire left ventricular free wall was cut away
from a whole, decellularized heart and C) further trimmed to fit the size of a E) simulated defect created by
removal of an imaginary infarct in a D) fresh porcine heart. Anastomoses were made between F) the
scaffold’s coronary artery and the heart’s aorta, and between G) the scaffold’s cardiac vein and the heart’s
coronary sinus. H) Tisseal™ fibrin glue was applied to the defect, and the flap portion was attached securely
with fibrin glue and sutures.
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6.2.2.2 Rabbit Heart Model:
We performed the simulated implantation of the scaffold in a fresh rabbit heart
(Animal Technologies; Tyler, TX) in the same manner as described above (Figure 6.5).
The only difference in the two methods was that a much smaller portion of scaffold had to
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be trimmed, and the portion needed to contain a vascular unit (an artery and vein that
connect to one another through a capillary network, thereby supplying a piece of tissue
with a functional vascular supply) (Figure 6.5A and B). This vascular unit was tested for
integrity by suturing open vessels and injecting water through both the arterial and venous
inlet to verify there were no leaks.

6.2.3 Results:
6.2.3.1 Porcine Heart Model:
Injection of red dye into the arterial anastomosis resulted in its migration through
the arterial vasculature and into the venous vasculature (Figure 6.4D, E, and F). Veins
were bulging with pressure, and after injection of more than 10 mL of dye solution, the
whole flap portion began to bulge out from the native heart. (Figure 6.4D and E). No
leaks were observed in the major vessels throughout the flap portion of the scaffold, but
the venous anastomosis leaked slightly (Figure 6.4E).
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Figure 6.4: In vitro test of scaffold implantation method, Part 2: A-C) Myocardial scaffold shown
securely attached to the left ventricle of a fresh porcine heart, and with anastomoses of the coronary and
venous conduits made to the fresh heart. D-F) Images of the scaffold following injection of water colored
with red food dye through the aortic anastomosis. D, E) The scaffold shown bulging outward from the
ventricular wall following dye injection. E, F) The scaffold’s vessels were clearly perfused with the dye, and
apparent bulging of the cardiac vein demonstrated intact connections between the arterial and venous vascular
channels of the scaffold.
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6.2.3.2 Rabbit Heart Model:
Anastomoses of the major vessels were made, but it was clear during the procedure
that they would not be functional. It was not possible to find the opening of either
anastomosis in order to inject fluid, so the functionality of the graft was not determined
(Figure 6.5C).
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Figure 6.5: In vitro test of scaffold implantation method, Part 3: A) Myocardial scaffold shown adjacent
to a fresh rabbit heart, and an outline of an attempt to identify a functional vascular unit (an efferent artery
and an afferent vein) to patch a B) defect created in the fresh heart. B) Vascular unit after being cut from the
myocardial scaffold and C, D) anastomoses of the coronary and venous conduits made to the fresh heart. C,
D) The lower part of the vascular unit was secured to the defect in the fresh heart using fibrin glue.

6.2.4 Discussion:
Migration of dye from the arterial to the venous circulation in the porcine model
demonstrated that the scaffold possessed intact arterioles, venules and capillaries. The
scaffold’s bulging veins showed that the anastomoses and, to some extent, the interface
between the scaffold and the native heart held pressure. Bulging of the scaffold indicated
some leakage was building up underneath the flap portion, but also that the seals around
the edge of the flap were intact. Leakage of the venous anastomosis was due to surgical
inexperience. This anastomosis was certainly the more challenging of the two because the
vein was flimsy and not as amenable to handling and suturing.
The rabbit model proved to be more technically challenging, and would probably
demand the use of microsurgical techniques in order to be done properly.

6.2.5 Conclusions:
The porcine model proved to be feasible, but the rabbit model seemed as if it would
present unnecessary complications due solely to its smaller anatomical features. The
difficulty of surgical procedures and stresses on animals will only become heightened with
each successive study described below. In view of this, we decided to move forward with
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studies which used pigs as the recipients of scaffolds, and to abandon the idea of using a
rabbit model.

6.3 Group 1: Acute Implantation Testing:
6.3.1 Methods:
6.3.1.1 Modification of Myocardial Scaffold with Vascular Scaffolds for Anastomosis:
To facilitate attachment of the myocardial scaffold’s coronary arterial inlet and
venous outlet to the pig vasculature, 6-10 cm lengths of DCELLed porcine carotid arteries,
or vascular scaffolds, were anastomotically attached to both of those vessels. This was
necessary to ensure that the surgeon had enough length of conduit with which to work, as
the graft’s own vessels may not have been long enough to reach the desired points of
anastomosis on the aorta and pulmonary artery.

6.3.1.1.1 Vascular Scaffold Preparation
Fresh, 6–12 cm long, porcine carotid arteries with internal diameter tapering from
about 8 mm to 3 mm were obtained from young animals via Animal Technologies (Tyler,
TX). The arteries were DCELLed in a bioprocessing system according to a recently
published protocol developed in our lab.[9] The system, shown below, used pressure
vessels and a peristaltic pump to generate translumenal pressure (50-80 mmHg) in
arteries mounted inside two custom-designed housings. The combined action of several
reagents and this pressure facilitated completely uniform DCELL of the arteries. Filling
and drainage ports enabled timely and convenient changing of solutions.
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Figure 6.6: Perfusion bioprocessor for decellularization of vascular scaffolds: Porcine carotid arteries
were mounted inside the clear housings, and a system of tubing and pressure heads was used to
continuously pump a series of reagents though the vessels until the cells were removed from the tissue.

6.3.1.1.2 Cleaning and Preparation
Once received, arteries were kept on ice and cleaned of excess fat. Luer lock
fasteners were zip-tied to each end of the arteries for eventual mounting in the
bioprocessing system. To test for leaks, one luer lock was closed off with a luer cap
while the luer on the opposite end was fastened onto a syringe filled with saline. The
arteries were pressurized and monitored for any leaks. If a leak was observed, the hole
was sutured shut using 3-0 Ethibond Excel braided polyester suture. The arteries were
once again checked for leaks before proceeding with the remainder of the process.

210

6.3.1.1.3 Tissue Decellularization and Sterilization
Samples were first treated overnight in 30 mM EDTA, 0.02% sodium azide
(NaN3) (pH to ~7) on an orbital shaker at 3.5 rpm at 4C. The following day, the arteries
were removed from the EDTA solution and mounted in the bioprocessing system. From
this point on, the DCELL process continued inside of the bioprocessing system. The
steps for DCELL and sterilization are listed below.
1.
2.
3.
4.

Mounted the arteries in the perfusion bioreactor.
Filled the bioreactor with 30 mM EDTA, 0.02% NaN3 solution and left overnight.
Rinsed bioreactor with ddH2O.
Introduced 1% SDS solution into the reservoir and ran with pressure for 12 days; changed solution
at 6 days.
5. Rinsed with ddH2O overnight with pressure.
6. Rinsed 3X with 1 L of 70% ethanol (EtOH).
7. Rinsed with ddH2O for 30 min with pressure.
8. Drained water, added 1400 mL of 0.1 M NaOH into system, incubated for 2 hr with pressure.
9. After 2 hr, rinsed with ddH2O.
10. Added 1400 mL PBS, circulated overnight with pressure.
11. Treated scaffolds with DNAse/RNAse solution (720 mUnits/mL DNAse, 720 mUnits/mL RNAse,
5 mM MgCl, in 1x PBS, pH=7.5 with 1% v/v antibiotic/antimycotic) for 96 hours at room
temperature.
12. Added 1400 mL PBS, circulated 1 hr with pressure.
The system was moved into a sterile hood to ensure sterility
13. Rinsed with ddH2O.
14. Rinsed 2X with 1400 mL of sterile PBS; circulated the last 500 mL for 20 min with pressure.
15. Placed in 1400 mL 0.1% w/v peracetic acid, circulated the last 500 mL for 2 hr with pressure at
room temperature.

Pigs (n=3) were used for testing and optimizing the surgical implantation of the
myocardial scaffold in healthy hearts and observed for 30 min -1 h (non-survival surgery).
Pigs were preanesthetized by an intramuscular injection of ketamine hydrochloride (20
mg/kg) and xylazine hydrochloride (2 mg/kg). The animals were positioned supine, and a
22-gauge indwelling needle was inserted in the central vein of the auricle for continuous
i.v. anesthetic injection. The animals were intubated with an endotracheal cannula (6
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French) and then connected to an artiﬁcial respirator with a stroke volume of 200–300
cm3/stroke and frequency of 20/min. Propofol (6 mg/kg/h) and vecuronium bromide (0.05
mg/kg/h) was continuously infused using a syringe pump. Pigs were prepped for aseptic
surgery using nolvasan scrub and sterile saline rinse in triplicate. Surgery was performed
using aseptic technique.
The animals were ﬁxed in a recumbent position so that the left thorax was exposed,
and a left thoracotomy was performed as follows: the outer layer of skin and muscles
between the third and fourth ribs were dissected. The distance between the third and fourth
ribs was widened with a rib spreader to allow a direct view of the left auricle LAD coronary
artery. The pericardium was dissected along the LAD from the upper part of the left auricle
(approximately 6 cm) to expose the myocardium. The myocardial scaffold was attached
to the descending aorta via its arterial vascular scaffold conduit and to the pulmonary aorta
via its venous vascular scaffold conduit. An area of about 10 cm2 was shaven off the lower
left anterior ventricle and the scaffold glued onto the shaven area with fibrin glue, followed
by placement of 6-8 sutures to secure the scaffold. The scaffold was allowed to stay in
place for 1 hour to allow blood to clot around the implant and also test for blood leakage.
After 1 hour, the pigs were humanely euthanized via intravenous injection of FatalPlus (1
mL/10 lb; supplying 390 mg/mL sodium pentobarbital) followed by performance of a
bilateral pneumothorax for euthanasia verification, and hearts and scaffolds were collected
for analysis via histology.
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6.4 Group 2: Induction of Myocardial Infarct:
Pigs (n=3) will undergo induction of MI by left anterior descending (LAD)
coronary artery ligation and be allowed to survive for 4 weeks. Electrocardiography
(EKG), echocardiography (ECG), blood chemistry and histology will ascertain induction
of MI at 4 weeks (survival surgery). EKG and ECG will be performed prior to surgery in
order to establish baseline levels for these signals. Pigs will be prepped for aseptic surgery
using nolvasan scrub and sterile saline rinse in triplicate. Surgery will be performed using
aseptic technique. Hearts will be exposed by left thoracotomy as described above. The
pericardium will be dissected along the LAD from the upper part of the left auricle
(approximately 6 cm) to expose the myocardium around the LAD. The LAD on the
proximal side, below the left auricle from the myocardium, will be exfoliated for
approximately 1 cm. A lidocaine hydrochloride jelly will be applied to anesthetize the
area. First, a complete ligation of the LAD will be made immediately distal to the second
diagonal branch using a 2-0 suture. Approximately 20 min later, an ameroid constrictor
(3.5 mm internal diameter) will be fastened around the coronary artery just distal to the left
circumflex artery branch using sutures. The ameriod constrictor is designed to slowly
(within 3-5 days) ligate the artery. To enhance the effect of the ameroid constrictor, 2
additional suture strings will be loosely rounded at the site of the ameroid so that these
strings will be located between (below) the ameroid constrictor and arterial wall. This dual
ligation approach has been shown to improve survivability of the procedure by reducing
the likelihood of fatal arrhythmia and to produce a more pathologically relevant model with
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respect to models generated using a single ligation point. Following ligation, the fascia
and intercostal space will be closed, buprenorphine (0.04 mg/kg) and prophylactic
antibiotics (ceftiofur; 5.0 mg/kg) administered i.m., and pigs allowed to recover.
Blood will be collected (described below) immediately before and after the surgical
procedure and troponin (TN), lactate dehydrogenase (LDH), creatine phosphokinase
(CPK) levels measured.

After 4 weeks, EKG and (ECG) will be performed under

anesthesia. For ECG, pigs will be scanned in a parasternal short-axis view with 2D and Mmode imaging and a broadband high-frequency (12-MHz) transducer. Left ventricular
internal diastolic diameter (LVIDd), end diastolic volume (LVEDV), internal systolic
diameter (LVIDs), and end systolic volume (LVESV) will be calculated and the left
ventricle ejection fraction (LVEF) will be calculated. ST segment elevation and abnormal
Q waves on EKG will be indicative of MI. Pigs will be euthanized under anesthesia as
described above. Hearts will be excised and analyzed for additional signs of infarction.

6.5 Group 3: Short-term Implantation Testing:
Pigs (n=3) will undergo induction of MI as previously described in Group 2 and be
allowed to survive for 4 weeks before implantation of the myocardial scaffold; following
scaffold implantation, pigs will be assessed for evidence of scaffold integration at 2 and 4
weeks post implantation (multiple survival surgery). At 4 weeks post-infarction, scaffolds
will be implanted as described in Group 1, with the exception that the area to be cut away
from the left ventricular wall will be the infarct scar. After ensuring hemostasis, the fascia
and intercostal space will be closed, buprenorphine (0.04 mg/kg) and prophylactic
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antibiotics (ceftiofur; 5.0 mg/kg) administered i.m., and pigs allowed to recover. At both
2 and 4 weeks, EKG and ECG will be performed as previously described, and pigs will be
euthanized after 4 weeks under anesthesia as described above. Hearts will be excised and
analyzed for evidence of scaffold integration.
Subdermal adipose tissue (post-mortem) and blood (pre-op/ante mortem and postop) will be collected for isolation of ADSCs and circulating endothelial progenitor cells,
respectively, which will be used for subsequent in vitro applications and future in vivo
studies (blood collected will primarily be used for assays germane to results of the studies).
Each collection procedure is described below.

6.5.1 Blood collection:[10]
While anesthetized, pigs will be laid laterally and the subcutaneous abdominal vein
will be located. The area will be swabbed with 70% ethanol to disinfect, and thumb
pressure will be applied on the proximal end of the vessel to occlude blood flow. A 21 G
or 19 G needle, depending on the animal size, will be introduced into the engorged vessel.
Approximately 50 mL of blood will be collected, and hemostasis will be achieved by
application of thumb pressure for about 5 min. Blood collection will be carried out before
and after the procedure described in Group 2, and also just prior to euthanasia in all groups
in order to isolate circulating endothelial progenitor cells.
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6.5.2 Fat collection:
Subcutaneous fat (10 g per pig) will be harvested from the dorsal abdominal and
inguinal areas of the pigs immediately following euthanasia. We will collect fat from these
areas and compare stem cell counts. After euthanasia, the subdermal adipose tissue is
accessed through a 15 cm longitudinal incision in the abdominal or inguinal area. After
tissue identification, 10 ml of saline solution containing 1:1,000,000 dilution of
epinephrine are added to minimize blood loss and after 3 minutes, a subdermal adipose
tissue (5-10 cm diameter) is collected for isolation of ADSCs.

6.5.3 Post-operative Recovery and Monitoring:
Immediately post-op, the respiratory rate, reflexes, mucus membrane color,
movement, and appetite of pigs will be monitored for 15-30 minutes, or until ambulatory.
We will also be alert to redness, swelling or oozing at the surgical site; changes in appetite,
attitude/activity, and temperature will be monitored every 6-12 hr for the first 48 hr, and
daily thereafter.
Pigs will be housed singly during post-op recovery and may be housed in groups
as determined by the attending veterinarian (AV).

If possible, single housing pen

construction should allow for social interaction, as pigs are social animals.
Other measures taken to monitor animal health include: 1) Appetite: documented
daily. 2) Hydration: documented by skin test daily. 3) Weight: measured 2 times per week
for the first 2 weeks, then weekly for 2 weeks. After 1 month every 2 weeks or at the
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discretion of the AV. 4) Behavior will be assessed daily and considered together with other
criteria over 3-4 days period. 5) Surgery site monitored daily for proper healing for first
week, every other day thereafter.

6.6 Results:
6.6.1 Group 1:
To date, 1 pig from this group underwent a surgical procedure. The anastomoses
of vascular scaffolds to the coronary artery and cardiac vein were carried out on a back
table in the operating room just prior to the surgery. The integrity of the anastomoses was
tested by inserting a syringe loaded with saline into the end of each vascular scaffold and
injecting the liquid. No leaks were observed (Figure 6.7A-C).
After opening the thoracic cavity of the animal and exposing the heart, the vascular
scaffold connecting the venous circulation was successfully anastomosed to the pulmonary
artery. When blood was allowed to flow through this connection, no leakage was observed,
and blood spread slowly through the venous circulation (Figure 6.7D and E). This
connection was clamped while the arterial anastomosis was made to an area of the
descending aorta just inferior to the aortic arch (Figure 6.7H). Blood was allowed to flow
through this connection, and flowed at a much greater volume and velocity. Leakage was
observed from several arterial branches of the LAD CA that fed the septum, as these had
been severed when the left ventricle was cut away from the rest of the heart. These leaks
were quickly closed with small metal clamps, and hemostasis was achieved shortly
thereafter.
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At the surgeon’s discretion, the procedure was halted at this point. There were no
complications which precipitated this decision – it was simply determined that the selected
approach of a left thoracotomy did not provide the correct angle for sufficient access to the
anterior left ventricle in order to proceed with resection and scaffold attachment.
Following anastomosis, blood was allowed to flow freely through the scaffold.
There was a clear change in its color, as it went from an opaque white to a reddish-pink
(Figure 6.7G and I). Blood was observed to perfuse the arteries and veins, even down to
vessels of a size barely discernable to the naked eye (Figure 6.7J). The scaffold was left
in this state and observed for a period of about 30 minutes, during which time no purpleing
of the blood was noticed. Palpation of the vascular scaffolds and the LAD CA also
indicated good pressure during this time, although a pulse was not detected in this manner.
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made and electrocautery equipment and retractor were used to cut down and open the thoracic cavity. E)
Anastomosis of the venous conduit to the pulmonary artery; shown clamped, but, when opened, low pressure
and low velocity flow of blood into the scaffold was observed. F) Myocardial scaffold shown as it would
lay on the heart once fully implanted; in clinical application, scaffold would be trimmed down significantly
from the size shown here. H) After both conduits had been anastomosed to their respective vessels (arterial
to the descending aorta (DA) and venous to the pulmonary artery (PA)), G) the scaffold’s vessels were clearly
perfused with blood, especially when compared to an I) unimplanted scaffold. J) Endocardial side of the
myocardial scaffold, where perfusion of the scaffold’s microvasculature is visible.

6.6.2 Histological Assessment of Scaffold Perfusion:
Histological sections obtained from both the arterial vascular scaffold conduit and
the myocardial scaffold showed extensive perfusion of the entire construct with host blood
(Figure 6.8). Vessels of wide-ranging diameters were perfused, and inspection of high
magnification micrographs revealed perfusion of vessels as small as 6-8 µm in diameter
(Figure 6.8B, D and F). A comparison of the blood within the vascular scaffold and that
within the smaller vessels in the myocardial scaffold demonstrated differences in its
structure. The former showed clumps of loosely coagulated erythrocytes, while the latter
appeared to be solid, compact fibrin with no identifiable erythrocytes (Figure 6.8G and
H).

Additionally, erythrocytes and leukocytes (unclear if they were neutrophils or

monocytes) were observed to attach to the vascular scaffold’s lumen (Figure 6.8C and E).

Figure 6.8 (below): Histological evaluation of acute implantation of myocardial scaffold: A, C, E, G)
Micrographs of a circumferential section of the arterial vascular scaffold conduit, increasing in magnification
downward. B, D, F, H) Micrographs of a section through the myocardial scaffold from a region about 1.5
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cm distal to the scaffold LAD CA, increasing in magnification downward. A) Vascular scaffold shown with
erythrocytes in lumen. B, D) Myocardial scaffold showing extent of perfusion throughout a wide range of
different-sized vessels. C, E) Erythrocytes and leukocytes shown adhering to the lumenal wall. F) High
magnification micrograph of myocardial scaffold identifies perfusion of vessels on the scale of capillaries.
G)

Magnification of erythrocytes in vascular scaffold lumen distinguishes individual cells, whereas

magnification of blood in a more distal artery shows dense, fully formed thrombus. A, B) 2.5X, bar=500µm;
C, D) 10X, bar=100µm; E-H) 40X, bar=20µm.
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6.7 Discussion:
It was not clear to what extent or how rapidly coagulation set in, but judging from
color alone, blood flow in the scaffold seemed to remain unobstructed for about 15-20 min.
Instead of darkening slightly as thrombus does, the blood remained a scarlet red. The lack
of purple coloration (indicating deoxygenation) also suggested that the direction of its flow
was from the arterial into the venous circulation. In addition to having the proper
directionality, this meant that blood must have flown through what remained of the
capillary beds. This confirmed the results of several in vitro methods we had previously
used to demonstrate that the scaffold vasculature was patent and intact down to this level
(see Chapter Three).
Histological evaluation of the scaffolds agreed with these observations, as vessels
of similar size to capillaries were perfused with blood. As was expected, thrombus
formation appeared to have begun first within smaller vessels and propagated proximally
through larger vessels.[9] This was supported by the observation that smaller vessels
contained only solid, coagulated plasma, while the lumen of the much larger vascular
scaffold contained identifiable erythrocytes that did not appear significantly coagulated.
It was also noted that we did not observe any dispersion of erythrocytes outside of
vessels and into the rest of the scaffold matrix, which would be indicative of leaks. This
suggested that all vessels within the scaffold retained their integrity post-DCELL. This
inference applies to capillaries as well, which is intriguing since a common question with
the DCELL approach is whether the capillary conduits are left intact once endothelial cells
are removed. Had capillary conduits not remained intact, we would expect to see many
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erythrocytes scattered throughout the scaffold because these cells would no longer be
contained once they reached that level of the vasculature.
Since this scaffold and its vascular channels consisted of bare collagen and other
ECM components, it was our expectation that coagulation and eventual occlusion of the
vasculature would occur.[11, 12] We noted conditions that seemed to suggest arterial to
venous blood flow for 15-20 min, implying patency of microvasculature during this time.
While this was encouraging, future grafts implanted in this manner will require
endothelialization, heparinization, or both to avoid the formation of significant
thrombus.[11]
To correct problems with accessibility to the ventricle, it was decided that future
surgeries would proceed through a median sternotomy approach. This approach involves
cutting down the midline of the sternum by using a saw, and can be more traumatic than a
left thoracotomy. Despite this, it is important to use an approach that allows unencumbered
access to the entire anterior surface of the heart so that an area of the ventricle can be
resected and replaced with the scaffold in future experiments.
Subsequent procedures should consider using longer lengths of vascular conduit so
as to reach the right atrium and avoid crossing the conduits over one another as seen in
Figure 6.7H. The right atrium was specified above, rather than the pulmonary artery,
because moving the point of venous anastomosis from the former to the latter would
provide a more favorable pressure gradient for blood flow through the scaffold. In contrast
to pulmonary arterial pressures, which can range from 30-50 mmHg, right atrial pressures
range from 5-12 mmHg. This would provide a greater pressure differential between arterial
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conduit inflow pressure (120 mmHg) and the retrograde resistance at the venous conduit,
increasing flow velocity through arterioles and capillaries and avoiding potentially
hypertensive conditions in these vessels. Capillary pressure, which largely influences the
extent of nutrient and waste exchange between blood and interstitial fluid, would be
normalized by this change and it is therefore highly recommended in future surgical
procedures.
It was also apparent that open branches in the scaffold should be ligated or sealed
prior to the surgical procedure. This will be done by injecting a colored solution (e.g.
sterile DMEM) through the vascular grafts and noting the position of any leaks before
sealing them. In doing so, hemostasis may be achieved more quickly.
Overall, we noted there were no complications with the pig during surgery, and
blood loss was limited to 250 mL or less. By our estimates (70 mL blood/kg in a 37 kg
pig), this volume was equal to about 10% of the circulating blood volume, well below the
maximum allowable blood draw of 15% in a single procedure.[13]
This was not the first instance of a successful procedure of this kind. Other
groups have attempted to employ this approach to solve the problem of providing a
vascular supply to tissue-engineered grafts.[1, 14] There is also precedent established for a
few of the key implantation techniques we intend to use, including the resection of
significant portions of the infarct scar to enable attachment of the device within the void
created, and the anastomosis of the vessels supplying the graft to the patient’s
vasculature.[14] For the former, the reasoning is that attachment of the graft adjacent to
any healthy, functional tissue will allow for greater electrical and vascular integration
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with the host than would its attachment directly over nonfunctional, less vascularized
infarct scar tissue (discussed in section 1.5.6). Robinson et al. demonstrated the
feasibility of scar resection prior to device implantation without compromising the
ventricular wall’s integrity under systolic pressures.[15] Ott et al. successfully
anastomosed the aorta of a whole, DCELLed rat heart to the abdominal aorta of another
rat, and showed that the acellular organ had an intact and patent vasculature that
conducted the host’s blood adequately without bursting or leaking.[14]
As discussed above, it will not be sufficient to merely connect grafts to the
vasculature in the future. Measures must be taken to prevent thrombus formation,
otherwise the functionality of such grafts will be compromised. Furthermore, vascular
integration at the interface of host tissue and the graft may be necessary to ensure
sufficient vascular supply, especially to peripheral portions of the graft.

6.8 Conclusions:
Given the functionality of the anastomoses and how well the surgery was
tolerated by the animal, we considered this initial procedure a success. We will continue
with these studies as planned in order to establish the feasibility of future implantations of
scaffolds seeded with cells. To correct problems with accessibility to the ventricle, it was
decided that future surgeries would proceed through a median sternotomy approach. It
may also be necessary to place pigs on heart-lung bypass in order to perform resection of
the ventricle. Moving the point of anastomosis of the venous conduit from the
pulmonary artery to right atrium may prove more beneficial to the overall vascular flow
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within the scaffold. It was also apparent that open branches in the scaffold should be
ligated or sealed prior to surgery in future procedures.
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CHAPTER SEVEN: CONCLUSIONS AND RECOMMENDATIONS FOR
FUTURE WORK

7.1 Summary of Project Development:
Based upon data furnished by the American Heart Association, an estimated 1.43
million individuals are currently at risk of developing CHF as a result of tissue damage
caused by MI. Costs to treat CHF represent a significant burden to our society;
currently, they stand at $44.6 billion but are predicted to double by 2030. Patients with
CHF perennially account for 6% of all Medicare beneficiaries, and are some of the most
expensive to treat. In fact, among the top 5% of patients in terms of overall expenditures,
patients with CHF comprise a full third of the population.[1] These facts and figures
clearly outline why developing practical and effective therapies to treat these patients is a
worthwhile cause.
After gaining an understanding of the pathological link between MI and CHF and
undertaking a critical evaluation of the current standards of care, limitations in our ability
to treat this population of patients were identified. These limitations represented an
opportunity for innovation, so we set out to develop a novel, translational approach to
treatment of the underlying causes of this condition. We relied on a knowledge of the
advantages offered by tissue engineering to inform our unique approach. After studying
some of the successes and failures by others in this application, we crafted an approach that
demanded the development of a tissue-engineered graft that was thick, fully vascularized,
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and functional (contained cells that mimicked the function of healthy myocardium) to
replace infarct scar tissue and prevent or reverse development of CHF in affected patients.

7.2 Progress toward Achievement of Specific Aims:
To accomplish the overall objective of this project, we established 4 specific, yet
interrelated aims and directed our efforts in toward achieving them. These aims were
described at length in Chapter Two but are presented in brief below:

Aim 1 (Chapter 3): To develop and characterize a decellularized, vascularized scaffold
for use in myocardial tissue engineering
Hypothesis: Acellular left ventricular porcine myocardium will serve as an ideal
supporting material for tissue engineered myocardial grafts due to its low immunogenicity,
potential as an excellent “niche” for inducing differentiation of stem cells toward cardiac
phenotypes, and its network of preserved, patent vascular channels.
Aim 2 (Chapter 4): To characterize the host response to scaffolds and optimize their
in vivo degradation rate
Hypothesis: Scaffolds which resist in vivo degradation for longer than 8 weeks will
provide implanted cells sufficient stability and time to integrate with host tissue, improving
functional outcomes. Treatment with a specialized cross-linking agent will mitigate the
severity of the immune response to implanted scaffolds.
Aim 3 (Chapter 5): To condition cell-seeded myocardial constructs in vitro into
functional grafts
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Hypothesis: Exposure to conditions mimicking the physiological environment of the
myocardium will induce stem cell differentiation and maturation of constructs into
functional myocardial grafts
Aim 4 (Chapter 6): To develop an animal model of infarction and demonstrate
feasibility of surgical replacement of infarct scar with tissue-engineered constructs
Hypothesis: A porcine model of infarction and surgical approach to construct
implantation must be developed and optimized.

Our progress toward completing these aims, as well as our conclusions in regards
to their attendant hypotheses, have been discussed at length in each of the indicated
corresponding chapters, but a summary of the major conclusions is as follows:

7.2.1 .Aim 1 (Chapter 3): To Develop and characterize a decellularized, vascularized
scaffold for use in myocardial tissue engineering:
1) We evaluated both the myocardial and arterial matrix of our scaffolds, and
found they are porous, retain collagen and elastin content and structure, exhibit
excellent mechanical properties, and are cytocompatible. Moreover, scaffolds
retain laminin, fibronectin, and collagen IV.

We’ve also preserved the

vasculature’s integrity and patency down to the capillary scale.
2) Cytocompatibility and support of CM survival indicate that our scaffold is
ideally suited for repopulation with relevant cardiac cell types as a tissueengineered construct for myocardial repair
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3) Given its composition, intact vasculature tree, mechanical properties, and
geometry, we believe constructs produced from this scaffold have the potential
to functionally integrate with healthy host myocardium and to be nourished by
direct anastomotic connection with the host’s own vasculature.
4) Constructs resulting from recellularization of this scaffold may also be useful
as physiologically accurate models for in vitro studies of cardiac physiology
and pathology.

7.2.2 Aim 2 (Chapter 4): To characterize the host response to scaffolds and optimize their
in vivo degradation rate:
1) The host response in a xenogeneic implantation study was directed
predominantly by cells commonly associated with immune functions (i.e. of
leukocytic lineages). The scaffold is “bioactive”, as opposed “inert”, with a
heavy infiltration of host cells.
2) Treatment of scaffolds with PGG can extend their lifetime up to, and possibly
beyond, 12 weeks – presumably a sufficiently long period for delivered cells to
integrate with host tissue in future implantations of recellularized scaffolds.
3) The host response to scaffolds does involve some elements of the classical
inflammatory response (FBGCs), but over time the environment becomes less
pro-inflammatory as evidenced by the predominance of M2 macrophages.
4) It was clear that this scaffold encouraged angiogenesis, which is a very desirable
quality for our overall approach in generating functional, vascularized muscle.
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5) We were unable to thoroughly describe the functionality, or “appropriateness”,
of the tissue ultimately formed by host remodeling of the scaffold, as this is
dependent upon the implantation site and the intended function of the implant.

7.2.3 Aim 3 (Chapter 5): To condition cell-seeded myocardial constructs in vitro into
functional grafts:
1) Use of myocardial scaffolds as a substrate for hADSC growth precipitated
expression of cardiac genes and proteins regardless of treatment with AZT.
2) Evidence of increased CM marker expression in hADSC grown on scaffold vs.
standard culture plastic was not abundant, but what little there was could be
explained by an inductive role of the structure and composition of myocardial
scaffolds in cardiomyogenic differentiation of hADSCs.
3) The addition of variables such as electrical and mechanical stimuli may be
necessary to achieve full differentiation of hADSCs into a CM phenotype.
4) We successfully engineered a system capable of delivering mechanical and
electrical stimuli in a coordinated manner to cell-seeded myocardial scaffolds.
5) Early indications are that this system will serve as an efficient platform for
testing the effects of these stimuli on the differentiation of hADSC into CM.
6) Flexcell International Corporation makes poorly designed and unreliable
products.
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7.2.4 Aim 4 (Chapter 6): To develop an animal model of infarction and demonstrate
feasibility of surgical replacement of infarct scar with tissue-engineered constructs:
1) The rabbit model seemed to present unnecessary complications due solely to its
smaller anatomical features, and was abandoned.
2) To correct problems with accessibility to the ventricle, it was decided that future
surgeries would proceed through a median sternotomy approach.
3) It was also apparent that open branches in the scaffold should be ligated or
sealed prior to the surgical procedure. This will be done by injecting sterile
DMEM through the vascular grafts and noting the position of any leaks before
sealing them. This will ensure that hemostasis is achieved more quickly.
4) The anastomoses were functional and hemostasis without significant blood loss.
The surgery was tolerated well by the animal; we considered this initial
procedure a success and surgeries will continue as planned.

7.2.5 Perspectives on Progress Made and Comments on Potential Continued Research:
The studies conducted and reported on here have fulfilled the objectives of Aim 1
and made significant progress toward completion of the other aims. Continued study of
the host response may lead to better understanding of outcomes of future experiments
wherein cells, autologous or otherwise, are delivered within scaffolds.
Development of the Flexcell platform carried with it significant technical
challenges, but as it is constituted now, the system should become a valuable tool in
working toward the completion of Aim 3. Along those lines, further experimentation with

233

the system may demonstrate that differentiation of hASDSs using only dynamic stimuli is
a less effective or practical approach than using human IPSC, which are now being shown
to be highly amenable to cardiomyogenic differentiation.[2-4]

In the context of our

translational approach, it is still the opinion of the author that hADSCs represent the most
practical option for reasons already delineated above. However, it may be advisable to
focus on using this platform as a tool to “condition” cells that already display a number of
CM traits to become more functional, rather than using it to affect fully de novo
differentiation.
Initial progress toward Aim 4 is both promising and exciting, and significant
thought and planning should be put into how future implantation studies are conducted, as
their results have the potential to make or break the translational potential of this therapy.
Regardless of future directions, it is expected that this research will have a positive
impact upon efforts to treat a growing population of patients suffering from complications
of MI. It will not only enable clinicians to prevent or reverse the progression towards
CHF—saving lives and improving the quality of life for recipients of this therapy—but
also contribute to the advancement of the cardiac tissue engineering field.

7.3 Recommendations for Future Work:
7.3.1 Aim 2:
Moving forward, we will be able to use either PGG-treated or non-treated scaffolds
in this translational approach, depending upon the desired degradation profile. The
response to scaffolds may also prove to be drastically different at the eventual target site,
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the heart, and when there is an autologous cellular presence within the scaffolds, as would
be the case with myocardial grafts. It is advised that future implantation studies examine
the response under these conditions.
As for things that can still be studied in samples from both Biocompatibility
Studies, a number of IHC and IF stainings can be done to look for certain factors of interest.
Sections could be stained for peroxisome proliferator-activated receptors (PPAR), whose
downregulation has been implicated in causing a phenotypic shift from M2 to M1, in order
to provide further confirmation of polarization and gain insight into its possible
mechanistic progression.[5] Stem cells that may be recruited to the vicinity of the implant
can be identified by staining for CD34 or CD29, mesenchymal stem cell markers.[6] Their
specific populations of origin may be determined by staining for the hematopoietic stem
cell, adipose-derived mesenchymal stem cell, and bone marrow-derived mesenchymal
stem cell markers CD144, CD146, and CD106, respectively.[6, 7] Other cell types such as
fibroblasts and smooth muscle cells can be identified by staining against HSP47 and
vimentin, and α-smooth muscle actin, respectively. Lastly, one can look for evidence of
newly secreted collagen within the scaffolds by staining for collagen type III and prolyl-4hydroxylase.

7.3.2 Aim 3:
Cell seeding of scaffolds is absolutely critical. The platform can function perfectly
and provide excellent conditions for cell differentiation, but that is meaningless without the
presence of cells on the scaffold.

Even with too few cells on the scaffolds their
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differentiation may be adversely affected, and evaluation of the effects of the experiment
may become too challenging because of a lack of cell density. Pilot experiments should
be conducted which directly compare the efficacy of different cell seeding methods.
Future experiments could investigate the co-culture of cardiac fibroblast seeded
along with hADSCs onto scaffolds and their effect when combined with the dynamic
conditions provided by the platform. The effects of changing the coordination of the
mechanical and electrical stimuli could also be tested. For example, the electrical impulse
can be alternatively delivered at the peak of the pressure waveform, simulating an
excitation followed by a compression of sorts (the relaxation of applied tensile force). It
might be determined that this method is more effective at producing differentiation and
contractility in hADSC than delivering the stimulus just prior to the beginning of the
pressure waveform.
The following is a suggested study once initial studies with the Flexcell system
have been used to determine which specific stimuli are useful in cell differentiation. This
information can then be applied in concert with the use of a perfusion bioreactor described
herein.

7.3.2.1 In Vitro Conditioning of Cell-Seeded Constructs in a Bioreactor
7.3.2.1.1 Bioreactor Design:
The bioreactor will be designed using SolidWorks software, and machined by
Clemson University Machining and Technical Services. We have extensive experience in
this area[8], and the process will be completed using formal methods of design. Based upon
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the results of the Flexcell studies, some of the design features described below may be
changed or excluded, but the design we envision includes the capability to deliver all
stimuli that will be tested in the Flexcell studies. Design features and outputs are as follows
(Figure 7.1): (1) a main housing with 6 chambers (one construct per chamber) which can
be filled with chemically defined cell culture media, (2) silicone membranes to which each
construct is fixed via suturing to extensions of lid that insert until nearly flush with bottom
of each chamber. The membranes will operate on the same principle as the Flexcell system,
cyclically rising and falling in response to increased or decreased air pressure (driven by a
compressed air source and controlled by LabView) in the chambers below them – this
imparts cyclic tensile and compressive forces on the constructs (Figure 7.1 bottom); (3)
insulated electrical leads extending from a LabView-controlled circuit which will be
attached to electrodes as in the Flexcell system, providing paced electrical stimulation
similar to the cardiac conduction system; the scale of the housing and chambers will be
such that the entirety of constructs will lie between the electrodes, exposing all resident
cells to the developed electrical field, (4) dynamic fluid circuit, digital peristaltic pumps,
and pinch valves to control fluid pressure and simulate pulsatile blood flow using
circulating culture media. Computational fluid dynamics (CFD) analysis will be conducted
on the pathway of fluid flow through the bioreactor. CFD analysis software (SolidWorks)
will provide measurements of wall shear stress at the coronary artery inlet.

These

measurements will be informative regarding possible responses of endothelial cells seeded
on the scaffold vascular lumen. Additional design considerations will include sterility,
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visibility, continuous monitoring of pressures, and ability to fit inside a standard cell culture
incubator (Figure 7.1 bottom).

Figure 7.1: Conceptual drawing of possible perfusion
bioreactor: At top, schematic of bioreactor components
and their layout. Components are as follows: (1) main
housing with 6 chambers (2) compliance chamber/pressure
head (3, 4) media reservoirs with attached micron-scale air
filters (6) pinch valve for pulsatile flow (7, 8) media routing
manifolds (9) data acquisition module and electrical
stimulus generator (10) media outflow lines. At bottom,
CAD software-generated drawings (Solidworks ™) of the
main housing and its features (isometric, lateral, and top
views of the housing, respectively, from top to bottom).
Blue arrows show path and action of air used to generate
positive pressure and deflect silicone membrane (horizontal
black line) upward. Red arrows indicate the path of media
flow in and out of the housing. A seeded construct (SC) is
shown occupying its designated position in one of the
chambers with electrodes (E) located on both sides and just
above it. The flow of media in and out of the seeded
construct is also denoted by red arrows.
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7.3.2.1.2 Scaffold Preparation:
DCELLed scaffolds (n=6) prepared as previously described will be trimmed to 3
cm x 3 cm at the distal or apical portion of the left ventricular wall so that the intrinsic
vasculature and afferent coronary artery are left attached; the resulting “flap” scaffolds will
be sterilized, rinsed, and serum neutralized

7.3.2.1.3 Cell seeding, incorporation of constructs into bioreactor, and conditioning:
Results of the Flexcell studies will determine which, if any, cell types (e.g.
fibroblasts) will be seeded in addition to hADSC. We will begin the seeding process by
injecting hADSC suspended in media at 5 x 106 cells/mL through the coronary vasculature
of the scaffolds described above.

The intent of seeding cells in this manner is to

reendothelialize the vasculature. There is evidence that hADSC can differentiate into an
endothelial cell phenotype under conditions of applied fluid shear stress, and we believe
that once attached to the lumens of vasculature, they will be differentiated into an
endothelial phenotype (hADSC-EC) by virtue of their exposure to the flow of media
through the bioreactor and constructs.[9] Prior to injection, the circumflex artery and the
more proximal diagonal branches of the coronary artery will be ligated with sutures, and
the edges of the scaffold, including the edge extending to the right ventricular wall and the
ventricular septum, will be tightly clamped to prevent any initial leakage of the perfused
cell suspension through severed vessels. The seeded scaffolds will then be laid flat and
cultured statically in a petri dish for 6 h to allow cells to attach securely to the vessel
lumens. At this point, the scaffolds will be turned over and laid on their opposite surface,
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and the above cell suspension perfusion process will be repeated. The reasoning behind
this is to ensure a more uniform coverage of the lumen, as cells will settle out of suspension
during static culture, thus covering only up to ½ of the lumen surface in each perfusion
step. Following another 6 h of static culture, scaffolds will be placed within their respective
housings in the bioreactor and the arterial and venous cannulas will be connected to inlets
and outlets, respectively. The scaffolds will be seeded with a combination hADSC (70%;
to be differentiated into CM; hADSC-CM) and human CF (30%; should they be found in
Phase 1 to be beneficial) cell suspension via injection at 15-20 points throughout the
scaffolds’ interstitium and also on the epicardial surface by drop-wise pipetting. At this
point, the bioreactor will be sealed and will continuously circulate culture media (DMEM
with 10% fetal bovine serum and 1% antibiotic/antimycotic) through the vasculature as
well as throughout the chambers (immersion-perfusion). We will adjust various stimuli
and conditions within the bioreactor to approximate normal physiological conditions of the
myocardium (fluid pressure = 120/80 mmHg, fluid shear = 12 dynes, fluid viscosity = 3-4
cP (using dextran), electrical stimulus = 1.25 Hz, 2-4 V/cm, mechanical force = 2 N
tension, 20% strain). With these conditions set, the system will be placed inside an
incubator at 37 °C and maintained in this state for 4 weeks to induce formation of interCM and CM-fibroblast electrical connections, growth of a confluent endothelial layer on
vessel lumens, development of global, synchronous contraction, and overall construct
maturation. Culture media will be changed every 4 days under sterile conditions.
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7.3.2.1.4 Cell Culture:
Each of the cell types listed above will be cultured individually in cell-specific
media and subcultured to attain sufficient numbers to seed the scaffolds (n=6) at about ¼
of the correct physiological cell density (5 x 107 cells/cm3)[10] of the native human
myocardium (roughly 0.35 billion cells/scaffold). We will use a cell culture scale-up
apparatus, the CellSTACK® (Corning®), to produce sufficient numbers of cells for this
study. To account for differing proliferation rates among cell types, the proportions of each
cell type seeded will be altered from their physiological levels (i.e. CF – 60% of total cell
number in myocardium, CM – 25 %, and EC – 5%)[11, 12] to levels which we estimate will
yield approximately correct ratios once conditioning and maturation is complete (i.e. CF –
30% of total seeded cell number, hADSC-CM – 67.5%, hADSC-EC – 2.5%). Should we
find that treatment with AZT enhances differentiation of hADSC into CM in the Flexcell
study, we will add AZT into the culture media in the bioreactor. For hADSC targeted for
EC differentiation, we will use endothelial cell growth supplement in cultures prior to
seeding and treat them with AZT or another DNA-demethylating reagent shown to induce
hADSC to EC differentiation, BIX-01294 (Sigma), just prior to harvest for seeding.[13]

7.3.2.1.5 Characterization of conditioned constructs:
After 4 weeks of culture within the bioreactor, we will evaluate constructs for cell
density and distribution, maintenance of cell viability, and adoption of cell and tissue
morphology, mechanical properties, and electrical stimulus propagation comparable to
native myocardium. Constructs will be cut into sections and processed for various methods
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of

evaluation:

1)

fixation

in

4%

paraformaldehyde

for

histology

and

immunofluorescence/IHC; 2) extraction of protein and DNA via Trizol® reagent and
homogenization for western blotting and RT-PCR, respectively; 3) preservation in cell
culture media for tests of cell/tissue viability and functionality, including micro-electrode
array (MEA) probing and patch clamping in both the presence and absence of agonists,
calcium transient imaging using Fluo-4, and measurement of the force of any contraction
produced by cells using a custom-designed force transducer. We will also prepare samples
of recellularized arteries for inspection via scanning electron microscopy to quantify
confluency and study features of the newly differentiated endothelium. These cells’ ability
to take up oxidized LDL will also be evaluated as a test of their functionality. We will
evaluate the mechanical properties (modulus of elasticity and burst pressure, respectively)
of both the arterial and myocardial portions of the tissue in the same manner as was done
previously to evaluate DCELLed scaffolds.
Histological sections will be stained via H&E and Masson’s trichrome methods to
visualize cellular dimensions, number, and distribution.

Tissue morphology and

maturation will be assessed with H&E, Movat’s pentachrome, Gomori’s trichrome, and
Voerhoff van Geisen (VVG) stains (to facilitate semiquantitative measurement of cell
types, elastin, and collagen content and structure). IHC and IF will be used to stain for cell
type-specific markers (CM: cardiac MHC, actin, α-sarcomeric actinin, troponin, and
desmin; CF: vimentin and discoidin domain receptor 1 (DDR-1); EC: CD31, Von
Willebrand factor, VE-cadherin). Image analysis software (NIH) will be used to count
nuclei in visual fields (taking into account that some CMs might be multinucleate), and the
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principle of Delesse (area density=volume density) will be applied as described by
Boyle[14] and Levkau[15] in order to determine cell density and proportions of specific cell
types. In addition, small samples (1 mm3) (n=6) of the constructs will be harvested, their
masses will be recorded, and they will be subjected to a PicoGreen assay and gel
electrophoresis to quantify DNA content as a measure of cell number. Cell viability will
be assessed by a colorimetric assay for cellular respiration (MTT/MTS) on small samples
(n=6) of the constructs and by performing Live/Dead staining on small samples (n=6). The
induction of electrical integration will be evaluated via IF staining for connexin43
(characteristic marker of gap junctions), and contractile force generation will be measured
via a force transducer connected to a data acquisition module.

Additionally, the

development of intercalated discs will be assessed semiquantitatively (using ImageJ)
following staining with antibodies against N-cadherin.[16]

7.3.2.1.6 Outcome Success Measures:
Wherever possible, all measurements of construct characteristics will be compared
with those of normal human myocardium, our control for these experiments. We have an
IRB protocol in place and collaborate with local cardiac surgeons who would provide
samples for us. We also have a contract with NDRI for obtaining human tissues. Cell
density of at least 75% of reported physiological cell density, or > 1.5 x 108 cells/cm3;
percentages of specific cell types which fall within 15% of those values reported in the
literature.[11] Cell viability > 90% and tissue morphology reasonably similar to that of
normal human myocardium. Mechanical properties of constructs deviate from normal
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myocardium by < 15%; generation of force > 0.5 N; calculated ratio of > 0.8 for number
of intercalated discs:number of CMs; morphology that approximates that of native
myocardium; positive staining for connexin43, actin, cardiac MHC, α-sarcomeric actinin,
troponin T, and desmin; evidence of cells producing endogenous ECM, including collagen
and basement membrane proteins.

7.3.2.1.7 Challenges and Alternative Strategies:
In the case of autologous stem cell therapies, hADSC are currently the population
most readily translatable to clinical use. Human IPSC may be a viable option in the future,
as many groups have recently demonstrated these cells’ ability to differentiate into a CM
phenotype.[17, 18] Concerns remain, however, regarding the safety of using viral vectors
and even small-molecule mediated methods to induce pluripotency, as well as the
epigenetic stability of these cells following reprogramming.[19,

20]

The aversion of

regulatory agencies towards these practices is a barrier that must be overcome before IPSC
can be pursued fully as a stem cell source for translational regenerative medicine and tissue
engineering approaches. Should we encounter adverse outcomes with our planned studies
involving low cell proliferation or differentiation, we will first attempt to alter our cell
culture methods. We will use 3D cell culture in the form of the hanging drop method to
form spheroids of hADSC for subsequent seeding onto scaffolds. Recent approaches for
differentiating IPSC into CM have employed spheroid cultures as opposed to 2D
monolayers, with the proposed benefit being that cells secrete endogenous ECM
components and paracrine factors that contribute to more successful targeted
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differentiation.[18] With this approach, hADSC may be nearly differentiated or more
primed for differentiation just prior to being seeded on the scaffolds.
We will also address another frequent concern of regulatory agencies—the use of
animal sera—in alternative strategies for cell culture. We will explore the use of serum
free media in culturing cells for seeding, which may not be as challenging as it sounds
given that they proliferate very well in media formulations with low serum concentrations.
Leakage and lack of cell engraftment or retention could be another challenge with seeding.
In the event this becomes an issue, we will use fibrin glue to seal microvascular leaks and,
as an alternative approach, lyophilize (freeze-dry) our scaffolds to encourage better
infiltration of cells. If oxygen diffusion is limited within the scaffolds, we will improve this
by adding oxygen carriers (perfluorocarbons) to the media.[21] Access to sufficient human
tissue to assemble data for control groups might be limited, although we do receive donated
tissue periodically. This deficiency will be remedied by using figures and data published
in the literature. In the event that constructs do not synchronously contract with a detectable
force, we will analyze contractile force in individual CMs using a method described by
Tasche et al.[22]

7.2.4 Aim 4:
Animal studies should proceed as described in Chapter Six and as outlined in
Figure 6.2.
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Figure 3.9: Continuous-flow, perfusion-immersion system for decellularization: A) (1) Inflow reservoir
(2) Scaffold immersed in decellularization solution on multi-stirrer plate (3) Overflow and collection
reservoir (4) Peristaltic pump. B) Expanded view of myocardial flap scaffold inside decellularization
container.
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Figure 3.10: Continuous-flow, perfusion-immersion system for whole heart decellularization: A) (1)
Inflow reservoir (2) Scaffold immersed in decellularization solution on multi-stirrer plate (3) Overflow and
collection reservoir (4) Peristaltic pump. B) Expanded view of a whole porcine heart being decellularized
within a specially designed container. C) Whole porcine heart shown securely attached to an aortic cannula
with zip-ties. All reagents flowed retrogradely across the aortic valve, into the left ventricle, and upward
through the mitral valve into the left atrium. Pressure was held in these chambers by suturing or plugging
the pulmonary veins. Reagents also flowed anteriogradely through the coronary circulation. D) CAD
rendering of the specially designed decellularization vessel shown in A and B. The vessel and other parts in
the assembly were designed using Solidworks software.
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